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1 Summary 
T cells are central players of adaptive immune responses. Engagement of the T cell receptor 
(TCR) by specific antigens together with a CD28 co-stimulus promotes T cell activation, 
proliferation, and differentiation into T cell effector subsets with distinct functions. 
TCR/CD28 co-ligation induces activation of the canonical NF-κB signaling cascade, which 
requires the assembly of CARMA1, BCL10, and MALT1 into a high-molecular weight 
complex called the CBM complex. The paracaspase MALT1 acts both as a molecular scaffold 
and as a protease to mediate T cell activation and effector functions. As part of the CBM 
complex, MALT1 scaffold recruits the E3 ligase TRAF6 to channel upstream TCR signaling 
to the canonical IKK/NF-κB pathway and JNK signaling. TCR ligation also induces MALT1 
protease activity, which modulates T cell responses by cleaving several signaling mediators 
and post-transcriptional regulators. In the present study, two alternative splice variants of 
MALT1, MALT1A and MALT1B, were identified. The aim was to analyze the impact of 
both MALT1 isoforms on T cell activation and functions, and to investigate the regulation of 
alternative MALT1 splicing. 
Database research revealed the existence of two isoforms of MALT1, MALT1A and 
MALT1B, which are highly conserved in mammals. Both isoforms harbor two C-terminal 
TRAF6 binding motifs (T6BM2/3), but differ in inclusion (MALT1A) or exclusion 
(MALT1B) of a 33 bp exon7, comprising an additional TRAF6 binding motif (T6BM1). 
Mutating individual TRAF6 binding sites demonstrated that T6BM1 within exon7 recruits 
TRAF6 and contributes to the activation of NF-κB and JNK signaling, revealing that the 
presence of exon7 enhances MALT1 scaffolding function. In contrast, exon7 inclusion is 
dispensable for MALT1 paracaspase activity. Furthermore, MALT1 isoform expression levels 
and functions have been analyzed in primary, murine CD4+ T cells. Whereas naive CD4+  
T cells expressed almost exclusively the shorter splice variant MALT1B, TCR stimulation 
triggered exon7 inclusion and thus MALT1A expression, which was also observed in T cells 
with an activated phenotype such as effector T cells and T follicular helper (TFH) cells. TCR-
driven MALT1A induction augmented NF-κB and JNK signaling and expression of T cell 
activation markers CD69, CD25, and IL-2, revealing that MALT1A upregulation is required 
for optimal T cell activation. In contrast, T cell differentiation processes are not affected by 
alternative MALT1 splicing, since both isoforms promoted TH1 and TH17 differentiation to 
the same extent. Screening of critical splicing factors controlling alternative MALT1 splicing 
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identified hnRNP U as a negative regulator of exon7 inclusion. Downregulation of hnRNP U 
promoted enhanced TCR-induced MALT1A expression and CD4+ T cell activation. hnRNP U 
associates with MALT1 pre-mRNA and two sequences of approximately 100 bp 5’ and 3’ of 
exon7 were identified as putative hnRNP U binding regions that facilitate exon7 exclusion. 
The data demonstrate that hnRNP U controls alternative splicing of MALT1 and that TCR-
induced splicing of MALT1 enhances relative MALT1A expression, which augments 
MALT1 scaffolding function to enhance downstream signaling and to promote optimal T cell 
activation. The findings reveal that the functions of the central T cell signaling mediator 
MALT1 are controlled by alternative splicing, and that this regulation shapes the outcomes of 
T cell responses.  
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1 Zusammenfassung 
T Zellen übernehmen eine zentrale Rolle bei der adaptiven Immunantwort. Die Stimulation 
des T Zell Rezeptors (TCR) durch ein spezifisches Antigen zusammen mit einem CD28 
Kostimulus führt zur Aktivierung, Proliferation und schließlich zur Differenzierung von 
naiven T Zellen in distinkte Effektor T Zellen. Auf molekularer Ebene bewirkt die 
TCR/CD28 Kostimulation unter anderem eine Aktivierung des kanonischen NF-κB 
Signalweges, wofür die Assemblierung des CARMA1/BCL10/MALT1 (CBM) Komplexes 
von entscheidender Bedeutung ist. Eine zentrale Komponente des CBM Komplexes stellt die 
Paracaspase MALT1 dar, welche sowohl als Gerüstprotein als auch als Protease fungiert. Die 
Gerüstfunktion ermöglicht MALT1 die E3 Ligase TRAF6 zu rekrutieren und schließlich 
TCR-Signale zum kanonischen IKK/NF-κB und JNK Signalweg zu übermitteln. Auch die 
Proteasefunktion von MALT1 wird nach TCR Stimulation aktiviert, welche verschiedene 
Signalmoleküle und posttranskriptionelle Regulatoren spaltet und dadurch T Zellantworten 
moduliert. In der vorliegenden Arbeit wurden zwei alternative Spleißvarianten von MALT1, 
MALT1A und MALT1B, identifiziert. Ziel dieser Arbeit war es den Einfluss beider MALT1 
Isoformen auf die Aktivierung und Funktion von T Zellen zu analysieren sowie die 
Regulation des alternativen Spleißprozesses zu untersuchen. 
Datenbank-Recherchen offenbarten, dass mit MALT1A und MALT1B zwei MALT1 
Isoformen existieren, die in Säugetieren stark konserviert sind. Beide Isoformen besitzen zwei 
TRAF6 Bindungsmotive im C-Terminus (T6BM2/3), aber unterscheiden sich in der Inklusion 
(MALT1A) oder Exklusion (MALT1B) eines 33 bp langen Exon7, welches eine zusätzliche 
TRAF6 Bindungsregion T6BM1 kodiert. Durch Mutation der individuellen TRAF6 
Bindungssequenz in Exon7 konnte gezeigt werden, dass T6BM1 in der Lage ist TRAF6 zu 
binden und zur Aktivierung des NF-κB und JNK Signalweges beizutragen. Dies lässt darauf 
schließen, dass die Gerüstfunktion von MALT1 durch die Anwesenheit von Exon7 verstärkt 
wird. Im Gegensatz dazu bleibt die Proteaseaktivität bei der Einfügung von Exon7 
unbeeinflusst. Weiterhin wurde die Expression und die Funktion beider Isoformen in 
primären, murinen CD4+ T Zellen untersucht. Dabei zeigte sich, dass naive CD4+ T Zellen 
fast ausschließlich die kürzere Isoform MALT1B exprimieren, während TCR Stimulation die 
Inklusion von Exon7 und somit die Expression von MALT1A bewirkte. Dieses Phänomen 
wurde auch in aktivierten T Zellen wie zum Beispiel in Effektor T Zellen und TFH Zellen 
beobachtet. Die TCR-vermittelte Induktion von MALT1A verstärkte die Aktivierung von  
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NF-κB und JNK sowie die Hochregulation der Aktivierungsmarker CD69, CD25 und IL-2, 
was darauf schließen lässt, dass eine erhöhte MALT1A Expression zu einer optimalen  
T Zellaktivierung beiträgt. Da beide Isoformen die Differenzierung in TH1 und in TH17 Zellen 
gleich stark begünstigten, wird deutlich, dass alternatives MALT1 Spleißen für die  
T Zelldifferenzierung irrelevant ist. Bei der Suche nach möglichen Spleißfaktoren, welche 
alternatives Spleißen von MALT1 regulieren, konnte hnRNP U als Negativregulator der 
Exon7 Inklusion identifiziert werden. Eine Herunterregulation von hnRNP U führte zu einer 
erhöhten MALT1A Expression nach TCR Stimulation und einer verstärkten  
T Zellaktivierung. hnRNP U bindet an die prä-mRNA von MALT1 und zwei Sequenzen mit 
einer Länge von 100 bp in der Nähe von Exon7 wurden als mögliche hnRNP U 
Bindungsregionen identifiziert. Unsere Daten zeigen, dass hnRNP U alternatives Spleißen 
von MALT1 reguliert und TCR-induziertes Spleißen von MALT1 zu einer vermehrten 
Produktion von MALT1A führt, was die Gerüstfunktion von MALT1 verstärkt und somit eine 
optimale T Zellaktivierung ermöglicht. Es wird deutlich, dass alternatives Spleißen die 
Funktion eines zentralen Signalschalters im T Zellsignalweg reguliert, welcher die finale  
T Zellantwort moduliert.  
2 Introduction 
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2 Introduction 
2.1 T cells in adaptive immune responses 
The mammalian immune system protects hosts effectively from foreign antigens, such as 
microbes, viruses, and toxins, and recognizes and eliminates cancer cells (Chaplin, 2010; 
Warrington et al., 2011). Two main defense strategies can be delineated: innate immunity and 
adaptive immunity. Whereas innate immunity provides an immediate, but unspecific (antigen-
independent) defense against infections (Gonzalez et al., 2011), adaptive immune responses 
are highly antigen-specific, but appear later as they require expansion of specific adaptive 
immune cells (Chaplin, 2010; Murphy et al., 2008). Key features of the adaptive immune 
system are its ability to distinguish between self and non-self, and to produce immunological 
memory (Abbas et al., 2014). Innate and adaptive immunity cooperate to combat an infection 
with high efficiency, and deregulation of both contributes to the development of diseases such 
as autoimmunity, immunodeficiency, and cancer (Warrington et al., 2011). 
2.1.1 The adaptive immune system 
The major players of the adaptive immune system are T and B lymphocytes. B lymphocytes 
arise from bone marrow stem cells and fully mature in secondary lymphoid organs (Murphy 
et al., 2008). Mature B cells are activated by soluble and cell-bound antigens and differentiate 
into antibody secreting plasma cells or long lived memory B cells (Abbas et al., 2014; 
Warrington et al., 2011). Secretion of antibodies can promote neutralization of pathogens or 
toxins, induction of phagocytosis, or activation of the complement system to protect the host 
from infection (Abbas et al., 2014; Parkin and Cohen, 2001). Thus, B cells play a crucial role 
in antibody-mediated immunity, also known as humoral immunity (Warrington et al., 2011). 
The humoral strategy mainly eliminates extracellular microbes, failing to detect intracellular 
pathogens. Defense against intracellular pathogens is facilitated by cell-mediated immunity, 
which relies on circulating T lymphocytes that originate from hematopoietic stem cells in the 
bone marrow and mature in the thymus to promote destruction of pathogen-infected 
phagocytes or other infected host cells (Abbas et al., 2014; Germain, 2002; McNeela and 
Mills, 2001).  
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In order to recognize distinct antigens, T and B lymphocytes express T cell receptors (TCRs) 
and B cell receptors (BCRs), respectively (Boehm, 2012). Due to the large array of foreign 
antigens, a high diversity of antigen-receptors differing in their antigen specificity is 
generated by somatic recombination of gene segments (Abbas et al., 2014). In contrast to  
B cells, T lymphocytes only detect foreign antigens that are presented by major 
histocompatibility complex (MHC) molecules, which are expressed on the surface of antigen 
presenting cells (APCs), such as dendritic cells, macrophages, B cells, or epithelial cells 
(Pitcher and van Oers, 2003; Warrington et al., 2011). MHC molecules can be classified as 
class I or class II molecules based on whether they present peptides derived from intracellular 
(class I) or extracellular (class II) proteins (Vyas et al., 2008). MHC class I and class II 
present both self-peptides as well as foreign peptide fragments. Two major subpopulations of 
T lymphocytes are known, which recognize different types of antigen-MHC complexes: CD4+ 
or T helper (TH) cells and CD8+ or cytotoxic T lymphocytes. Whereas CD8+ T cells recognize 
peptides bound to MHC class I molecules expressed on all nucleated cells, CD4+ T cells are 
restricted to MHC class II-bound antigens located on professional APCs such as dendritic 
cells, macrophages, and B cells (Vyas et al., 2008; Warrington et al., 2011). Thereby, CD4+ 
and CD8+ T cells can distinguish between self-antigens and foreign antigens. CD8+ T cells are 
involved in the destruction of nucleated cells infected with intracellular pathogens like viruses 
or cytoplasmic bacteria. In contrast, CD4+ T cells do not possess any cytotoxic activity, but 
are able to activate other immune cells including B cells, macrophages, and other leukocytes, 
to mediate an immune response (Chaplin, 2010). Upon encountering their cognate antigens, 
CD4+ and CD8+ T lymphocytes become activated, proliferate and differentiate into effector or 
memory T cells, which are able to provide immediate or long-term protection, respectively 
(Abbas et al., 2014; Chang et al., 2014).   
2.1.2 T cell activation and differentiation 
Mature CD4+ and CD8+ T cells are released from the thymus into the blood stream and are 
considered to be naive before they encounter a specific antigen (Abbas et al., 2014; Zhu et al., 
2010). They migrate to secondary lymphoid organs such as the spleen and lymph nodes, 
where they encounter and recognize their cognate antigen. Naive T cells are characterized by 
high levels of the surface markers CD62L (CD62 ligand or L-selectin) and CCR7 (CC 
chemokine receptor 7), which facilitate T cell entrance into lymph nodes through high-
endothelial venules (HEVs) by detecting adhesion molecules and chemokines (Berard and 
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Tough, 2002). Upon recognition of a foreign antigen, T cells enlarge and proliferate. They 
downregulate CD62L and secrete cytokines, like interleukin (IL)-2, that further supports their 
proliferation and survival (Bachmann and Oxenius, 2007). Activated T cells upregulate the 
activation markers CD69, CD25 and CD44 on their surface. While the C-type lectin CD69 
supports retention of activated T lymphocytes in secondary lymphoid organs (Shiow et al., 
2006), upregulation of the IL-2 receptor subunit CD25 further amplifies IL-2-mediated 
expansion (Malek, 2008). Surface expression of the hyaluronic acid receptor CD44 occurs 
later and is considered to be critical for the migration of effector T cells to sites of infection 
(Baaten et al., 2010). 
Depending on the cytokine milieu, the antigen dose and the type of APC, CD4+ and CD8+  
T cells differentiate into specific effector cells (Ley, 2014; Luckheeram et al., 2012; Zhu et 
al., 2010). Regarding CD4+ T cell differentiation, several distinct effector subtypes can be 
distinguished (Figure 2.1).  
 
Figure 2.1: CD4+ T helper cell differentiation. Depending on the cytokine milieu and other factors, CD4+ T cells 
can differentiate into TH1, TH2, TH17, TFH and iTreg cells. Each subtype secretes a distinct set of cytokines and 
thus adopts a specific function within the immune system. BCL6 (B cell chronic lymphocytic 
leukemia/lymphoma 6), FOXP3 (forkhead box p3), GATA3 (GATA binding protein 3), IFN (interferon), IL 
(interleukin), iTreg (induced regulatory T cell), RORγt (RAR-related orphan receptor gamma t), T-bet (T-box 
transcription factor), TFH (follicular T helper), TGFβ (transforming growth factor beta), TH (T helper). 
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In response to cytokines such as IFNγ (interferon γ) and IL-12, CD4+ T cells differentiate into 
TH1 cells characterized by the expression of the transcription factor T-bet (T-box transcription 
factor) (Szabo et al., 2000). TH1 cells further secrete IFNγ, which represents a positive 
feedback loop to reinforce TH1 differentiation and induces the activation of phagocytes to 
eliminate intracellular pathogens (Luckheeram et al., 2012). To combat extracellular parasites, 
T cells of the TH2 subtype are generated in response to IL-4 (Swain et al., 1990). TH2 cells 
express GATA3 (GATA binding protein 3) and produce IL-4, IL-5 and IL-13, which are 
critical for IgE (immunoglobulin E) production of B cells, eosinophil activation, and mucus 
secretion (Deo et al., 2010; Ley, 2014). Therefore, TH2 cells play a key role in allergic 
diseases (Luckheeram et al., 2012). In addition to TH1 and TH2 cells, a third lineage of 
effector T helper cells has been identified called TH17 cells (Korn et al., 2009; Luckheeram et 
al., 2012). TH17 cell differentiation relies on the cytokines IL-6, IL-21, IL-23, and TGFβ 
(transforming growth factor beta), as well as the transcription factor RORγt (RAR-related 
orphan receptor gamma t) (Figure 2.1) (Ivanov et al., 2006; Korn et al., 2009). By producing 
IL-17A, IL-17F, IL-21 and IL-22, TH17 cells induce the release of antimicrobial peptides and 
the recruitment of neutrophils and thus contribute to the clearance of bacterial and fungal 
infections (Waite and Skokos, 2012). An additional CD4+ T cell subtype are follicular  
T helper (TFH) cells characterized by the expression of PD-1 (programmed cell death protein-
1), ICOS (inducible T cell co-stimulator), and CXCR5 (CXC chemokine receptor type 5) as 
well as the transcription factor BCL6 (B cell chronic lymphocytic leukemia/lymphoma 6) (Ma 
et al., 2012). TFH cells develop in response to cytokines like IL-21 and IL-6. In turn, they are 
able to secrete IL-21 and IL-10 and thus provide help for B cells to differentiate into 
antibody-producing plasma cells or long-lived memory B cells (Luckheeram et al., 2012; Ma 
et al., 2012). In order to prevent disproportionate immune responses, CD4+ T cells can also 
differentiate into suppressor T cells, known as induced regulatory T cells (iTregs), which are 
distinct from thymus derived natural Tregs (nTregs) (Chaplin, 2010). iTreg differentiation 
requires TGFβ and IL-2. Those cells are characterized by the expression of the transcription 
factor FOXP3 (forkhead box p3) and the secretion of anti-inflammatory cytokines IL-10 and 
TGFβ, which suppress immune activation (Luckheeram et al., 2012). Therefore, Tregs play a 
major role in the maintenance of immune homeostasis and peripheral self-tolerance 
(Sakaguchi et al., 2009).  
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2.2 TCR-induced signaling pathways 
2.2.1 T cell receptor and co-receptors 
T cell-mediated immune responses require the detection of a foreign antigen by the TCR. The 
TCR consists of a highly variable α/β heterodimer that recognizes peptide antigens presented 
by MHC proteins (Murphy et al., 2008). It associates with the CD3 complex, consisting of 
CD3γ, CD3δ and CD3ε protein chains, and a homodimer of ζ chains to form the TCR 
complex (Figure 2.2). Both, the CD3 complex and the ζ dimer harbor one or more 
immunoreceptor tyrosine-based activation motifs (ITAMs), which are crucial for coupling 
TCR ligation to the activation of intracellular signaling pathways (Love and Hayes, 2010; 
Malissen, 2008). Engagement of a TCR by an antigen-MHC complex initiates 
phosphorylation of ITAMs creating a binding platform for molecules involved in proximal 
TCR signaling (Sharpe and Abbas, 2006). Recognition of antigen-MHC complexes is 
supported by the co-receptors CD4 or CD8, which bind to MHC class II or MHC class I 
molecules, respectively (Gascoigne, 2008; Vyas et al., 2008). CD4 and CD8 co-receptors also 
contribute to ITAM phosphorylation by associating with the tyrosine kinase LCK 
(lymphocyte-specific protein tyrosine kinase) (Schulze-Luehrmann and Ghosh, 2006). 
However, productive T cell activation requires a second signal, since TCR stimulation alone 
leads to apoptosis or a state of unresponsiveness, called anergy (Schmitz and Krappmann, 
2006). Therefore, T cells express co-stimulatory molecules such as CD28 co-receptors, which 
specifically recognize the proteins B7.1 (CD80) or B7.2 (CD86) expressed on the surface of 
APCs (Abbas et al., 2014; Chen and Flies, 2013). Co-receptor-mediated signaling augments 
weak TCR-induced signals to promote efficient T cell activation and a productive immune 
response (Schmitz and Krappmann, 2006). Collectively, the additional co-stimulatory signal 
provides a mechanism to prevent autoreactive and aberrant T cell responses (Chen and Flies, 
2013).   
2.2.2 Proximal T cell receptor signaling events 
Upon stimulation of the TCR together with a co-stimulus, the T cell undergoes extensive 
cytoskeletal remodeling resulting in the formation of the immunological synapse (IS), which 
forms at the cell-cell interface between APC and T cell (Alarcon et al., 2011; Smith-Garvin et 
al., 2009). Proximal signaling molecules and receptors are enriched within the IS and 
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associate with the TCR. The synapse consists of supramolecular activation clusters (SMACs), 
which can be divided into the central SMAC (cSMAC), the surrounding peripheral SMAC 
(pSMAC), and the distal SMAC (dSMAC) (Kumari et al., 2014; Yu et al., 2013). pSMAC 
and dSMAC mainly contain integrin adhesion molecules, glycoproteins, and protein tyrosine 
phosphatases and thereby promote synapse formation and stabilization. The cSMAC, 
however, clusters TCRs together with CD28 co-receptors and other signaling molecules such 
as PKCθ (protein kinase C θ) enabling sustained TCR signaling (Alarcon et al., 2011; Smith-
Garvin et al., 2009). Upon prolonged T cell activation, co-inhibitory molecules are recruited 
to the IS leading to termination of TCR signaling (Chen and Flies, 2013). Thus, the 
immunological synapse provides a platform for the recruitment and enrichment of receptors 
and accessory proteins that induce both signal amplification and termination (Guy and 
Vignali, 2009; Yu et al., 2013).    
The initiation of proximal T cell signaling requires the recruitment of Src family kinases to 
the TCR (Paul and Schaefer, 2013; Schulze-Luehrmann and Ghosh, 2006). Upon antigen 
binding, FYN and the CD4/CD8-associated kinase LCK are recruited to the TCR complex 
and phosphorylate conserved ITAM motifs within the CD3 subunits (Figure 2.2) (Schulze-
Luehrmann and Ghosh, 2006; Smith-Garvin et al., 2009). Phosphorylation of ITAMs allows 
the recruitment and activation of ZAP70 (zeta-chain-associated protein kinase 70 kDa), which 
is central for the activation of downstream signaling mediators (Paul and Schaefer, 2013; 
Smith-Garvin et al., 2009). ZAP70 phosphorylates several substrates such as the 
transmembrane adapter LAT (linker for activation of T cells) and the cytosolic protein SLP76 
(Src homology 2 (SH2)-domain containing leukocyte protein of 76 kDa) (Paul and Schaefer, 
2013). In turn, both proteins serve as docking sites for the recruitment of effector molecules 
such as PLCγ1 (phospholipase C γ1), the p85 subunit of PI3K (phosphoinositide 3 kinase), 
the adapters GRB2 (growth factor receptor-bound protein 2) and GADS (GRB2-related 
adapter downstream of Shc) as well as the GEFs (guanine nucleotide exchange factors) 
VAV1 and SOS (son of sevenless) (Figure 2.2) (Schulze-Luehrmann and Ghosh, 2006; 
Smith-Garvin et al., 2009).  
The activation of PLCγ1 results in the hydrolysis of PIP2 (phosphatidyl inositol 4,5-
bisphosphate), generating the second messengers inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG) (Paul and Schaefer, 2013). Whereas IP3 triggers activation of the 
transcription factor NFAT (nuclear factor of activated T cells), membrane-associated DAG 
together with the GEF SOS promotes activation of the Ras (rat sarcoma)-ERK1/2 
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(extracellular signal-regulated kinase 1/2) pathway resulting in activation of the transcription 
factor AP-1 (activator protein-1) (Brownlie and Zamoyska, 2013; Smith-Garvin et al., 2009). 
Moreover, production of DAG is critical for PKCθ-dependent activation of CARMA1 
(caspase-recruitment domain (CARD)-containing MAGUK 1), which in turn recruits BCL10 
(B cell chronic lymphocytic leukemia/lymphoma 10) and its constitutive binding partner 
MALT1 (mucosa associated lymphoid tissue lymphoma translocation protein 1) (Schulze-
Luehrmann and Ghosh, 2006; Thome et al., 2010). CARMA1, BCL10 and MALT1 assemble 
to form the high-molecular weight CBM complex that links TCR ligation to the canonical 
NF-κB (nuclear factor kappa B) pathway (see section 2.3). Overall, TCR stimulation triggers 
the activation of three major transcription factors: NFAT, AP-1 and NF-κB (Figure 2.2) 
(Padhan and Varma, 2010). 
 
Figure 2.2: Proximal T cell receptor signaling. Antigen presentation by the MHC class II complex triggers 
activation of CD4+ T cells. Upon TCR ligation, the Src family kinases FYN and LCK phosphorylate ITAM 
motifs (marked in yellow) within the CD3 subunits resulting in the activation of receptor proximal kinases. In 
turn, the adapter proteins LAT and SLP76 are phosphorylated and recruit several signaling mediators to 
stimulate activation of the transcription factors NFAT, AP-1 and NF-κB. Stimulation of the CD28 co-receptor 
further supports TCR-induced signaling. Abbreviations are explained in the main text. 
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To induce efficient T cell activation, stimulatory signals from the CD28 co-receptor are 
necessary. It has been suggested, that CD28 co-engagement supports T cell signaling by 
triggering activation of two pathways (Figure 2.2) (Schmitz and Krappmann, 2006; Schulze-
Luehrmann and Ghosh, 2006). On the one hand, the CD28 co-receptor associates with the p85 
regulatory subunit of PI3K. Upon ligand binding, PI3K is activated and converts PIP2 into 
PIP3 (phosphatidyl inositol 3,4,5-trisphosphate) serving as a docking site for several 
pleckstrin homology (PH) domain-containing proteins, including phosphoinositide-dependent 
kinase 1 (PDK1), its target protein kinase B (PKB or AKT), and the GEF VAV1 (Schulze-
Luehrmann and Ghosh, 2006; Smith-Garvin et al., 2009). Binding of PDK1 to PIP3 activates 
PDK1 and induces its binding to PKCθ and CARMA1 at the immunological synapse, thereby 
prompting PKCθ activation, CBM complex assembly and NF-κB signaling (see section 2.3) 
(Park et al., 2009). The second pathway that is induced upon CD28 co-receptor ligation relies 
on GRB2 and VAV1 (Schulze-Luehrmann and Ghosh, 2006; Thaker et al., 2015). Via GRB2, 
VAV1 is recruited to the CD28 co-receptor and activated inducing signaling in many 
directions: VAV1 drives actin cytoskeleton reorganization, supports activation of NF-κB via 
PKCθ, and is also involved in NFAT, AP-1 and JNK (c-Jun N-terminal kinases) signaling 
(Schmitz and Krappmann, 2006; Schulze-Luehrmann and Ghosh, 2006; Thaker et al., 2015). 
Collectively, CD28 co-receptor signaling augments TCR signals (Park et al., 2009; Schulze-
Luehrmann and Ghosh, 2006). 
2.2.3 NFAT, ERK and AP-1 activation 
Activation of NFAT is regulated by calcium (Ca2+) release into the cytosol in response to IP3 
binding to receptors on the endoplasmatic reticulum (Macian, 2005). Increased cytosolic Ca2+ 
levels promote activation of the Ca2+-dependent phosphatase calcineurin, which in turn 
dephosphorylates cytosolic NFAT proteins, enabling their nuclear translocation (Figure 2.2) 
(Padhan and Varma, 2010). NFAT activation exclusively requires TCR ligation without 
CD28 co-stimulation. Upon TCR ligation without a co-stimulus, active NFAT proteins 
promote the expression of anergy-inducing genes. However, in the case of TCR/CD28 co-
stimulation, NFAT can interact with other transcription factors such as AP-1 to induce 
transcription of target genes that play a major role in T cell proliferation and differentiation 
(Heissmeyer et al., 2004; Macian, 2005).  
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T cell activation also triggers activation of the MAPK (mitogen activated protein kinase) 
ERK1/2, which is facilitated by Ras (Figure 2.2) (Kortum et al., 2013; Smith-Garvin et al., 
2009). Two GEFs, DAG-dependent RasGRP (Ras guanyl nucleotide-releasing protein) and 
SOS are required to convert Ras-GDP into Ras-GTP resulting in Ras activation (Kortum et 
al., 2013; Stone, 2011). In turn, Ras activates the serine-threonine kinase RAF-1, which 
triggers a protein kinase cascade leading to activation of the MAPKs ERK1/2 (Smith-Garvin 
et al., 2009). Specifically, the MAPK activation cascade relies on the activation of MAPK 
kinase kinases (MAP3Ks) such as RAF-1 that stimulates MAPK kinases (MAP2Ks or 
MKKs), which in turn activate MAPKs. Finally, MAPKs drive activation of the transcription 
factor AP-1 (Chuang et al., 2000; Smith-Garvin et al., 2009). AP-1 represents a large family 
of dimeric protein complexes mainly composed of members of the Fos or Jun family (Padhan 
and Varma, 2010; Shaulian and Karin, 2002). Activation of ERK1/2 causes induction of  
c-Fos mRNA and elevates c-Fos protein levels (Padhan and Varma, 2010). c-Fos binds to pre-
existing Jun proteins (mainly c-Jun) in the nucleus to form the transcription factor AP-1. AP-1 
regulates a broad range of cellular processes as cell proliferation, death, survival and 
differentiation (Padhan and Varma, 2010; Shaulian and Karin, 2002; Zhang and Liu, 2002).  
2.3 CARMA1, BCL10 and MALT1 facilitate canonical NF-κB and JNK 
signaling 
Activation of the TCR by antigenic ligands stimulates activation of PKCθ, which initiates 
formation of a high-molecular weight complex consisting of CARMA1, BCL10, and MALT1 
(CBM complex). The CBM signalosome channels upstream TCR/CD28 signaling to 
canonical NF-κB signaling and JNK activation (Blonska and Lin, 2009; Wegener and 
Krappmann, 2007). Mice with a specific deletion in CARMA1, BCL10 or MALT1 fail to 
activate NF-κB and to induce a productive immune response, indicating the necessity of 
theses signaling mediators in lymphocyte activation (Thome et al., 2010). 
2.3.1 The transcription factor NF-κB 
The transcription factor NF-κB plays a key role in the immune system, as its activation 
promotes immune and inflammatory responses, drives cell survival and proliferation, and thus 
contributes to the development and the maintenance of the immune system (Hayden and 
Ghosh, 2012; Oeckinghaus and Ghosh, 2009). Due to its broad physiological role, it is not 
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surprising that deregulation of NF-κB signaling contributes to the development of severe 
diseases such as immunodeficiency, autoimmunity, and cancer (Oeckinghaus and Ghosh, 
2009). 
In mammals, the NF-κB transcription factor family consists of five members: c-Rel, p65 
(RelA), RelB, p50 (NF-κB1), and p52 (NF-κB2), which are able to form homo- or 
heterodimers with distinct transcriptional activity (Gerondakis et al., 2014; Oeckinghaus and 
Ghosh, 2009). All members contain an N-terminal Rel-homology domain (RHD), which 
harbors sequence elements enabling dimerization, binding to inhibitory IκB (inhibitor of NF-
κB) proteins, as well as nuclear translocation and the recognition of DNA elements 
(Gerondakis et al., 2014; Schulze-Luehrmann and Ghosh, 2006). However, only the Rel 
proteins p65 (RelA), c-Rel and RelB possess a conserved transactivation domain (TAD) in the 
C-terminus, allowing them to initiate transcription. In resting cells, NF-κB is maintained in an 
inactive state in the cytosol by the binding of cytosolic inhibitory IκB proteins such as IκBα, 
IκBβ, and IκBε (Gerondakis et al., 2014; Gilmore, 2006; Hayden and Ghosh, 2012). These 
inhibitory proteins contain multiple ankyrin repeats mediating interaction with the RHD 
domain of NF-κB proteins and thereby masking the nuclear localization sequence (NLS) and 
DNA binding regions (Gerondakis et al., 2014; Oeckinghaus and Ghosh, 2009). NF-κB 
activation requires stimulus-induced IκB degradation allowing NF-κB nuclear translocation 
and concomitant target gene expression (Oeckinghaus and Ghosh, 2009). Active NF-κB 
promotes re-synthesis of IκB proteins such as IκBα representing a negative regulatory 
feedback mechanism to limit the NF-κB response (Oeckinghaus and Ghosh, 2009). As IκBα 
harbors a nuclear export sequence (NES), newly synthesized IκBα removes NF-κB dimers 
from DNA, masks their NLS and supports their export into the cytosol (Karin, 1999).  
In general, the NF-κB pathway can be divided into the classical or canonical pathway, and the 
alternative or non-canonical NF-κB signaling pathway (Hayden and Ghosh, 2012). Canonical 
signaling depends on p50, p65 (RelA), and c-Rel, whereas the non-canonical pathway 
promotes nuclear translocation of p52-RelB dimers (Gerondakis et al., 2014). Stimulation of 
the TCR by antigenic ligands primarily drives canonical NF-κB signaling, which relies on 
activation of the IκB kinase (IKK) complex consisting of the catalytic subunits IKKα (IKK1) 
and IKKβ (IKK2) and the regulatory component NEMO (NF-κB essential modulator)/IKKγ 
(Hinz and Scheidereit, 2014). 
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2.3.2 CBM complex components 
TCR-induced IKK activation specifically requires formation of the CBM complex consisting 
of the molecular scaffold protein CARMA1, the adaptor BCL10, and its constitutive binding 
partner MALT1 that contains proteolytic activity (Thome et al., 2010).  
CARMA1 (also known as CARD11 or Bimp3) was initially identified in a bioinformatic 
approach as a 130 kDa CARD containing scaffold protein (Bertin et al., 2001; Gaide et al., 
2001; McAllister-Lucas et al., 2001). It is one of three members of the CARMA family, 
including CARMA1, CARMA2 and CARMA3, which share high sequence and structure 
homology, but differ in their tissue expression pattern. In contrast to CARMA2 and 
CARMA3, CARMA1 is the only CARMA protein expressed in hematopoietic tissues 
(Blonska and Lin, 2011). CARMA1 contains several protein-protein interaction domains 
(Figure 2.3). It encodes an N-terminal CARD domain, which serves as a protein-protein 
interaction site (Hara and Saito, 2009; Kao et al., 2015). Via heterotypic CARD-CARD 
interactions, CARMA1 recruits the adapter protein BCL10 upon TCR stimulation (Gaide et 
al., 2002; Li et al., 2012). The CARD domain is followed by the coiled-coil (CC) domain and 
the linker region (Thome et al., 2010). The CC domain is critical for signal activation by 
facilitating CARMA1 oligomerization, but it also stabilizes a closed, inactive conformation of 
CARMA1 (see below), which is underscored by the finding that various mutations in the CC 
region promote constitutive NF-κB signaling (Lamason et al., 2010; Lenz et al., 2008; Tanner 
et al., 2007). The linker region contains multiple phosphorylation sites, which are necessary 
for CBM complex formation upon TCR stimulation (Matsumoto et al., 2005; Sommer et al., 
2005). In resting cells, the linker acts as a repressor by interacting with CARMA1 CARD-CC 
keeping CARMA1 in a closed, inactive conformation (McCully and Pomerantz, 2008). 
Furthermore, CARMA1 contains a C-terminal MAGUK domain, consisting of a PDZ (PSD-
95/DLG/ZO1 homology), a SH3 (Src homology 3), and a GUK (guanylate kinase) domain 
(Funke et al., 2005). The MAGUK mediates membrane association, which is crucial for the 
recruitment of CARMA1 to the immunological synapse (Hara et al., 2004; Wang et al., 2004). 
On top of this, intra- or intermolecular interactions of the SH3 and GUK domains facilitate 
CARMA1 multimerization, required for CBM complex assembly (Hara et al., 2015).   
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Figure 2.3: Molecular structure of CARMA1, BCL10, and MALT1. The scaffold protein CARMA1 contains an 
N-terminal CARD domain that mediates recruitment of the adapter protein BCL10 via heterotypic CARD-
CARD interactions. In turn, BCL10 is constitutively associated with the N-terminus of the paracaspase MALT1. 
CARD (caspase-recruitment domain), CC (coiled-coil), PDZ (PSD-95/DLG/ZO1 homology), SH3 (Src 
homology 3), GUK (guanylate kinase), S/T (Ser/Thr)-rich domain, DD (death domain), Ig (immunoglobulin)-
like domains, T6BM1/2/3 (TRAF6 binding motifs 1/2/3). 
The adapter protein BCL10 (27 kDa) was originally identified as a recurrent t(1;14)(p22;q32) 
translocation in MALT lymphoma leading to its overexpression (Willis et al., 1999). It 
consists of an N-terminal CARD domain, which binds to CARMA1 CARD upon stimulation 
(Figure 2.3) (Thome et al., 2010). In its monomeric form, BCL10-CARD contains a highly 
dynamic structure, which tends to form stable filaments especially in the presence of 
CARMA1 (Bertin et al., 2001; Guiet and Vito, 2000). While BCL10 binds to CARMA1 only 
upon stimulation, it is constitutively associated with MALT1 and this interaction is mediated 
by the BCL10 CARD and adjacent residues (Langel et al., 2008; Wegener et al., 2006). 
Moreover, BCL10 harbors an unstructured Ser/Thr-rich region in the C-terminus, which 
stabilizes BCL10-MALT1 interaction and can be modulated by phosphorylation (Wegener et 
al., 2006). Collectively, BCL10 serves as a critical bridging factor within the CBM complex. 
MALT1 was first identified from the recurrent translocation t(11;18)(q21;q21) in MALT 
lymphoma that creates the oncogenic fusion protein cIAP2 (cellular inhibitor of apoptosis 2)-
MALT1 (also API2-MALT1), consisting of the N-terminal domain of cIAP2 and the  
C-terminal paracaspase-Ig3 domain of MALT1 (Rosebeck et al., 2016). MALT1 is a 92 kDa 
protein harboring an N-terminal death domain (DD), three immunoglobulin-like domains (Ig-
like domains), and a paracaspase (caspase-like) domain (Figure 2.3). In addition, MALT1 
contains three binding motifs for the E3 ligase TRAF6 (tumor-necrosis factor associated 
receptor-associated factor 6) (T6BM1/2/3) (Noels et al., 2007; Sun et al., 2004). The 
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interaction between MALT1 and BCL10 relies on the N-terminal DD and the Ig1 and Ig2 
domains within MALT1 (Langel et al., 2008; Lucas et al., 2001).  
MALT1 is a protease, whose activity is induced upon CBM complex assembly (Coornaert et 
al., 2008; Rebeaud et al., 2008). In mammals, MALT1 protease shares high sequence 
homology to caspases (Hulpiau et al., 2015; Uren et al., 2000). MALT1 is a cysteine protease 
harboring two conserved residues, Cys464 and His415, within the caspase-like domain 
mediating its catalytic activity (Wiesmann et al., 2012; Yu et al., 2011). However, while 
caspases exhibit their enzymatic activity by cleaving their substrates after Asp residues, 
MALT1 is an Arg-specific protease revealing that MALT1 is more closely related to 
Arg/Lys-specific metacaspases found in plants, fungi and parasites (Hachmann et al., 2012; 
Uren et al., 2000; Vercammen et al., 2007). The exact mechanism how MALT1 is activated 
within the CBM complex upon antigen-receptor stimulation is incompletely understood. 
However, resolution of the paracaspase structure has provided new insights into the functional 
mechanism of MALT1 activation and, based on this, a two-step activation model has been 
suggested (Wiesmann et al., 2012; Yu et al., 2011). In its unliganded form, MALT1 protease 
is in a dimeric but inactive state. The C-terminal Ig3 domain exerts an auto-inhibitory 
function by folding back to the caspase-like domain, preventing formation of the catalytic 
machinery and thus the processing of substrates (Wiesmann et al., 2012). Upon substrate 
binding, the paracaspase-Ig3 domain undergoes conformational changes resulting in the 
release of Ig3-mediated auto-inhibition of the caspase-like domain (Staal and Beyaert, 2012; 
Wiesmann et al., 2012; Yu et al., 2011). In contrast to many caspases, MALT1 activation 
does not require an auto-proteolytic cleavage reaction and is only active in its full-length form 
(Eitelhuber et al., 2015; Hachmann et al., 2015). Interestingly, monoubiquitination of Lys644 
within the Ig3 domain has been reported to induce MALT1 activity upon T cell stimulation, 
which further underscores the relevance of the Ig3 domain for MALT1 activation (Pelzer et 
al., 2013). 
2.3.3 CBM assembly triggers NF-κB and JNK signaling 
Upon T cell co-stimulation, CARMA1, BCL10 and MALT1 assemble into a high-order 
filamentous signaling complex (Oeckinghaus et al., 2007; Qiao et al., 2013). Initial CBM 
complex assembly requires structural rearrangements within CARMA1. In resting cells, 
CARMA1 adopts a closed, inactive conformation mediated by intra-molecular interactions 
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between the linker and the CARD-CC domains (Jattani et al., 2016; McCully and Pomerantz, 
2008). Following T cell stimulation, CARMA1 is recruited to the immunological synapse and 
is phosphorylated on Ser552 and Ser645 by PKCθ causing a shift from its closed (auto-
inhibitory) to its open (active) conformation (Matsumoto et al., 2005; Sommer et al., 2005). In 
its open conformation, CARMA1 recruits pre-assembled BCL10-MALT1, which induces the 
formation of BCL10 filaments and the activation of MALT1 protease (Qiao et al., 2013). The 
critical role of Ser645 phosphorylation for CBM assembly is underscored by the identification 
of the phosphatase, PP2A (protein phosphatase 2A) that counteracts CARMA1 
phosphorylation, CBM complex formation and NF-κB activation (Eitelhuber et al., 2011). 
PKCθ-mediated phosphorylation of CARMA1 is essential for initial CBM assembly, but it is 
not sufficient to trigger robust downstream signaling. A number of other phosphorylation 
events on CARMA1 by numerous protein kinases are required for downstream signaling. For 
example, CARMA1 is also phosphorylated by HPK1 (hematopoietic progenitor kinase1), 
AKT, and CamKII (calmodulin-dependent protein kinase II) promoting enhanced CARMA1-
induced signaling (Brenner et al., 2009; Cheng et al., 2014; Ishiguro et al., 2006). 
As well as providing an activating function, phosphorylation of CARMA1 can also promote 
CBM disassembly and signaling termination (Bidere et al., 2009; Moreno-Garcia et al., 2009). 
In addition, phosphorylation and ubiquitination of BCL10 dampens CBM activity (Ishiguro et 
al., 2007; Lobry et al., 2007; Scharschmidt et al., 2004; Wegener et al., 2006; Zeng et al., 
2007). For example, IKKβ phosphorylates a stretch of Ser residues (134/136/138/141/145) in 
the C-terminus of BCL10 and thereby disturbs its interaction with MALT1, and impairs NF-
κB signaling and ensuing T cell activation (Wegener et al., 2006). Thus, TCR ligation does 
not only promote CBM assembly, but also initiates several negative feedback mechanisms to 
prevent aberrant T cell signaling. 
Assembly of the CBM complex serves as a critical step for activation of the IKK complex 
(Figure 2.4) (Thome et al., 2010). Recruitment of the IKK complex to the CBM signalosome 
is facilitated by the attachment of K63-linked polyubiquitin chains to BCL10 and MALT1, 
which are specifically recognized by the polyubiquitin binding motif of NEMO (Oeckinghaus 
et al., 2007; Wu and Ashwell, 2008). In line with this, removal of MALT1 ubiquitin chains by 
the deubiquitinase A20 (also known as tumor necrosis factor α-induced protein 3 (TNFAIP3)) 
counteracts T cell activation (Duwel et al., 2009). Initiation of K63-linked ubiquitination 
events mainly relies on the scaffolding function of MALT1, as it recruits the E3 ligase 
TRAF6 through its TRAF6 binding motifs (Oeckinghaus et al., 2007). Subsequently, TRAF6 
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oligomerizes and becomes activated, which results in the conjugation of K63-linked 
polyubiquitin chains to MALT1 and NEMO (Oeckinghaus et al., 2007; Shambharkar et al., 
2007). In addition, formation of Met1-linked ubiquitin chains on BCL10 by the linear 
ubiquitin chain assembly complex (LUBAC) may contribute to IKK recruitment and thus 
canonical NF-κB signaling (Satpathy et al., 2015). The LUBAC consists of HOIL1 (heme-
oxidized IRP2 ubiquitin ligase 1), the catalytic subunit HOIP (HOIL1-interacting protein; also 
known as RNF31), and SHARPIN (SHANK-associated RH domain interacting protein) 
(Tokunaga and Iwai, 2012). The association of LUBAC with the CBM complex contributes to 
canonical NF-κB signaling (Dubois et al., 2014; Tokunaga and Iwai, 2012). 
 
Figure 2.4: NF-κB and JNK activation by the CBM complex. TCR ligation activates PKCθ, which in turn 
phosphorylates CARMA1 triggering CBM complex assembly. MALT1 recruits the E3 ligase TRAF6, inducing 
ubiquitination of MALT1 and NEMO. The linear ubiquitin chain assembly complex (LUBAC) supports NF-κB 
signaling by associating with the CBM complex and potentially by conjugating linear ubiquitin chains to 
BCL10. Finally, overall polyubiquitination recruits the IKK and the TAB2/3-TAK1 complex resulting in IKKβ 
phosphorylation. Active IKKβ phosphorylates IκBα and triggers its ubiquitin-dependent proteasomal 
degradation, which enables translocation of canonical NF-κB members into the nucleus to promote target gene 
expression. TAK1 also activates MKK7 to phosphorylate JNK, which contributes to c-Jun accumulation and 
thus AP-1 activation. Abbreviations are explained in the main text. 
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IKK complex activation depends on phosphorylation of two Ser residues (Ser177/181) within 
IKKβ (Hinz and Scheidereit, 2014). IKKβ phosphorylation is induced by TAK1 (transforming 
growth factor β activated kinase-1), which is recruited to ubiquitinated BCL10, MALT1 and 
NEMO via the ubiquitin-binding domains of its adapters TAB2 and TAB3 (TAK1 binding 
protein 2/3) (Figure 2.4) (Oeckinghaus et al., 2007; Sun et al., 2004). In turn, the activated 
IKK complex phosphorylates inhibitory IκB proteins such as IκBα on Ser32 and Ser36 
(Israel, 2010; Oeckinghaus and Ghosh, 2009). Phosphorylated IκBα is recognized by β-
transducin repeat containing protein (β-TrCP), which serves as a subunit of the SCF (Skp1-
Cullin-Roc1/Rbx/Hrt1-F-box) E3 ligase complex. SCFβ-TrCP induces K48-linked 
ubiquitination of phosphorylated IκBα leading to its proteasomal degradation and a 
concomitant release of NF-κB dimers, most commonly p50:p65 heterodimers, which then 
translocate into the nucleus to promote target gene expression (Hayden and Ghosh, 2012). 
Canonical NF-κB signaling controls inflammatory responses, proliferation and survival and 
therefore its activity must be transient and properly controlled, for example by the NF-κB-
dependent induction of the negative regulator IκBα (Shih et al., 2011). 
Upon TCR/CD28 stimulation, CBM complex formation also promotes activation of the JNK 
pathway (Figure 2.4). The JNK family is a subfamily of MAPKs and consists of three 
proteins (JNK1, JNK2 and JNK3), which are all expressed in two different isoforms (46 kDa 
and 54 kDa) and activate a number of transcription factors, including AP-1 (Johnson and 
Lapadat, 2002). Whereas JNK3 expression is restricted to the brain, heart, and testis, JNK1 
and JNK2 are ubiquitously expressed and play important roles in T cell activation (Blonska 
and Lin, 2009). JNKs phosphorylate c-Jun and drive phosphorylation of the AP-1 family 
member ATF2 (activating transcription factor 2), resulting in c-Jun induction and thus 
increased AP-1 levels (Padhan and Varma, 2010; Shaulian and Karin, 2002). Activation of 
JNK depends on phosphorylation by the upstream kinases MKK4/MKK7 (Liu and Lin, 2005; 
Zarubin and Han, 2005). CARMA1-deficient T cells exhibit defects in JNK signaling and it 
has been suggested that the CBM complex facilitates the recruitment of kinases mediating 
JNK phosphorylation and activation (Hara et al., 2003; Jun et al., 2003). Indeed, it has been 
reported that the IKK activating kinase TAK1 serves as an upstream kinase of JNK. TCR 
stimulation triggers the recruitment of TAK1 to CARMA1-activated BCL10 oligomers, 
which are also associated with the MAP2K MKK7 and JNK2 facilitating JNK2 activation and 
concomitant c-Jun accumulation (Blonska and Lin, 2009; Blonska et al., 2007). In line with 
this, MALT1 is also required for optimal JNK signaling in T cells (Gewies et al., 2014; 
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Jaworski et al., 2014). Thus, CARMA1, BCL10 and MALT1 not only activate IKK/NF‐κB 
signaling, but also mediate crosstalk to the JNK pathway. In addition to JNK activation, CBM 
complex formation also supports activation of the MAPK p38 (see Figure 2.2), but the 
underlying mechanisms are not well defined. 
2.3.4 MALT1 in T cell activation 
MALT1 plays a crucial role in lymphocyte activation. This is evidenced by the fact, that  
T lymphocytes from MALT1-deficient mice display impaired TCR-induced NF-κB signaling 
and concomitant activation, proliferation, and cytokine responses (Ruefli-Brasse et al., 2003; 
Ruland et al., 2003). This is recapitulated in humans, where patients with a genetic MALT1 
defect show abrogated NF-κB activation and T cell proliferation (Jabara et al., 2013; 
McKinnon et al., 2014; Punwani et al., 2015). MALT1 also adopts a key role in T cell fate 
decisions (Brustle et al., 2015; Brustle et al., 2012). 
In an attempt to further dissect the functions of MALT1, in particular its scaffolding and 
paracaspase activities in lymphocytes, mice expressing paracaspase mutant MALT1 (Malt1PM 
mice) have been generated (Bornancin et al., 2015; Gewies et al., 2014; Jaworski et al., 2014; 
Yu et al., 2015). MALT1 protease inactivation resulted in reduced T cell proliferation and  
IL-2 secretion, revealing that MALT1 protease supports optimal T cell activation. Moreover, 
MALT1 knockout mice show severe defects in TH17 cell differentiation, demonstrating the 
importance of MALT1 in T cell fate decisions (Brustle et al., 2012). Analysis of MALT1 
paracaspase mutant mice revealed that the proteolytic activity of MALT1 is required for the 
generation of TH17 cells (Bornancin et al., 2015). Consequently, both MALT1-deficient and 
MALT1 paracaspase mutant mice were protected from TH17-driven experimentally induced 
autoimmune encephalomyelitis (EAE) suggesting that MALT1 paracaspase might serve as a 
promising target for the treatment of autoimmune diseases (Bornancin et al., 2015; Brustle et 
al., 2012; Gewies et al., 2014; Jaworski et al., 2014). In addition to the generation of effector 
T cells such as TH17 cells, the development of Treg cells also relies on MALT1 and in 
particular on its paracaspase activity (Bornancin et al., 2015; Brustle et al., 2015; Gewies et 
al., 2014; Jaworski et al., 2014). MALT1 protease dead mice developed severe autoimmune 
diseases as the residual lymphocyte activation by MALT1 scaffolding function can no longer 
be counterbalanced due to a lack of Treg cells. It thus becomes clear that MALT1 plays a dual 
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role, functioning not only to promote immune activation, but also to regulate immune 
homeostasis.  
With the discovery of MALT1 protease, several MALT1 substrates have been identified 
(Figure 2.5). MALT1 cleaves its substrates after Arg and the consensus cleavage motif 
LXP/SR↓G has been suggested (Klein et al., 2015). By cleaving a subset of regulators 
involved in NF-κB and JNK signaling, it was initially believed that MALT1 paracaspase 
promotes optimal T cell activation by modulating TCR-induced signaling pathways. For 
example, the deubiquitinase A20 negatively regulates NF-κB activation by removing K63-
linked polyubiquitin chains from MALT1 and is cleaved by MALT1 upon TCR ligation 
(Coornaert et al., 2008; Duwel et al., 2009). Moreover, MALT1-directed cleavage of the non-
canonical NF-κB family member RelB appears to strengthen canonical NF-κB activation as 
inactivated RelB can no longer interfere with RelA or c-Rel DNA binding (Hailfinger et al., 
2011). MALT1 not only inactivates negative regulators of NF-κB signaling, but also cleaves 
positive regulatory factors, such as the LUBAC subunit HOIL-1, upon T cell stimulation 
(Douanne et al., 2016; Elton et al., 2015; Klein et al., 2015). In addition, MALT1-mediated 
inactivation of the deubiquitinase CYLD (cylindromatosis) results in enhanced JNK signaling 
in Jurkat T cells (Staal et al., 2011). However, data from MALT1 paracaspase mutant mice 
demonstrate that MALT1 protease activity has only limited effects on TCR-driven IKK/NF-
κB activation and is not required for JNK signaling (Gewies et al., 2014; Jaworski et al., 
2014). Of note, MALT1 also cleaves itself (auto-cleavage) as well as its constitutive binding 
partner BCL10 (Baens et al., 2014; Rebeaud et al., 2008). Although it has been demonstrated 
that BCL10 cleavage supports T cell adhesion to fibronectin, the relevance of both MALT1 
auto-cleavage and BCL10 inactivation for lymphocyte activation remains unclear. 
The identification of the ribonuclease Regnase-1 (also known as Zcc3h12a and MCPIP1) and 
the RNA-binding proteins Roquin-1 and Roquin-2 as MALT1 substrates has revealed new 
insights into the biological function of MALT1 paracaspase (Figure 2.5) (Jeltsch et al., 2014; 
Uehata et al., 2013). Regnase-1, Roquin-1, and Roquin-2 destabilize numerous pro-
inflammatory transcripts to prevent aberrant T cell activation (Leppek et al., 2013; Matsushita 
et al., 2009; Uehata et al., 2013). Consequently, MALT1-directed cleavage of Regnase-1 and 
Roquins resulted in stabilization of pro-inflammatory transcripts including Il2, Iκbns, and 
IκBζ, which are crucial for the generation of TH17 cells (Jeltsch et al., 2014; Uehata et al., 
2013). Thus, in contrast to MALT1 scaffolding function, MALT1 paracaspase mainly has a 
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modulatory role: it contributes to optimal T cell activation and differentiation by regulating 
post-transcriptional gene expression.  
Since constitutive MALT1 activity is associated with autoimmune diseases and lymphoma, 
many efforts have been undertaken to develop specific MALT1 inhibitors. Small molecule 
inhibitors, such as the phenothiazine-derivatives Mepazine and Thioridazine represent 
promising candidates for pharmacologic inhibition of MALT1 protease as they reportedly 
attenuate EAE induction and have shown promising effects in preclinical lymphoma models 
(Mc Guire et al., 2014; Nagel et al., 2012). 
 
Figure 2.5: MALT1 protease promotes optimal T cell activation. Upon TCR stimulation, MALT1 paracaspase is 
activated, which cleaves several substrates such as BCL10, MALT1 itself, HOIL1, CYLD, A20, RelB and the 
RNA regulators Regnase-1 and Roquin. MALT1 paracaspase activity thereby regulates NF-κB and JNK 
signaling, cell adhesion, as well as mRNA stability. Abbreviations are explained in the main text. 
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2.4 Alternative splicing 
Alternative splicing serves as a crucial mechanism to regulate gene expression as it generates 
multiple distinct mRNAs from a given gene and thus enriches the coding capacity of the 
genome (Martinez and Lynch, 2013; Tazi et al., 2009). About 95 % of human multi-exon 
genes are affected by alternative splicing (Pan et al., 2008; Wang et al., 2008). Several studies 
have identified changes in alternative splicing during T cell activation that modulate T cell 
antigen responses (Ip et al., 2007; Martinez et al., 2012; Sandberg et al., 2008; Wu et al., 
2008).  
2.4.1 General concept of alternative splicing 
Pre-mRNA splicing is essential for the expression of genes in eukaryotes. The basic splicing 
process, performed by a macromolecular ribonucleoprotein complex, the so-called 
spliceosome, involves the removal of non-coding introns and the concomitant fusion of exons 
(Black, 2003; Chen and Manley, 2009; Matlin et al., 2005; Wahl et al., 2009). The 
spliceosome consists of five small nuclear ribonucleoprotein particles (snRNPs), U1, U2, U4, 
U5, and U6 as well as auxiliary factors like U2AF (U2 auxiliary factor), and recognizes pre-
mRNA sequences positioned at the exon-intron boundaries: the 5’ splice site (5’ SS), the 3’ 
splice site (3’ SS), branch point sequences (BPS), and the polypyrimidine tract (PPT) (Figure 
2.6) (Wahl et al., 2009). The 5’ end of an intron harbors the 5’ SS and is defined by the 
consensus sequence CAG↓GURAGU (where R is A or G), whereas the 3’ end is 
characterized by BPS, PPT and the 3’ SS AG↓G (Busch and Hertel, 2012; De Conti et al., 
2013). Spliceosome binding to the splice sites is facilitated by base-pair interactions between 
the snRNA of the snRNPs and the RNA sequences of the splice sites (Martinez and Lynch, 
2013; Wahl et al., 2009). Upon recognition of the splicing signals, the spliceosome catalyzes 
the splicing reaction resulting in exon ligation (De Conti et al., 2013). 
Alternative splicing refers to different combinations of exon joining, resulting in the 
generation of multiple mRNA variants that encode proteins with distinct and sometimes even 
opposing functions (Busch and Hertel, 2012; Kornblihtt et al., 2013; Lynch, 2004). The most 
common type of alternative splicing involves alternative inclusion or exclusion of an internal 
“cassette” exon (Martinez and Lynch, 2013). A further form represents alternative splice site 
usage (alternative 5’ SS or 3’ SS), which occurs when two or more splice sites are located 
near the end of one exon (Keren et al., 2010). More rare subtypes of alternative splicing 
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Figure 2.6: Regulatory sequences and factors in alternative splicing. Exons are defined by conserved sequences 
located at the exon-intron boundaries: the 5’ splice site (SS), the 3’ SS, branch point sequences (BPS) and the 
polypyrimidine tract (PPT), which are recognized by components of the spliceosome (depicted in grey). Binding 
of trans-acting factors (SR and hnRNP proteins) to cis-regulatory sequences (ESE, ESS, ISE, ISS) within the 
pre-mRNA either enhances or inhibits splice site recognition and usage. ESE (exonic splicing enhancer), ESS 
(exonic splicing silencer), ISE (intronic splicing enhancer), ISS (intronic splicing silencer). 
include mutually exclusive exons, intron retention, alternative promoter usage, and alternative 
polyadenylation (Keren et al., 2010; Martinez and Lynch, 2013; Pohl et al., 2013). 
Exon definition, meaning which 5’ SS and 3’ SS are selected by the spliceosome, depends on 
the strength of competing splice sites (Douglas and Wood, 2011; Wahl et al., 2009). Splice 
site strength is defined by how well a sequence matches the consensus sequence. Whereas 
strong splice sites generally lead to constitutive splicing, weak splice sites are thought to be 
less efficiently recognized (Kornblihtt et al., 2013; Lim and Burge, 2001; Roca et al., 2005). 
However, most mammalian splice sites are rather weak and thus cannot account for correct 
exon recognition. Therefore additional sequence elements are required to enable proper splice 
site selection (Wahl et al., 2009). Those cis-regulatory elements include sequences within 
exons, such as exonic splicing enhancers (ESEs) and exonic splicing silencers (ESSs), as well 
as intronic sequences like intronic splicing enhancers (ISEs) and intronic splicing silencers 
(ISSs) (Figure 2.6) (Martinez and Lynch, 2013). These elements are bound by trans-acting 
factors such as Ser/Arg-rich (SR) proteins and heterogeneous nuclear ribonucleoproteins 
(hnRNPs), which either positively or negatively regulate exon inclusion (Busch and Hertel, 
2012; Kornblihtt et al., 2013). SR proteins usually bind to enhancer elements like ESEs via 
their RNA recognition motifs (RRMs). Due to their Arg/Ser (RS) domain, SR proteins are 
able to interact with other splicing factors and to facilitate the recruitment of the splicing 
machinery to the splice sites, such as U1 snRNP to 5’ SS and U2 snRNP to the 3’ SS. Thus, 
SR proteins mainly enhance exon recognition and thus promote exon inclusion (Busch and 
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Hertel, 2012; Douglas and Wood, 2011). hnRNP proteins also contain a RNA binding 
domain, in most cases the RRM domain, to recognize certain pre-mRNA sequences. To 
interact with other protein regulators, most hnRNPs harbor Arg/Gly/Gly repeats (RGG boxes) 
and glycine-, acidic- or proline-rich domains (Busch and Hertel, 2012). hnRNPs preferentially 
associate with silencer sequences and thus act as splicing repressors (Chen and Manley, 2009; 
Wahl et al., 2009). They exert their repressive function for example by preventing recruitment 
of snRNPs to the splice site (Zhu et al., 2001), by blocking snRNP interactions (Izquierdo et 
al., 2005; Sharma et al., 2005), or by looping out entire exons (Nasim et al., 2002). However, 
SR proteins can also function as splicing suppressors and hnRNP proteins can enhance 
splicing events (Martinez and Lynch, 2013). Of note, most transcripts are bound by multiple 
SR, hnRNP, and other regulatory proteins, and the selection of an exon for splicing is 
determined by the balance between the competing factors (Martinez and Lynch, 2013).  
Alternative splicing can be modulated in many ways. Epigenetic factors, like chromatin 
structure and histone modifications, play a key function in regulating alternative splicing 
(Luco et al., 2011). More recently, it was also revealed that splicing can occur co-
transcriptionally (Kornblihtt et al., 2013). Thereby, the pace of RNA polymerase II influences 
exon inclusion or exclusion (Shukla and Oberdoerffer, 2012). In addition, secondary 
structures like stem-loop structures in the transcript influence splice site selection (Douglas 
and Wood, 2011; Jin et al., 2011). Finally, alternative splicing depends on the expression and 
the activity of trans-acting factors, which can be modulated by external stimuli. Signaling 
pathways can alter subcellular localization, binding preferences to interaction partners, 
stability, and thus cellular expression levels of splicing factors (Douglas and Wood, 2011; 
Heyd and Lynch, 2011). In T cells, TCR signaling impacts on the function of numerous 
splicing factors and thus alters the pattern of alternative splicing.  
2.4.2 Alternative splicing in T cell activation 
Alternative splicing plays a crucial role for T cell-mediated immune responses, as many genes 
with known immunological functions undergo alternative splicing during T cell activation (Ip 
et al., 2007; Martinez et al., 2012). Alternative splicing regulates genes encoding cell surface 
receptors, cytokines, transcription regulators, RNA-processing molecules, and signaling 
molecules (Martinez and Lynch, 2013). Although numerous examples have been identified to 
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date, it remains largely unknown which specific factors regulate the alternative splicing 
events and how these factors are controlled by signaling. 
One well-investigated example of alternative splicing upon T cell activation is splicing of the 
transmembrane phosphatase CD45 (Hermiston et al., 2003). CD45 is involved in antigen-
receptor-mediated signaling and harbors three alternatively spliced exons (4, 5 and 6). The 
variable exons encode for segment elements that are heavily O-glycosylated in the CD45 
surface protein (Zikherman and Weiss, 2008). In resting cells, distinct CD45 isoforms with 
variable amounts of O-glycosylated segments are expressed. However, T cell activation 
drives skipping of all three exons and thus promotes an increase in the expression of the 
shortest isoform, which lacks the O-glycosylated domains (Hermiston et al., 2003; Zikherman 
and Weiss, 2008). Skipping of the segments allows CD45 homodimerization, which results in 
a reduction in CD45 phosphatase activity and a concomitant decrease in TCR-induced 
signaling (Martinez and Lynch, 2013). In resting cells, exclusion of the variable exons 4, 5 
and 6 can be facilitated by binding of the splicing factor hnRNP L to an activation responsive 
motif (ARS), which is part of silencer sequences located in exon 4 and 6 (Rothrock et al., 
2003; Rothrock et al., 2005; Tong et al., 2005). However, the massive increase in exon 
skipping upon T cell stimulation relies on the recruitment of hnRNP LL (Oberdoerffer et al., 
2008; Topp et al., 2008; Wu et al., 2008). Moreover, PTB-associated splicing factor (PSF) 
also contributes to TCR-induced CD45 exon repression (Heyd and Lynch, 2010). 
Collectively, multiple splicing factors cooperate to fine tune CD45 function and thus T cell 
signaling strength.   
In addition to CD45, a number of other immune regulators are also alternatively spliced upon 
T cell activation. For example, TCR-induced splicing of the JNK kinase MKK7 serves a 
positive feedback loop to increase JNK activity and concomitant T cell activation (Martinez et 
al., 2015). In addition, the common-γ chain (γc or CD132), which serves as the critical 
signaling unit for cytokine receptors like the IL-2 receptor, undergoes alternative splicing in 
response to T cell activation, which results in the generation of a soluble γc splice isoform 
that counteracts cytokine signaling, but enhances TH17 responses (Hong et al., 2014). In 
summary, TCR-induced alternative splicing modulates T cell activation and also impacts on  
T cell fate decisions to facilitate optimal immune responses. 
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2.5 Aims of the study     
Alternative splicing is a critical mechanism to control T cell functions in immune responses. 
Global analysis has revealed widespread alterations in the splicing pattern of genes with 
known functions in immune responses. Although alternative splicing of several immune 
regulators has been reported, little is known about alternative splicing of signaling mediators 
and its impact on T cell signaling, activation, and differentiation.    
MALT1 paracaspase is a central regulator in adaptive immune responses and thus plays a key 
role in T cell activation. It acts as a scaffolding protein to activate canonical NF-κB signaling, 
but also contains proteolytic activity, which modulates T cell responses (Thome et al., 2010). 
Database analysis identified two alternative isoforms of MALT1, MALT1A and MALT1B, 
which only differ in inclusion or exclusion of exon7 that encodes for 11 amino acids (aa). 
However, neither the expression nor the functions of both MALT1 isoforms have been 
investigated so far. Moreover, nothing is known about the regulatory mechanisms controlling 
alternative exon7 splicing.  
The main aim of this study was to investigate the role of MALT1A and MALT1B in T cell 
responses and how the process of alternative MALT1 splicing is regulated. Initially, the 
expression levels of the two MALT1 isoform in T lymphocytes were determined. 
Furthermore, it was dissected whether exon7 inclusion modulates MALT1 scaffolding 
function and MALT1 paracaspase activity and thereby affects the activation of T cell 
signaling pathways. It was of high interest to elucidate the role of alternative MALT1 splicing 
in T cell activation and whether both isoforms differentially control T cell fate decisions. A 
further aim was to identify putative MALT1 splicing factors in a screening approach and to 
verify potential candidates in cellular assays. The study aimed to gain more insight into the 
mechanism of how splicing factors control alternative exon7 inclusion, and whether those 
regulators might modulate MALT1 isoform-mediated T cell responses. 
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3 Results 
3.1 Functional analysis of MALT1 isoforms 
As part of the CBM complex, MALT1 bridges upstream TCR signaling to canonical IKK/NF-
κB signaling (Thome et al., 2010). MALT1 acts as a scaffolding protein and recruits the E3 
ligase TRAF6, which conjugates K63-linked ubiquitin chains to the C-terminus of MALT1 
(Oeckinghaus et al., 2007). These ubiquitin chains serve as a docking site for the recruitment 
of NEMO and thus for the activation of the IKK complex (Oeckinghaus et al., 2007). Besides 
its scaffolding function, MALT1 also contains proteolytic activity that is induced upon TCR 
stimulation and modulates T cell activation and effector functions (Jaworski and Thome, 
2015).  
3.1.1 Evolutionary conservation of MALT1 isoforms 
Two alternative splice variants of MALT1 have been identified by analyzing mammalian 
transcriptome databases: MALT1A (824 aa) and MALT1B (813 aa) (Griesbach, 2012). Both 
isoforms harbor a death domain (DD) and two Ig-domains (Ig1 and Ig2) in the N-terminus as 
well as a paracaspase domain, a third Ig domain (Ig3), and two C-terminal TRAF6 binding 
motifs (T6BM2/3) (Figure 3.1). However, MALT1A and MALT1B differ in a short region of 
11 amino acids (aa 309-319), which is encoded by a 33 bp long exon7 located between the 
Ig2 and the paracaspase domain in human MALT1. 
Whereas exon7 inclusion leads to the expression of MALT1A (824 aa), its exclusion 
promotes expression of MALT1B (813 aa). Interestingly, exon7 encodes a third TRAF6 
binding motif (T6BM1), which was previously identified in the API2-MALT1 fusion 
oncoprotein comprising the N-terminus of API2 fused to the C-terminus of MALT1, and can 
induce constitutive NF-κB signaling in MALT lymphomas (Noels et al., 2007; Rosebeck et 
al., 2016). The exon7 amino acid sequence, the exon/intron boundaries, the T6BM1, and the 
expression of the two MALT1 isoforms are highly conserved among humans, chimpanzees, 
mice, and rats. This evolutionary and structural conservation in mammals implies a functional 
relevance of maintaining the expression of both MALT1A and MALT1B.  
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Figure 3.1: Domain structure and evolutionary conservation of MALT1 isoforms. MALT1A (824 aa) and 
MALT1B (813 aa) harbor two C-terminal TRAF6 binding motifs 2 and 3 (T6BM2/3), but only MALT1A 
contains an additional T6BM1 encoded by exon7. The exon7 sequence is highly conserved in mammals (shown 
below). T6BMs are highlighted in blue or orange and other protein domains are illustrated by grey boxes. DD 
(death domain), Ig (immunoglobulin)-like domains. 
3.1.2 Design of MALT1 mutants to analyze individual TRAF6 binding sites 
MALT1 harbors two functional C-terminal TRAF6 binding sites (T6BM2 and 3) (Sun et al., 
2004). A previous study from our group revealed that upon TCR stimulation, the E3 ligase 
TRAF6 binds to the C-terminal T6BMs and conjugates K63-linked ubiquitin chains to 
MALT1 (Oeckinghaus et al., 2007). The additional, highly conserved TRAF6 binding motif 
(T6BM1) within MALT1A was shown to be functional upon overexpression of MALT1 
together with BCL10 in HEK293 cells, but its role in T cell signaling remains unknown 
(Noels et al., 2007). Therefore, the aim was to investigate the contribution of the individual 
T6BMs, in particular T6BM1, for the activation of downstream T cell signaling pathways.  
First, several MALT1A and MALT1B constructs, mutated in one or more TRAF6 binding 
sites, were generated (Figure 3.2a). Specifically, the critical glutamates (E) within the T6BMs 
were mutated to alanine (A) (Sun et al., 2004). All constructs were fused to a C-terminal Flag-
Strep-Strep-tag (StrepTagII) for efficient precipitation, and cloned into a lentiviral transfer 
vector as lentiviruses integrate into the target cell genome and allow stable MALT1 
expression (see section 6.2.3). To eliminate interference of endogenous MALT1, we used 
MALT1-deficient Jurkat T cells (MALT1-/-), that had been generated by CRISPR/Cas9 in our 
laboratory (established by T. Gehring, AG Krappmann). After lentiviral transduction, 
infection efficiency of MALT1-deficient T cells was assessed by co-expression of the cell 
surface marker human (h)ΔCD2 and was > 90 % in each case (Figure 3.2b). Although hΔCD2  
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Figure 3.2: Generation of Jurkat T cell lines stably expressing MALT1 TRAF6 binding mutants. (a) Design and 
generation of MALT1 TRAF6 binding mutants. Different TRAF6 binding mutants were generated, containing 
glutamate (E) to alanine (A) point mutations within the T6BMs of MALT1A and MALT1B. (b,c) Stable 
expression of different MALT1 constructs in MALT1-deficient Jurkat T cells. MALT1-deficient Jurkat T cells 
generated by CRISPR/Cas9 were transduced with StrepTagII (mock) or MALT1-StrepTagII variants. (b) 
Infection efficiency was assessed by co-expression of the cell surface marker human (h)ΔCD2 using flow 
cytometry. Uninfected MALT1-deficient cells were used as a negative control. (c) Protein expression of 
MALT1-StrepTagII constructs was analyzed by Western Blot using a MALT1-specific antibody. β-ACTIN 
served as loading control. (MALT1-deficient Jurkat T cells were generated by T. Gehring, AG Krappmann). 
surface expression varied slightly between different constructs, Western Blot (WB) analysis 
revealed similar protein expression levels (Figure 3.2c).  
Initially, the potential of Jurkat wildtype (WT) and mock infected MALT1-deficient T cells to 
activate NF-κB and MAPK signaling was compared. Thereby, cells were stimulated with P/I 
(Phorbol 12-myristate 13-acetate (PMA)/Ionomycin), which bypasses TCR signaling as PMA 
directly stimulates PKCθ and Ionomycin triggers the influx of Ca2+. Consequently, IκBα is 
phosphorylated and concomitantly degraded by the proteasome, promoting NF-κB activation. 
As expected, MALT1-deficient T cells reconstituted with the vector alone (mock) were 
unable to activate NF-κB signaling (Figure 3.3). This was due to the lack of IκBα 
phosphorylation and subsequent degradation, preventing release and nuclear translocation of 
NF-κB. In addition, JNK and p38 phosphorylation were reduced in MALT1-deficient T cells, 
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Figure 3.3: MALT1 is required for NF-κB and JNK signaling. (a,b) Jurkat WT cells and mock reconstituted 
MALT1-deficient Jurkat T cells (MALT1-/-) were stimulated with P/I for the indicated time points. (a) MALT1 
expression, IκBα phosphorylation and degradation were analyzed by Western Blot using the indicated 
antibodies. NF-κB DNA binding was analyzed by EMSA. β-ACTIN and OCT1 served as loading controls for 
Western Blot and EMSA, respectively. (b) MAPK signaling was investigated using the indicated phospho-
specific and total protein antibodies. 
whereas ERK signaling was not affected (Figure 3.3). These results are in line with 
observations from Malt1 knockout mice (Ruland et al., 2003) and demonstrate that MALT1 is 
required for TCR-induced NF-κB and JNK signaling, but is dispensable for ERK signaling. 
3.1.3 T6BM1 encoded by MALT1 exon7 contributes to the activation of T cell signaling 
pathways 
To assess the necessity of the TRAF6 binding site within exon7 for downstream signaling, the 
signaling potential of MALT1A or B to that of their respective mutants was compared (Figure 
3.4). Upon reconstitution of MALT1-deficient Jurkat T cells with MALT1A WT, NF-κB and 
MAPK activation were markedly induced (Figure 3.4a,b). According to NF-κB signaling, NF-
κB DNA binding was strongest after 30 min P/I stimulation, which correlated with robust 
IκBα degradation (Figure 3.4a). After 60 min, NF-κB activity decreased slightly due to the re-
synthesis of IκBα, which again inhibits nuclear translocation of NF-κB. Mutation of either 
T6BM1 in exon7 (T6BM1 EA) or T6BM3 in the C-terminus (T6BM3 EA) had no effect on 
IκBα phosphorylation, degradation, and NF-κB DNA binding compared to MALT1A WT 
(Figure 3.4a). Only the combined mutation of T6BM1 and T6BM3 (T6BM1/3 EA) abolished 
NF-κB signaling. Activation of JNK and p38 followed the same pattern: whereas single 
mutation of T6BM1 and T6BM3 did not alter JNK and p38 phosphorylation, the combined 
mutation of both sites impaired activation of JNK and p38 (Figure 3.4b). ERK signaling was 
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Figure 3.4: T6BM1 encoded by MALT1A exon7 supports NF-κB and MAPK activation. (a-d) MALT1-
deficient Jurkat T cells were reconstituted with Strep-tagged MALT1A, MALT1B, or TRAF6 binding mutants. 
Reconstituted cells were stimulated with P/I for the indicated time points. (a,c) MALT1 expression, IκBα 
phosphorylation and degradation were analyzed by Western Blot using the indicated antibodies. NF-κB DNA 
binding was assessed by EMSA. β-ACTIN and OCT1 were used as loading controls for Western Blot and 
EMSA, respectively. (b,d) MAPK signaling was investigated by Western Blot using phospho-specific and total 
protein antibodies as indicated. β-ACTIN served as loading control. 
not altered by mutation of the TRAF6 binding sites within MALT1A. In addition, the effect 
of MALT1B TRAF6 binding site mutations on NF-κB and MAPK signaling was determined 
(Figure 3.4c,d). 
Again, MALT1B WT promoted robust activation of NF-κB and MAPK. Mutation of T6BM2, 
located next to the Ig3 domain of MALT1B, did not alter NF-κB and MAPK signaling, 
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whereas disruption of the most C-terminal TRAF6 binding site (T6BM3) completely impaired 
NF-κB and JNK activation and decreased p38 phosphorylation (Figure 3.4c,d). Of note, 
mutation of TRAF6 binding sites 2 or 3 did not change ERK activity. The data reveal that 
T6BM3 in MALT1B and T6BM1/T6BM3 in MALT1A contribute to the activation of 
downstream signaling pathways, whereas T6BM2 located within the Ig3 domain is 
dispensable for signaling. Similar results were observed upon reconstitution of primary, 
murine CD4+ T cells with different MALT1 constructs (Griesbach, 2012). 
3.1.4 MALT1 exon7 supports TRAF6 and NEMO recruitment to reinforce MALT1 
scaffolding function 
As demonstrated in the previous section (section 3.1.3), mutation of individual T6BMs within 
MALT1 affects the activation of downstream T cell signaling pathways. To analyze whether 
the observed effects are due to alterations in TRAF6 recruitment and CBM complex 
formation, we performed a Strep-Tactin pulldown (StrepT-PD) of C-terminal Strep-tagged 
MALT1 constructs after 30 min P/I stimulation and assessed CARMA1, BCL10, and TRAF6 
binding in the pulldown fractions (Figure 3.5a). Constitutive association of MALT1 with 
BCL10 was not affected by mutations of T6BMs or by deletion of exon7 in MALT1B, and 
stimulation-induced recruitment of CARMA1 was similar among the MALT1 constructs. 
However, exon7 deletion in MALT1B, as well as the single mutation of T6BM1 or T6BM3 in 
MALT1A, clearly reduced the association between TRAF6 and MALT1. Consistent with the 
data from the signaling experiments (see Figure 3.4), mutation of T6BM3 in MALT1B or the 
combined mutations of T6BM1/T6BM3 in MALT1A completely impaired recruitment of 
TRAF6 (Figure 3.5a). This clearly demonstrates that in MALT1A, both the exon7-encoded 
T6BM1 and the most C-terminally located T6BM3 are functional, but redundant for TRAF6 
binding. 
The E3 ligase TRAF6 mediates MALT1 ubiquitination, which is required for recruitment and 
activation of the IKK complex (Oeckinghaus et al., 2007). To check whether changes in 
TRAF6 recruitment affect MALT1 modifications and IKK complex recruitment, pulldown 
fractions were stained with a MALT1-specific antibody (B12) that also detects MALT1 
ubiquitin modifications. Polyubiquitination of MALT1 results in a high molecular weight 
smear, which appears above the main band of MALT1 (indicated by *). As expected, exon7-
lacking MALT1B displayed reduced ubiquitination (indicated by *) compared to MALT1A 
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Figure 3.5: T6BM1 within MALT1 exon7 is functional and enhances MALT1 scaffolding function. (a) TRAF6 
binds to T6BM1 encoded by MALT1 exon7 and contributes to NEMO recruitment. CBM complex formation 
and TRAF6 recruitment of MALT1 reconstituted cells were investigated by StrepT-PD after 30 min P/I 
stimulation. NEMO recruitment to MALT1 was monitored after NEMO IP. Precipitates and cell lysates were 
analyzed by Western Blot using the indicated antibodies. Modification of MALT1 by ubiquitination is marked 
by an asterisk (*). (b) MALT1 exon7 contributes to MALT1 ubiquitination. Reconstituted cells were stimulated 
with P/I for 30 min prior MALT1 protein precipitation by StrepT-PD. Pulldown and lysate samples were 
analyzed by Western Blot with the depicted antibodies. MALT1 ubiquitination was monitored by staining the 
precipitates with an ubiquitin-specific antibody. 
(Figure 3.5a). In addition, the MALT1 ubiquitin smear was severely reduced in the absence of 
any functional TRAF6 binding site leading to a decreased association with the IKK subunit 
NEMO, which was monitored upon immunoprecipitation (IP) of NEMO (Figure 3.5a). In 
summary, both T6BM1 and T6BM3 within MALT1 are required for optimal TRAF6-
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mediated MALT1 ubiquitination and subsequent IKK complex association, and therefore lead 
to an elevated scaffolding activity of MALT1A compared to MALT1B.  
To date, TRAF6 is the only identified E3 ligase facilitating MALT1 ubiquitination in T cells 
(Oeckinghaus et al., 2007). To address, whether mutation of the TRAF6 binding sites impairs 
overall MALT1 ubiquitination, precipitated MALT1 was stained with an ubiquitin-specific 
antibody (Figure 3.5b). MALT1 ubiquitination was slightly reduced upon single mutation of 
T6BM1 in MALT1A and exon7 deletion in MALT1B, but was not further decreased by the 
combined mutation of T6BM1/3 in MALT1A, or the single mutation of T6BM3 in MALT1B. 
This suggests that additional E3 ligases than TRAF6 can promote MALT1 ubiquitination. 
However, although MALT1A T6BM1/3 EA and MALT1B T6BM3 EA maintain some 
residual ubiquitin chains, this is insufficient to activate downstream signaling. Collectively, 
the mutagenesis analysis reveals that both T6BM1 and T6BM3 boost TRAF6 recruitment, 
which supports activation of downstream T cell signaling pathways. 
3.1.5 MALT1 isoforms do not differ in their protease function 
MALT1 does not solely function as a scaffolding protein, but also possesses a proteolytic 
activity that is induced upon TCR stimulation (Coornaert et al., 2008; Rebeaud et al., 2008). 
Activated MALT1 protease cleaves several substrates involved in signaling and post-
transcriptional gene regulation to facilitate robust T cell responses, including BCL10, A20, 
HOIL1, CYLD, RelB, Regnase-1 and Roquin (Coornaert et al., 2008; Elton et al., 2015; 
Hailfinger et al., 2011; Jeltsch et al., 2014; Klein et al., 2015; Rebeaud et al., 2008; Staal et 
al., 2011; Uehata et al., 2013). To assess whether exon7 inclusion affects MALT1 protease 
function, proteolytic MALT1 activity was measured using a MALT1 activity based probe 
(ABP) (Figure 3.6a) (Eitelhuber et al., 2015). ABPs have the ability to distinguish between 
active and inactive enzymes. The MALT1 ABP contains the BCL10-derived cleavage 
sequence LRSR as recognition motif and harbors a reactive electrophile AOMK 
(acyloxymethyl ketone), which covalently binds to MALT1. ABP-labeling with the 
fluorophore BODIPY (boron-dipyrromethene) enables detection of active MALT1-ABP 
complexes in a fluorescence scan (Eitelhuber et al., 2015). To analyze MALT1 activity, 
StrepT-PDs of mock, MALT1A and MALT1B expressing cells were performed and the 
precipitates were labeled with fluorescently-labeled ABP (Figure 3.6b). Upon P/I stimulation 
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Figure 3.6: Inclusion of exon7 does not alter MALT1 protease activity. (a) An activity-based probe (ABP) 
containing the BCL10-derived cleavage sequence LRSR was used to specifically measure proteolytic MALT1 
activity. Binding to MALT1 is facilitated by AOMK and active MALT1-ABP complexes are detectable by the 
fluorophore BODIPY. (b) MALT1 isoforms display similar proteolytic MALT1 activity. Mock, MALT1A or 
MALT1B expressing Jurkat T cells were stimulated for 20 min with P/I prior to StrepT-PD. Precipitates were 
incubated with BODIPY-labeled ABP before loading onto a 9 % SDS gel and active MALT1-ABP complexes 
were visualized by a fluorescence scan. Pulldown samples and cell lysates were analyzed by Western Blot, 
where β-ACTIN served as loading control. (c) CYLD cleavage is comparable in MALT1A and MALT1B 
expressing cells. Reconstituted Jurkat T cells were stimulated with P/I for the indicated time points. Lysates were 
analyzed for CYLD cleavage by Western Blot using the indicated antibodies. The applied CYLD antibody 
detects full-length and the C-terminal CYLD cleavage fragment appearing at ~ 70 kDa (CYLD Ct). 
MALT1 activity was induced, but did not differ between MALT1A and MALT1B expressing 
cells (Figure 3.6). In accordance with previous experiments, active MALT1 was heavily 
polyubiquitinated after stimulation indicated by the high molecular weight smear above  
100 kDa. To confirm the observed results, MALT1 activity was further monitored by 
analyzing MALT1 substrate cleavage. Upon TCR stimulation, MALT1 cleaves the 
deubiquitinase CYLD (~ 110 kDa) generating an N-terminal (40 kDa) and a C-terminal 
(CYLD Ct, 70 kDa) fragment, whereby the latter can be detected using a CYLD-specific 
antibody raised against the C-terminus (Staal et al., 2011). CYLD cleavage was induced upon 
P/I stimulation of transduced Jurkat T cells and was similar in both MALT1A and MALT1B 
expressing cells (Figure 3.6c). As expected, mock transduced cells were unable to cleave 
CYLD due to the lack of endogenous MALT1. Collectively, the data reveal that alternative 
splicing of MALT1 does not affect MALT1 protease activity and subsequent substrate 
cleavage.  
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3.2 Role of MALT1 isoforms in T cell activation and differentiation 
3.2.1 T cell receptor signaling induces MALT1A expression in primary CD4+ T cells 
Inclusion of exon7 in MALT1 contributes to the activation of downstream signaling pathways 
in transduced Jurkat T cells. As exon7 is highly conserved in mammals, it was investigated 
whether alternative MALT1 splicing is also relevant for signaling and activation in primary 
mouse T cells. We first designed primer pairs that selectively amplify Malt1A (ex5-ex7/8) or 
Malt1B (ex5-ex6/8) (Figure 3.7a). To analyze mRNA expression levels in murine T cells, 
CD4+ T cells were freshly isolated from spleen and lymph nodes of BALB/c mice and 
MALT1 isoform expression was measured by quantitative PCR (qPCR or real-time (RT) 
PCR), whereby hydroxymethylbilane synthase (Hmbs) served as internal control.  
 
Figure 3.7: Primary CD4+ T cells lack Malt1A and predominantly express Malt1B. (a) Schematic of Malt1 
primers used for specific amplification of murine Malt1A (ex5-ex7/8; 214 bp) and murine Malt1B (ex5-ex6/8; 
194 bp). (b) Malt1A and Malt1B mRNA levels in CD4+ T cells from BALB/c mice were analyzed by qPCR 
using isoform-specific ex5-ex7/8 or ex5-ex6/8 primers. Transcript levels were normalized to Hmbs mRNA 
levels. Depicted is the mean ± SD (n=3) (b). ***p < 0.001; unpaired t-test. 
Quantitative PCR revealed a more than ~ 100 fold higher expression of the shorter isoform 
Malt1B compared to Malt1A (Figure 3.7b). As MALT1A was hardly detectable, one can 
conclude that primary, unstimulated CD4+ T cells contain reduced levels of the longer splice 
variant MALT1A and mainly express MALT1B.  
T cell activation correlates with drastic changes in alternative splicing patterns (Martinez et 
al., 2012). Therefore, Malt1A and Malt1B mRNA expression levels were further elucidated 
after 3 h anti-CD3 and/or anti-CD28 stimulation (Figure 3.8a). Whereas CD3 antibodies 
engage the TCR, CD28 antibodies stimulate the CD28 co-receptor. Stimulation of CD4+  
T cells with anti-CD3 alone or anti-CD3/ CD28 in combination induced Malt1A expression 
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by a factor 10-12, whereas incubation with anti-CD28 alone failed to upregulate Malt1A 
expression. In contrast, Malt1B levels were only slightly altered by anti-CD3 or anti-
CD3/CD28 treatment (factor 2-4). TCR-induced induction of Malt1A was further confirmed 
by semi-quantitative PCR (semi-qPCR), in which the samples are compared within the 
exponential amplification phase of the PCR reaction (Figure 3.8b). Thereby, Malt1A levels 
markedly increased after 3 h or 6 h anti-CD3 stimulation, but decreased again after 18 h 
(Figure 3.8b left panel). Compared to anti-CD3/CD28 or anti-CD28 alone, 6 h of anti-CD3 
treatment induced Malt1A most efficiently (Figure 3.8b right panel). Again, Malt1B was only 
moderately enhanced, which was also observed for overall Malt1 expression (Griesbach, 
2012). Thus, T cell activation mediates exon7 inclusion and anti-CD3 stimulation alone was 
sufficient to induce alternative splicing of MALT1.  
As CD3 antibodies only stimulate the TCR-associated CD3 complex, and do not directly 
engage the antigen-binding pocket, it was determined whether alternative MALT1 splicing is 
also induced upon stimulation of the TCR antigen-binding site with a real antigenic peptide. 
Therefore, OT-II T cells were utilized, which bear a transgenic TCR that specifically 
recognizes a chicken ovalbumin peptide (OVA, aa 323-339) presented by MHC class II 
proteins expressed on the surface of APCs.  
First, irradiated, T cell-depleted APCs (TCRβ-) from wt mice were incubated with OT-II T 
cells (TCRβ+) in a ratio 1:1 (Figure 3.8c upper panel). To activate OT-II T cells, APCs were 
pulsed with OVA peptide and incubated with OT-II T cells for different time points. To check 
OVA-mediated OT-II activation, we gated on OT-II cells (TCRβ+) and examined surface 
expression of the activation marker CD69, whose expression was enhanced with increasing 
time points (Figure 3.8c lower panel). Since splicing occurs earlier than CD69 upregulation, 
alternative MALT1 splicing was analyzed after 6 h OVA stimulation (Figure 3.8d). 
Consistent with the effects observed following anti-CD3 stimulation, OVA-mediated OT-II 
stimulation promoted Malt1A induction, but only mildly altered Malt1B levels (Figure 3.8d). 
The effects were not as pronounced as in the anti-CD3 treated T cells, but the upregulation of 
Malt1A was statistically significant. Thus, TCR stimulation with a MHC/peptide complex 
also induces alternative splicing of MALT1 leading to exon7 inclusion. Although MALT1B is 
the dominant isoform, TCR stimulation increases the MALT1A versus MALT1B expression 
ratio in CD4+ T cells. 
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Figure 3.8: TCR stimulation induces exon7 inclusion and thus MALT1A expression in CD4+ T cells. (a,b) CD4+ 
T cells from BALB/c mice were stimulated with anti-CD3, anti-CD28, or both antibodies for the indicated time 
points. (a) Malt1A and Malt1B expression was measured by qPCR using isoform-specific primers and 
normalized to Hmbs levels. Relative induction was calculated relative to unstimulated control. (b) For semi-
qPCR analysis, amplification of Malt1A and Malt1B was stopped after 35 cycles and 28 cycles, respectively. 
Hmbs served as internal control. (c,d) T cell-depleted APCs (TCRβ-) from wt mice were incubated with OT-II  
T cells (TCRβ+) in a ratio 1:1. For OT-II T cell activation, APCs were pulsed with 1 µg/ml OVA peptide and 
incubated with OT-II T cells for the indicated time points. (c) OT-II T cell activation was monitored by gating 
CD69 surface expression in TCRβ+ cells using flow cytometry. (d) Malt1A and Malt1B expression levels were 
analyzed in OT-II CD4+ T cells cultured for 6 h with wt APCs unloaded or loaded with 1 µg/ml OVA. Transcript 
levels were normalized to Hmbs. Relative induction was determined comparative to unloaded APCs cultured 1:1 
with OT-II T cells. Data show the mean ± SD (n=3) (a,d). *p < 0.05; n.s. not significant; unpaired t-test. 
3.2.2 MALT1A expression is enhanced in activated T cell subsets 
TCR ligation promotes T cell activation and differentiation into distinct effector subsets such 
as TH1, TH2, TH17 and the more recently identified TFH cells (Chang et al., 2014). All 
subtypes differ in their cytokine expression pattern to fulfill distinct functions during an 
immune response (Luckheeram et al., 2012). As alternative MALT1 splicing is induced upon 
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T cell stimulation (see Figure 3.8), it was determined whether elevated MALT1A levels are 
also seen in activated T cell effector subsets. To promote the generation of effector T cells, 
BALB/c mice were immunized and splenic CD4+ T cells were isolated after 7 days. Out of the 
pool of CD4+ T cells (~ 71 %), naive T cells (CD62L+CD44-, ~ 62 %), effector T cells 
(CD62L-CD44+, ~ 24 %) and specifically TFH cells (CXCR5+PD-1+, ~ 12 %) were purified 
(Figure 3.9a) (performed by J. Kranich, Institute for Immunology, LMU München).  
 
Figure 3.9: Activated T cell subsets display enhanced MALT1A expression levels. (a) Splenic CD4+ T cells 
were isolated from immunized BALB/c mice and were further sorted for naive CD62L+CD44- T cells, activated 
CD62L-CD44+ effector T cells and CXCR5+PD-1+ T follicular helper (TFH) cells as indicated. (Immunization 
and sorting was performed by J. Kranich, Institute for Immunology, LMU München). (b) After RNA isolation, 
Malt1A and Malt1B mRNA expression was investigated by semi-qPCR using isoform-specific primer pairs. 
Again, Hmbs served as internal control. Depicted is one of four independent experiments. 
RNA was isolated from different T cell subsets and mRNA expression levels of Malt1A and 
Malt1B were analyzed by semi-qPCR using isoform-specific primers (see Figure 3.7a). For 
semi-qPCR, we first varied the number of PCR cycles to determine the exponential phase of 
the PCR reactions. Afterwards, the samples were reamplified, stopped in the exponential 
phase and loaded on an agarose gel to compare isoform expression levels. Whereas Malt1B 
transcript levels were similar between naive and effector T cells, Malt1A expression was 
upregulated in effector cells and TFH cells, but not in the naive T cell subset (Figure 3.9b). 
Thus, alternative MALT1 splicing also drives MALT1A induction in vivo in activated T cells, 
which might be required to facilitate optimal immune responses. 
3.2.3 Alternative MALT1 splicing is induced in human CD4+ T cells 
MALT1A was induced in murine CD4+ T cells upon T cell activation. To elucidate if 
alternative MALT1 splicing also occurs in human T cells, we purified CD4+ T cells from 
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peripheral blood mononuclear cells (PBMCs) from four healthy donors and assessed MALT1 
isoform levels in resting cells and upon anti-CD3/CD28 stimulation. After RNA isolation, 
mRNA expression levels were analyzed using human MALT1A (ex6/7-ex10) and B (ex5-
ex6/8) specific primers (Figure 3.10a). Unstimulated human CD4+ T cells expressed more 
MALT1B than MALT1A (factor 4-5) (Figure 3.10b left panel), and anti-CD3/CD28 stimulation 
induced MALT1A expression (5 fold), but not as strong as in murine CD4+ T cells (Figure 
3.10b right panel). Moreover, MALT1B levels were also upregulated by a factor 2-3 upon 
stimulation, which only slightly increases the MALT1A/MALT1B ratio. Although the effects 
are less pronounced than in murine CD4+ T cells, one can conclude that MALT1 also 
undergoes alternative splicing in human, peripheral T cells. 
 
Figure 3.10: TCR stimulation upregulates MALT1A expression in human CD4+ T cells. (a) Schematic depiction 
of primers specific for human MALT1A (ex6/7-ex10; 177 bp) and human MALT1B (ex5-ex6/8; 195 bp). (b) 
Primary human CD4+ T cells were isolated from peripheral blood mononuclear cells (PBMCs) from four donors. 
Purified cells were stimulated with anti-CD3/CD28 for 3 h and MALT1 isoform expression was measured by 
qPCR using human MALT1A- or MALT1B-specific primers. MALT1 transcript levels were normalized to RNA 
polymerase II (RP2) mRNA levels and relative induction was calculated compared to unstimulated cells. 
Depicted is the mean ± SD (n=4) (b). **p < 0.01; ***p < 0.001; unpaired t-test. 
3.2.4 Design and evaluation of morpholino oligomer to prevent MALT1A expression 
As MALT1 exon7 supported signaling in Jurkat T cells, it was investigated whether exon7 
inclusion also supports signaling and activation in primary, murine T cells. Therefore, a vivo-
morpholino oligomer (MO) was designed, which targets the exon7-intron7 boundary of the 
Malt1 pre-mRNA and thereby should prevent splice site selection resulting in exon7 skipping 
(Figure 3.11a). First, it was tested how efficiently the designed MO blocked exon7 inclusion 
in mouse embryonic fibroblasts (MEFs), which express both MALT1 isoforms and thus do 
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Figure 3.11: Design of morpholino to prevent MALT1A induction. (a) Model for vivo-morpholino (MO)-
induced prevention of MALT1A expression. MO was designed against the exon7-intron7 boundary (5’ splice 
site) in Malt1 pre-mRNA to prevent spliceosomal recognition and exon7 inclusion. (b) Design of primer pairs 
for the simultaneous amplification of Malt1A and Malt1B (ex6-ex9/10; 146 bp Malt1A; 113 bp Malt1B). (c,d) 
Morpholino treatment impairs MALT1A expression in mouse embryonic fibroblasts (MEFs). MEFs were treated 
with morpholino against MALT1A (AMO), control MO (cMO) or remained untreated. (c) Malt1A and Malt1B 
mRNA expression was analyzed by semi-qPCR and isoform size was assessed by loading MALT1A and 
MALT1B plasmid DNA. Hmbs transcript levels served as internal control. (d) MALT1A was precipitated by 
using a MALT1A-specific antibody raised against MALT1 exon7. Precipitates and cell lysates were stained with 
a total MALT1 antibody. β-ACTIN served as loading control. 
not require stimulation-induced MALT1A induction. After incubation with MALT1A 
morpholino (AMO) or control morpholino (cMO) for 3 h or 6 h, MEFs were analyzed for 
their MALT1 isoform expression levels by semi-qPCR using a primer pair (ex6-ex9/10) that 
amplifies Malt1A and B simultaneously (Figure 3.11b,c).  
AMO treatment completely abolished Malt1A mRNA expression and shifted alternative 
splicing towards enhanced Malt1B levels (Figure 3.11c). In contrast, cMO incubation did not 
alter the Malt1 isoform ratio (Figure 3.11c). AMO treatment also reduced MALT1A protein 
expression (Figure 3.11d). This was monitored by MALT1A IP using an antibody raised 
against MALT1 exon7, whose specificity has been confirmed in previous experiments upon 
ectopic MALT1A expression in HEK293 cells (Griesbach, 2012). Thus, the designed MO 
selectively reduced MALT1A expression in MEFs. 
The efficiency of MO incubation was further tested in murine CD4+ T cells, which require 
TCR ligation to initiate alternative MALT1 splicing. Therefore, isolated CD4+ T cells were 
incubated with AMO or cMO prior to anti-CD3 or anti-CD3/CD28 stimulation and Malt1 
isoform expression was analyzed by semi-qPCR and qPCR (Figure 3.12a-c).  
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Figure 3.12: Morpholino prevents TCR-induced MALT1A induction in CD4+ T cells. (a-c) CD4+ T cells from 
BALB/c mice were treated with AMO, cMO or left untreated for 3 h before anti-CD3 or anti-CD3/CD28 
stimulation for the indicated time points. (a) Malt1A and Malt1B mRNA expression was investigated by semi-
qPCR using isoform-specific primer pairs. MALT1 plasmid DNA was loaded to check isoform size. Hmbs served 
as internal control. (b,c) Malt1 isoform levels were analyzed by qPCR using the same primers as in (a). 
Transcript levels were normalized to Hmbs and relative induction was determined in comparison to unstimulated 
samples. Depicted is the mean ± SD (n=3) (b,c). 
Selective amplification with Malt1A- or B-specific primer pairs revealed that AMO treatment 
completely abolished anti-CD3- or anti-CD3/CD28-mediated Malt1A induction, whereas 
Malt1B expression was not affected (Figure 3.12). Again, anti-CD3 stimulation alone induced 
a more efficient Malt1A upregulation (Figure 3.12a,b) than anti-CD3/CD28 treatment (Figure 
3.12a,c). In summary, the designed MO against MALT1A serves as a useful tool to 
selectively prevent MALT1A upregulation in CD4+ T cells. 
Although unstimulated, primary CD4+ T cells lack MALT1A expression, it was examined, 
whether MO treatment of resting cells may have unwanted side effects and already influences 
T cell signaling pathways. Therefore, freshly isolated murine CD4+ T cells were left untreated 
or incubated with AMO or cMO before they were stimulated with anti-CD3/CD28 or P/I. As 
exon7 inclusion in Jurkat T cells mainly influences JNK and NF-κB signaling, we focused on 
the analysis of those signaling pathways. Neither NF-κB signaling nor JNK activation was 
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Figure 3.13: Morpholino does not affect T cell signaling in the absence of MALT1A. (a,b) After MO treatment, 
CD4+ T cells were directly stimulated with anti-CD3/CD28 (a) or P/I (b) for the indicated time points. JNK 
phosphorylation and IκBα degradation were analyzed by Western Blot using the indicated antibodies. NF-κB 
activation was monitored by EMSA. 
altered in AMO treated cells, revealing that AMO does not interfere with T cell signaling in 
the absence of MALT1A (Figure 3.13a,b). Thus, AMO can be further used for the analysis of 
downstream signaling pathways upon MALT1A upregulation. 
3.2.5 MALT1A upregulation supports NF-κB and JNK signaling 
TCR ligation triggers exon7 inclusion and thus MALT1A induction. Since exon7 harbors a 
functional TRAF6 binding motif and can contribute to the activation of NF-κB and JNK 
signaling in Jurkat T cells, the aim was to investigate whether upregulation of MALT1A in 
murine CD4+ T cells augments T cell signaling. Therefore, freshly isolated CD4+ T cells were 
pre-treated with anti-CD3 to induce MALT1A expression, and activation of downstream 
signaling was monitored after re-stimulation with P/I to bypass upstream TCR stimulation 
that might be altered upon CD3 pre-treatment.  
Without pre-treatment, IκBα is phosphorylated within 10 min and completely degraded after 
20 min P/I stimulation resulting in nuclear translocation of NF-κB (Figure 3.14a). NF-κB 
signaling was strongly enhanced upon anti-CD3 pre-treatment. With respect to MAPK 
signaling, anti-CD3 pre-treated cells showed pronounced JNK activation, whereas ERK and 
p38 signaling were not affected (Figure 3.14b). To determine whether enhanced NF-κB and 
JNK activation is due to MALT1A upregulation, the designed AMO was utilized. Primary  
T cells were incubated with AMO or cMO prior to anti-CD3 pre-treatment and re-stimulated 
with P/I. Again, CD3 pre-treatment promoted stronger NF-κB activation and slightly 
enhanced JNK phosphorylation in untreated or cMO treated cells (Figure 3.14c,d). In T cells, 
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which lack MALT1A expression due to AMO incubation, NF-κB DNA binding was 
dramatically reduced compared to cMO treated cells (~ 4 fold at 30 min) and was comparable 
to CD4+ T cells without anti-CD3 pre-treatment (Figure 3.14c). IκBα levels are low after 
AMO incubation, which could be due to decreased re-synthesis of IκBα in the presence of 
AMO. Regarding MAPK activation, JNK phosphorylation was slightly reduced after AMO 
treatment, but ERK and p38 activation were not affected (Figure 3.14d). Collectively, TCR-
mediated MALT1A induction enhances MALT1 scaffolding function to promote optimal NF-
κB and JNK activation.  
 
Figure 3.14: TCR-induced MALT1A induction augments T cell signaling. (a,b) Anti-CD3 pre-treatment of 
CD4+ T cells enhances NF-κB and JNK signaling. CD4+ T cells from BALB/c mice were either pre-treated with 
anti-CD3 for 4 h or left untreated. Afterwards, the cells were stimulated with P/I for the indicated times. (a) To 
analyze NF-κB signaling, IκBα phosphorylation and degradation were analyzed by Western Blot using the 
indicated antibodies. NF-κB activation was assessed by EMSA. β-ACTIN and OCT1 were used as loading 
controls. (b) MAPK signaling was investigated by monitoring JNK, ERK and p38 phosphorylation in Western 
Blot analysis with the illustrated antibodies. (c,d) Anti-CD3-mediated MALT1A induction accounts for optimal 
NF-κB and JNK activation. Untreated, AMO or cMO treated CD4+ T cells were pre-treated with anti-CD3 for  
4 h prior to secondary P/I stimulation. (c) NF-κB signaling was analyzed as in (a). NF-κB fold induction was 
calculated by quantification of NF-κB signal relative to OCT1 control. Active NF-κB levels in untreated, 
unstimulated cells were set to 1. (d) Analysis of MAPK signaling was performed as in (b). 
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It has been reported that JNK activation depends on CYLD cleavage by MALT1 paracaspase 
in Jurkat T cells (Staal et al., 2011). As JNK activation was slightly enhanced upon MALT1A 
induction in primary CD4+ T cells (see Figure 3.14), it was investigated whether proteolytic 
MALT1 activity and concomitant CYLD cleavage is augmented upon MALT1A 
upregulation.  
 
Figure 3.15: Inhibition of MALT1A induction does not alter MALT1 protease function. (a) Schematic of an 
ABP probe used for detecting active MALT1. The structure of the ABP is similar to the probe described in 
Figure 3.6a, but contains a Biotin detection marker. (b) MALT1 proteolytic activity is independent of MALT1A 
induction. CD4+ T cells were treated with AMO, cMO or kept untreated prior to anti-CD3 pre-treatment. 
Afterwards, cells were re-stimulated with P/I for 20 min before incubation with the biotinylated MALT1 ABP 
probe. Active MALT1 ABP complexes were immobilized on a streptavidin-coated plate and were detected by an 
enzyme-linked activity-sorbent assay (ELASA). MALT1 activity was calculated relative to background levels. 
Depicted is one experiment (n=1). (c) CYLD cleavage is not affected by MALT1A induction. CD4+ T cells were 
treated with MO or kept untreated prior to anti-CD3 pre-treatment and subsequent P/I re-stimulation for the 
indicated time points. CYLD cleavage was analyzed by Western Blot using a CYLD antibody detecting full-
length and the C-terminal CYLD cleavage fragment appearing at ~ 70 kDa. 
For monitoring MALT1 paracaspase activity, a Biotin-coupled MALT1 ABP was used 
(Figure 3.15a) (Eitelhuber et al., 2015). CD4+ T cells were incubated with AMO or cMO and 
pre-treated with anti-CD3 followed by P/I re-stimulation and incubation with the Biotin-ABP. 
MALT1 ABP complexes can be immobilized on streptavidin-coated plates and active 
MALT1 is detectable using a MALT1-specific antibody.  
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As expected, T cell stimulation induced activation of MALT1 paracaspase (Figure 3.15b). 
However, MALT1 activity did not differ between AMO and cMO treated cells, revealing that 
inhibition of MALT1A induction does not affect MALT1 protease function. Regarding 
MALT1 substrate cleavage, CYLD cleavage was reduced upon anti-CD3 pre-treatment, but 
was not altered by AMO incubation upon P/I re-stimulation (Figure 3.15c). Finally, MALT1 
protease activity is not influenced by MALT1A induction and therefore does not account for 
enhanced JNK activation. 
3.2.6 TCR-induced MALT1A expression supports T cell activation 
MALT1A induction leads to enhanced NF-κB and JNK signaling (see Figure 3.14). As 
activation of both pathways is required for optimal T cell activation, it was addressed whether 
an increase in MALT1A expression results in a more robust T cell activation. T cell activation 
correlates with upregulation of the surface markers CD69 and CD25, which prolong 
lymphocyte retention in secondary lymphoid organs and support T cell expansion, and can be 
monitored by flow cytometry (Malek, 2008; Shiow et al., 2006).  
Stimulation of murine CD4+ T cells with anti-CD3/CD28 promoted a strong induction of 
CD69 and CD25 surface expression, but was reduced in the absence of MALT1A (Figure 
3.16a). This was further confirmed by quantification of CD69 and CD25 mean fluorescence 
intensity (MFI) (Figure 3.16b). Moreover, activated T cells produce IL-2, whose expression is 
induced by several transcription factors including NF-κB (Schulze-Luehrmann and Ghosh, 
2006). IL-2 is an important cytokine for mediating T cell survival, proliferation, and 
differentiation (Bachmann and Oxenius, 2007). When cells were stained for intracellular IL-2, 
the amount of IL-2 positive cells in AMO treated CD4+ T cells was reduced (Figure 3.16c,d), 
which correlates with decreased Il2 transcript levels (Figure 3.16e). The results reveal that 
TCR-induced MALT1A upregulation is required to promote optimal CD69, CD25 and IL-2 
expression and thus to facilitate more robust T cell activation. 
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Figure 3.16: MALT1A induction is required for optimal CD69 and CD25 upregulation and IL-2 production.  
(a-e) CD4+ T cells from BALB/c mice were left untreated or were treated with AMO or cMO before 6 h anti-
CD3/CD28 stimulation. (a) Cell surface expression of CD69 and CD25 was monitored by flow cytometry. (b) 
Calculation of mean fluorescence intensity (MFI) of CD69 and CD25. (c) Viable CD4+ T cells were fixed and 
stained for intracellular IL-2 and staining was analyzed by flow cytometry. Fluorescence of IL-2 was plotted 
against the empty channel red laser 2 (RL-2). (d) The number of IL-2 positive cells as gated in (c) was quantified 
comparative to stimulated control cells (no MO). (e) Il2 mRNA expression levels in CD4+ T cell (no MO, AMO 
or cMO treated) were analyzed by qPCR using Il2-specific primers. Hmbs levels served as internal control. 
Depicted is the mean ± SD (n=3) (b,d,e). *p < 0.05; **p < 0.01; ***p < 0.001; unpaired t-test. 
3.2.7 Alternative MALT1 splicing does not influence T cell fate decisions  
Upon activation, CD4+ T cells differentiate into distinct effector subsets (Luckheeram et al., 
2012). Data from MALT1 paracaspase mutant mice revealed that MALT1 protease is required 
for the generation of TH17 cells, which play a crucial role in the defense against bacterial and 
fungal infections and are associated with several autoimmune diseases (Bornancin et al., 
2015; Waite and Skokos, 2012). To elucidate the relevance of alternative MALT1 splicing for 
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T cell differentiation, TH1 and TH17 differentiation conditions were first optimized in wt and 
Malt1-/- T cells. Thereby, limiting stimulation conditions were used to gain an optimal readout 
for monitoring MALT1 isoform-specific effects in subsequent experiments. In particular, 
naive CD4+ T cells from wt and Malt1-/- mice were stimulated with irradiated APCs and 
increasing concentrations of anti-CD3 (0.1-3 µg/ml), and were subsequently analyzed for 
their potential to differentiate into IL-17A-producing TH17 cells and IFNγ-secreting TH1 cells. 
As expected, MALT1-deficient CD4+ T cells were unable to differentiate into TH17 cells, but 
also TH1 differentiation was reduced under the used stimulation conditions (Figure 3.17). At a 
concentration of 1 µg/ml anti-CD3, differentiation into TH1 and TH17 cells was optimal and 
used for further experiments. 
 
Figure 3.17: Optimization of TH1 and TH17 cell differentiation conditions. CD4+ T cells from wt and Malt1-/- 
mice were treated with irradiated APCs in a ratio 1:10 with increasing concentrations of anti-CD3 antibodies 
under TH1 or TH17 polarizing conditions. After re-stimulation, intracellular expression of the TH1 marker IFNγ 
and the TH17 marker IL-17A in viable CD4+ T cells were determined by flow cytometry. 
To analyze the impact of exon7 inclusion on TH1 and TH17 differentiation, an adenoviral 
approach was used (Warth and Heissmeyer, 2013). We infected naive CD4+ T cells from 
Malt1-/-R26/CAG-CARΔ1stop-flCd4-Cre mice with adenoviruses encoding MALT1A, 
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Figure 3.18: Alternative MALT1 splicing does not influence T cell effector differentiation. (a-c) CD4+ T cells 
from Malt1-/-R26/CAG-CARΔ1stop-flCd4-Cre mice were transduced with adenoviruses containing mock, 
MALT1A, MALT1B or MALT1A C464A and co-expressing IRES–GFP. (a) Scheme of adenoviral constructs 
used for MALT1 expression in CD4+ T cells. GFP expression was investigated by flow cytometry and GFP+ 
cells were used for further analysis. (b) Adenovirally reconstituted CD4+ T cells were cultured under TH1 or 
TH17 polarizing conditions and re-stimulated with P/I. GFP+ T cells were analyzed for intracellular IFNγ and  
IL-17A levels by flow cytometry. Numbers in quadrants represent percentage of IFNγ or IL-17A-positive cells. 
(c) The number of IFNγ and IL-17A positive cells was calculated relative to mock infected cells. Data show 
mean ± SD (n=4) (c). *p < 0.05; **p < 0.01; n.s. not significant; unpaired t-test. 
MALT1B or a catalytically inactive mutant MALT1A C464A (Figure 3.18a). CD4+ T cells 
from Malt1-/-R26/CAG-CARΔ1stop-flCd4-Cre mice are susceptible to adenoviral transduction 
as they express a truncated, signaling-deficient version of the human coxsackie adenovirus 
receptor (CARΔ1) (Heger et al., 2015).  
Transduction efficiency was determined by co-expression of the infection marker green 
fluorescent protein (GFP). An infection efficiency of either ~ 9 % (MALT1A C464A) or  
~ 20 % (GFP control, MALT1A, MALT1B) was obtained (Figure 3.18a). Using the 
optimized differentiation conditions, TH1 and TH17 cell differentiation of reconstituted cells 
was monitored by staining for IFNγ and IL-17A (Figure 3.18b,c). TH17 cell differentiation 
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was similar in MALT1A and B expressing cells. Although the frequencies of IFNγ-producing 
TH1 cells were enhanced in MALT1B reconstituted T cells compared to MALT1A expressing 
cells, the difference was not significant. As expected, T cells reconstituted with the 
catalytically inactive mutant MALT1A C464A failed to differentiate into TH17 cells and only 
a small population became TH1 cells (Figure 3.18c,d), confirming the necessity of MALT1 
protease activity for effector T cell differentiation. The results demonstrate that modulation of 
MALT1 scaffolding function by alternative splicing is crucial for T cell activation, but does 
not affect MALT1 protease activity and thus T cell fate decisions. 
3.3 Regulation of alternative MALT1 splicing by the splicing factor hnRNP U  
3.3.1 A siRNA screen identifies hnRNP U as a critical splicing regulator of alternative 
MALT1 splicing  
The decision as to whether an alternative exon is included or excluded in the mature mRNA 
largely depends on protein regulators, which bind to cis-regulatory sequences within exons or 
introns and thereby modulate splice site recognition (Chen and Manley, 2009; Kornblihtt et 
al., 2013). To identify putative splicing regulators controlling alternative MALT1 splicing, a 
small interfering RNA (siRNA) screen was conducted in Jurkat T cells expressing both 
MALT1 isoforms. In this approach, Jurkat T cells were transfected with different smart pool 
siRNAs in order to knock down RNA-binding proteins that have been associated with 
splicing, and analyzed the MALT1A versus MALT1B expression ratio. In an initial approach, a 
siRNA library containing 76 siRNAs against RNA-binding factors with putative splicing 
activity was used and relative MALT1 expression was determined by radioactive PCR (Figure 
3.19a). 
Knockdown of several factors like RBMS1 (RNA-binding motif single-stranded-interacting 
protein 1), hnRNP C or hnRNP H2 influenced the MALT1 isoform ratio by promoting exon7 
skipping (Figure 3.19a). However, knockdown of hnRNP U (also known as scaffold 
attachment factor A [SAF-A]) had the strongest effect on alternative MALT1 splicing: 
hnRNP U downregulation caused a ~ 2 fold enhancement in exon7 inclusion and thus shifted 
the MALT1 isoform ratio towards MALT1A expression (Figure 3.19a).  
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Figure 3.19: The splicing regulator hnRNP U negatively regulates exon7 inclusion and thus MALT1A 
expression in Jurkat T cells. (a-c) Identification of RNA-binding proteins involved in alternative MALT1 
splicing using two siRNA approaches. (a) Jurkat T cells were transfected with smart pool siRNAs targeting 
putative splicing regulators. MALT1A/B mRNA expression was measured by radioactive PCR. (b) Jurkat T cells 
were transfected as in (a) and analyzed by qPCR using RP2 as internal control. In (b), relative MALT1A versus 
MALT1B expression of control cells was set to 1. (c) hnRNP U knockdown was confirmed by qPCR. hnRNP U 
expression was normalized to RP2 and calculated relative to si-control (d) Jurkat T cells were transfected with a 
smart pool siRNA against hnRNP U and MALT1 isoform expression was analyzed by semi-qPCR. RP2 
transcript levels served as internal control. (d) After transfection of si-control or three independent siRNAs 
against hnRNP U, the MALT1A/MALT1B ratio was analyzed by qPCR. Transcript levels were normalized to RP2 
and the MALT1 isoform ratio of control cells was set to 1. (e) Knockdown of hnRNP U by three independent si-
RNAs (#1, #2, #3) was monitored by Western Blot using the indicated antibodies. Depicted is the mean ± SD 
(n=3) (c,e). **p < 0.01; ***p < 0.001; unpaired t-test. 
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In parallel, we performed a second, more focused screen targeting 22 splicing factors, which 
have already been described to regulate alternative splicing events. A siRNA library was used 
to knock down the potential splicing regulators and the MALT1 isoform ratio was evaluated 
using qPCR (Figure 3.19b). Knockdown of hnRNP U was confirmed by qPCR (Figure 3.19c) 
and an increase in MALT1A expression upon hnRNP U knockdown was also observed by 
semi-qPCR (Figure 3.19d). Comparing both screens, depletion of protein factors like  
hnRNP C, hnRNP K, or hnRNP R had differential effects on alternative MALT1 splicing, 
which can be due to different siRNA libraries and experimental conditions. However, hnRNP 
U popped up in both approaches with the most striking effect on MALT1 isoform expression 
and thus served as the most reliable candidate. The relative increase in MALT1A versus 
MALT1B expression was further confirmed using three independent siRNAs against  
hnRNP U (Figure 3.19e), whose knockdown efficiency was monitored by WB (Figure 3.19f). 
In summary, our results indicate that hnRNP U serves as a negative regulator of exon7 
inclusion and thus MALT1A expression in Jurkat T cells, as hnRNP U downregulation 
resulted in an increased MALT1A versus MALT1B ratio. 
3.3.2 mRNA stability of MALT1 isoforms is not affected by hnRNP U 
hnRNP U is involved in various biological processes including gene transcription (Kim and 
Nikodem, 1999; Kukalev et al., 2005; Obrdlik et al., 2008), X chromosome inactivation 
(Hasegawa et al., 2010), and modulation of splicing events (Huelga et al., 2012; Vu et al., 
2013; Xiao et al., 2012; Ye et al., 2015). It has been also reported that hnRNP U regulates 
mRNA stability by binding to the 3’ untranslated region (3’ UTR) (Yugami et al., 2007). 
Although MALT1A and B are transcribed from the same gene and thus harbor an identical  
3’ UTR, it needs to be excluded whether the observed effect of hnRNP U on MALT1A/B 
ratio is due to alterations in mRNA stability. Therefore, control and hnRNP U-depleted Jurkat 
T cells were treated with Actinomycin D, which blocks transcription and thereby enables 
determination of mRNA decay. MALT1A and MALT1B mRNA levels were measured by 
qPCR and calculated relative to untreated cells.  
Upon downregulation of hnRNP U, MALT1A mRNA was slightly more stabilized compared 
to si-control treated cells, but the increase was not significant (Figure 3.20a). Regarding 
MALT1B, no differences in the mRNA decay rate were observed between control and hnRNP 
U-depleted cells (Figure 3.20b). Although only slight effects were monitored, the data imply 
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Figure 3.20: mRNA stability of MALT1 isoforms is not affected by hnRNP U. (a,b) Jurkat T cells were 
transfected with smart pool siRNA against hnRNP U and afterwards treated with Actinomycin D (5µg/ml) for  
0 h, 2 h, 4 h, 6 h or 8 h. MALT1A (a) and MALT1B (b) mRNA expression were measured by qPCR and 
normalized to RP2, PPIB, GAPDH and 18S rRNA levels. MALT1 isoform expression of untreated samples was 
set to 1. Depicted is the mean ± SD (n=5) (a,b). 
that hnRNP U does not stabilize MALT1B mRNA or destabilize MALT1A mRNA. Therefore, 
one can conclude that hnRNP U rather modulates MALT1 isoform ratio by alternative 
splicing.  
3.3.3 hnRNP U binds to MALT1 pre-mRNA in proximity to exon7 
hnRNP proteins can exert splicing enhancing or silencing activities by binding to regulatory 
sequences located within exons or introns (Kornblihtt et al., 2013). More recently, genome-
wide analysis revealed that hnRNP proteins preferentially bind near alternatively spliced 
exons (Huelga et al., 2012). Therefore, the binding of hnRNP U to MALT1 pre-mRNA near 
exon7 (between intron5 and intron9) and in a more distant region (exon2) was investigated. 
This was performed in Jurkat T cells by RNA-binding protein IP (RIP) using anti-hnRNP U 
or IgG control antibodies. Thereby, enrichment of distinct MALT1 pre-mRNA regions was 
analyzed by qPCR (Figure 3.21a). Upon precipitation of hnRNP U, the pre-mRNA of MALT1 
around exon7 was enriched compared to IgG control and hnRNP U-depleted cells. Moreover, 
hnRNP U binding was highest within or in close proximity to exon7. No significant 
accumulation of an intron1-exon2 fragment was observed upon hnRNP U RIP, revealing that 
hnRNP U specifically binds to exon7 surrounding regions. Association of hnRNP U with 
MALT1 pre-mRNA was also seen by semi-qPCR using primers specifically amplifying the 
region in6/ex7-in7 (Figure 3.21b). Collectively, hnRNP U binds to MALT1 pre-mRNA in 
vicinity to the alternatively spliced exon7. 
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Figure 3.21: hnRNP U binds to MALT1 pre-mRNA near exon7. (a,b) After transfection with si-control or si-
hnRNP U, Jurkat T cells were lysed and incubated with IgG control or anti-hnRNP U antibodies. 10 % of total 
lysate were saved as input. (a) Precipitates were analyzed for MALT1 pre-mRNA enrichment by qPCR using 
primers amplifying the depicted fragments. RIP RNA fractions were normalized to RNA input and calculated 
relative to IgG control (IgG control set as 1). Primers amplifying in1-ex2 of MALT1 pre-mRNA served as 
negative control. (b) Association with MALT1 pre-mRNA was detected by semi-qPCR using primers amplifying 
the in6/ex7-in7 fragment. mRNA expression of MALT1, hnRNP U and RP2 in the input fraction were used as 
controls. Depicted is the mean ± SD (n=2) (a). 
3.3.4 hnRNP U-mediated exon7 skipping depends on exon7 adjacent intronic sequences 
Splicing regulation can be facilitated by binding of hnRNP or SR proteins to exonic or 
intronic sequences within the pre-mRNA (Chen and Manley, 2009). hnRNP U attaches to 
MALT1 pre-mRNA around exon7 (see Figure 3.21), but it remains unknown whether cis-
regulatory sequences around exon7 contribute to exon inclusion or skipping.  
Therefore, we made use of a minigene containing constitutive exon3 and exon7 of the 
transmembrane phosphatase CD45, which are efficiently recognized by the splicing 
machinery and thus permanently spliced (Figure 3.22a) (Motta-Mena et al., 2010). In order to 
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investigate alternative exon7 usage, MALT1 exon7 and adjacent intronic sequences of variable 
length (minigenes M5 and M6) were cloned into the CD45 minigene, between exon3 and 
exon7 (Figure 3.22a). Minigenes M5 and M6 were transfected into Jurkat T cells and exon7 
usage was analyzed by PCR using two vector backbone primers (Figure 3.22b). Whereas 
transfection of the longer construct M6 resulted in equivalent exon7 inclusion/exclusion, 
exon7 was almost completely skipped in cells expressing the shorter minigene M5 (Figure 
3.22b), revealing that regulatory sequences around exon7 control alternative exon7 splicing. 
Enhanced exon7 inclusion in M6 transfected cells might be due to additional enhancer 
elements, which are located within M6 but are absent in M5. To elucidate the impact of 
hnRNP U on exon7 splicing, hnRNP U was knocked down prior to minigene transfection. 
hnRNP U downregulation led to enhanced exon7 inclusion in both minigenes (Figure 3.22b), 
which further demonstrates its negative regulatory function regarding exon7 splicing. Thus, 
alternative MALT1 splicing is regulated by enhancer and silencer elements located within or 
in proximity to exon7. hnRNP U most probably binds to silencer sequences and thereby 
counteracts exon7 inclusion. 
 
Figure 3.22: Cis-regulatory sequences around exon7 control alternative MALT1 splicing. (a) Design of exon7 
spanning minigenes M5 and M6. MALT1 pre-mRNA fragments comprising exon7 were cloned into a vector 
harboring two constitutive CD45 exons (exon3 and exon7). CD45 forward (fw) and CD45 reverse (rev) primers 
(indicated by arrows) were used for splicing analysis. (b) Control and hnRNP U knockdown cells were 
transfected with minigenes M5 or M6 and alternative exon7 inclusion was monitored by PCR utilizing CD45-
specific primer pairs. RP2 served as internal control. hnRNP U levels were analyzed by Western Blot, in which 
β-ACTIN was used as loading control. 
To further localize the cis-regulatory sequences required for hnRNP U-mediated exon7 
exclusion, four additional minigenes (M1, M2, M3 and M4) were generated by stepwise 
removal of intronic sequences upstream and downstream of exon7 (Figure 3.23a). Together 
with M5 and M6, minigenes M1, M2, M3, and M4 were transfected into Jurkat T cells and 
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Figure 3.23: hnRNP U-mediated exon7 skipping is regulated by two regulatory sequences located 100-200 bp 
upstream and downstream of exon7. (a) Schematic of exon7-spanning minigenes M1-M6. MALT1 pre-mRNA 
comprising minigenes harboring exon7 and flanking intronic sequences were cloned into a CD45 exon3/exon7-
containing plasmid. CD45 forward (fw) and CD45 reverse (rev) primers were used for splicing analysis. (b) 
Minigenes M1-M6 were transferred into si-control and si-hnRNP U transfected cells and afterwards analyzed for 
exon7 inclusion and exclusion by PCR using CD45-specific primers. Amplification of RP2 was used as loading 
control. hnRNP U and β-ACTIN levels were analyzed by Western Blot. (c) Quantification of relative exon7 
inclusion. Exon7 expression was quantified and normalized to RP2 levels. To determine the percentage of exon7 
inclusion, exon7 expression was calculated relative to total minigene expression. Data show the mean ± SD 
(n=3) (c). *p < 0.05; **p < 0.01; ***p < 0.001; n.s. not significant; unpaired t-test. 
alternative exon7 usage was monitored by PCR. Again, exon7 inclusion was reduced in M5 
compared to M6 expressing cells. Exon7 was almost completely excluded in shorter 
minigenes M1-M4 indicating the presence of exon7 surrounding silencer sequences (Figure 
3.23b).  
To investigate hnRNP U-related effects, exon7 splicing was monitored upon hnRNP U 
knockdown. While hnRNP U downregulation promoted increased exon7 inclusion in 
minigenes M5 and M6, exon7 was less included in M3 and M4 and was completely absent in 
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M1 and M2 (Figure 3.23b). Quantification of three experiments revealed that hnRNP U 
knockdown most strongly affected exon7 inclusion of minigene M5, which comprises 200 bp 
5’ and 197 bp 3’ of exon7 (Figure 3.23c). As M1 and M2 are insensitive but M3 and M4 are 
still responsive to hnRNP U knockdown, the data suggest that hnRNP U regulated sequences 
are positioned between 200 bp and 100 bp 5’ and 94 bp and 197 bp 3’ of exon7. 
3.3.5 TCR-induced exon7 inclusion in CD4+ T cells is modulated by hnRNP U  
In previous experiments, hnRNP U was identified as a critical regulator of alternative MALT1 
splicing in Jurkat T cells. To investigate whether hnRNP U also regulates TCR-mediated 
exon7 inclusion in primary CD4+ T cells, hnRNP U knockdown was performed in CD4+ T 
cells from R26/CAG-CARΔ1stop-flCd4-Cre mice by using small hairpin RNA (shRNA) 
expressing adenoviruses. Thereby, two independent shRNAs against hnRNP U (hnRNP U #1 
and #2) were used, and U6 empty served as control virus. Infected CD4+ T cells were sorted 
based on GFP co-expression (Figure 3.24a) and afterwards stimulated with anti-CD3/CD28 to 
induce exon7 inclusion. Analysis of hnRNP U transcript levels revealed that adenoviral 
transfer of sh-hnRNP U #1 and #2 led to efficient downregulation of hnRNP U (Figure 
3.24b). To investigate the effects on MALT1 splicing, Malt1A and Malt1B mRNA levels 
between control and hnRNP U knockdown cells were compared. Indeed, Malt1A expression 
was increased (~ 3 fold) upon TCR stimulation in the absence of hnRNP U, whereas Malt1B 
levels were only mildly affected (Figure 3.24c).  
To assess whether enhanced exon7 inclusion upon TCR ligation correlates with a decrease in 
hnRNP U expression, CD4+ T cells were stimulated with anti-CD3 and changes in hnRNP U 
transcript levels were analyzed. Surprisingly, expression of the exon7 suppressor hnRNP U 
was increased upon T cell stimulation, but also exon7 splicing enhancers that had been 
identified in both screens (like hnRNP L, hnRNP R, SRSF3) were upregulated (Figure 3.24d). 
In summary, one can conclude that hnRNP U acts as a regulator of TCR-induced alternative 
splicing of MALT1. However, the degree of exon7 inclusion might not be controlled by a 
single splicing factor, but rather by a complex network of splicing enhancers and silencers. 
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Figure 3.24: hnRNP U acts as a negative regulator of MALT1A induction in CD4+ T cells. (a) Scheme of 
adenoviral construct targeting hnRNP U knockdown. U6 promotor drives sh-hnRNP U expression, whereas 
PGK promoter enables GFP co-expression. Successful transduction of CD4+ T cells from R26/CAG-CARΔ1stop-
flCd4-Cre mice with control or sh-hnRNP U adenoviruses was monitored by GFP co-expression. (b,c) After 
adenoviral transduction of CD4+ T cells with either control (U6 promoter only) or two hnRNP U adenoviruses 
(#1 and #2), GFP+ CD4+ T cells were sorted and stimulated with anti-CD3/CD28 stimulation for 6 h. (b) By 
using qPCR, hnRNP U knockdown was analyzed relative to Hmbs expression. hnRNP U levels in control 
infected cells were set to 1. (c) Analysis of Malt1A and Malt1B transcript levels of either control or sh-hnRNP U 
transduced cells. qPCR was performed using Hmbs as internal control and Malt1 isoform expression of control 
infected cells was set to 1. (d) Expression levels of different Sr and hnRNP proteins in CD4+ T cells from Balb/c 
mice were investigated after anti-CD3 stimulation using qPCR. Hmbs levels were used for normalization and 
relative induction was determined relative to unstimulated cells. Depicted is the mean ± SD (n=3) (b,c,d).  
*p < 0.05; **p < 0.01; ***p < 0.001; n.s. not significant; unpaired t-test. 
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3.3.6 hnRNP U counteracts T cell activation 
TCR stimulation induces alternative MALT1 splicing leading to MALT1A upregulation, 
which is required for sustained T cell activation (see section 3.2.6). As hnRNP U is critical for 
alternative MALT1 splicing, the question was raised whether modulation of alternative 
MALT1 splicing by hnRNP U also accounts for T cell activation. Therefore, we again 
knocked down hnRNP U by adenoviral transduction of CD4+ T cells from R26/CAG-
CARΔ1stop-flCd4-Cre mice and checked for T cell activation markers after stimulation. 
Infection of CD4+ T cells with control or two sh-hnRNP U adenoviruses was monitored by 
GFP co-expression. According to sh-hnRNP U transduced cells, GFPlow cells represent 
uninfected T cells with normal hnRNP U levels, whereas GFPhigh cells express sh-hnRNP U 
facilitating hnRNP U knockdown. By gating on GFPlow cells, no differences in CD69 or 
CD25 surface expression levels were observed between control and sh-hnRNP U infected 
cells (Figure 3.25a-c). However, GFPhigh cells, which downregulate hnRNP U expression, 
display enhanced CD25 and CD69 levels in comparison to control infected cells (Figure 
3.25a-c). Notably, the effects on CD69 levels were quite weak, which can be explained by the 
rapid upregulation of intracellular CD69 at the cell surface upon T cell activation. MFI 
calculation of GFPlow and GFPhigh expressing cells further revealed that CD69, and especially 
CD25, surface expression are increased in GFPhigh hnRNP U-depleted cells (Figure 3.25b,c). 
To analyze IL-2 production upon hnRNP U downregulation, we sorted for GFP+ CD4+ T cells 
to exclude effects from uninfected cells and measured Il2 transcript and IL-2 protein levels. 
Knockdown of hnRNP U by sh-hnRNP U #1 augmented Il2 mRNA levels (Figure 3.25d) and 
also enhanced the number of IL-2 positive cells in comparison to control infected cells 
(Figure 3.25e). Our findings reveal that hnRNP U negatively regulates T cell activation most 
likely by dampening MALT1A induction. Upon hnRNP U knockdown, MALT1A induction 
is enhanced resulting in a more robust CD69 and CD25 upregulation as well as IL-2 
production. Taken together, the splicing factor hnRNP U counteracts exon7 inclusion and 
thereby modulates the cellular MALT1 isoform expression ratio, which shapes the outcome of 
T cell activation. 
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Figure 3.25: Knockdown of hnRNP U diminishes activation of CD4+ T cells. (a-e) CD4+ T cells from 
R26/CAG-CARΔ1stop-flCd4-Cre mice were infected with control or sh-hnRNP U and afterwards stimulated with 
anti-CD3/CD28. (a) Infected cells were gated for GFPlow and GFPhigh expression and analyzed for their CD69 
and CD25 surface levels. (b,c) MFI values of CD69 (b) and CD25 (c) expression were compared between 
GFPlow (no hnRNP U knockdown) and GFPhigh (hnRNP U knockdown) cells and calculated relative to control 
infected, GFPlow expressing cells. (d,e) After adenoviral transduction, GFP+ CD4+ T cells infected with control or 
sh-hnRNP U#1 were sorted prior to anti-CD3/CD28 stimulation. (d) Relative Il2 mRNA levels were determined 
by qPCR using Hmbs as housekeeping gene. (e) Intracellular IL-2 levels were analyzed by flow cytometry. 
Depicted is the mean ± SD (n=3) (b,c,d). *p < 0.05; **p < 0.01; n.s. not significant; unpaired t-test 
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4 Discussion 
Recognition of a specific antigen by the TCR activates a network of downstream signaling 
pathways and consequently triggers T cell activation, proliferation, and differentiation into 
specific effector subsets. As part of the CBM complex, MALT1 paracaspase is a key player in 
adaptive immune responses, and mice lacking MALT1 expression are immunodeficient 
(Ruefli-Brasse et al., 2003; Ruland et al., 2003). MALT1 acts as a scaffolding protein by 
recruiting the E3 ligase TRAF6 to promote IKK activation (Oeckinghaus et al., 2007; Sun et 
al., 2004), but also harbors proteolytic activity to modulate T cell responses (Coornaert et al., 
2008; Rebeaud et al., 2008). Recently, high-throughput genomic studies have revealed that  
T cell activation is accompanied by widespread changes in alternative splicing patterns, 
indicating an essential role of alternative splicing for T cell functions during an immune 
response (Ip et al., 2007; Martinez et al., 2012). Although proteins with known 
immunological functions have been described to undergo alternative splicing, little is known 
about how alternative splicing modulates the functions of intracellular signaling mediators 
and how this affects T lymphocyte biology.  
In the present study, it was demonstrated that expression and function of MALT1 is 
modulated by alternative splicing, which influences the activation of downstream signaling 
pathways and thereby shapes the outcome of T cell activation. Alternative splicing of MALT1 
generates two splice variants, MALT1A and MALT1B, that differ in inclusion (MALT1A) or 
exclusion (MALT1B) of an 11 aa long exon7. TCR stimulation induces MALT1A expression, 
which augments MALT1 scaffolding function and fosters CD4+ T cell activation. The splicing 
factor hnRNP U negatively regulates exon7 inclusion and thereby modulates T cell activation. 
Based on the obtained results, one can suggest the following model (Figure 4.1). Murine, 
resting CD4+ T cells predominantly express the shorter isoform MALT1B, which lacks exon7 
and only harbors the two C-terminal TRAF6 binding sites (T6BM2/3). hnRNP U impairs 
exon7 inclusion and thus MALT1A expression by binding to exon7 adjacent sequences within 
the MALT1 pre-mRNA. Initial stimulation of primary MALT1B expressing CD4+ T cells 
results in CBM complex formation (not shown) and TRAF6 recruitment to the C-terminal 
T6BM3 within MALT1B leading to IKK/NF-κB and JNK/AP-1 activation. NF-κB and AP-1 
promote target gene expression, which causes a basal induction of T cell activation markers 
CD69, CD25, and IL-2. Whereas MALT1A expression is still suppressed by hnRNP U upon 
initial stimulation, prolonged T cell activation leads to increased exon7 inclusion and thus 
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Figure 4.1: Putative model for modulation of T cell activation by alternative MALT1 splicing. In naive CD4+ T 
cells, exon7 inclusion is repressed by hnRNP U leading to the expression of the shorter splice isoform MALT1B. 
Upon initial T cell activation, MALT1B recruits the E3 ligase TRAF6 via its C-terminal TRAF6 binding motif 
promoting IKK and JNK activation (not shown), which leads to IKK/NF-κB and JNK/AP-1 activation. As a 
result, T cells upregulate the activation markers CD69 and CD25 and secrete IL-2. Prolonged T cell stimulation 
promotes exon7 inclusion probably by releasing hnRNP U from the MALT1 pre-mRNA leading to MALTA 
induction. In contrast to MALT1B, MALT1A recruits TRAF6 via two functional TRAF6 binding sites and 
activates NF-κB and JNK more strongly resulting in more robust expression of CD69, CD25, and IL-2. 
MALT1A induction. Thereby, hnRNP U is probably replaced from the MALT1 pre-mRNA. 
MALT1A harbors an additional functional TRAF6 binding site (T6BM1) that strongly 
enhances NF-κB and slightly increases JNK signaling, forcing more robust NF-κB and AP-1 
activation, which strengthens T cell activation. Although hypoactive MALT1B is still the 
dominant isoform, elevated levels of the hyperactive isoform MALT1A, in combination with 
MALT1B, drive more robust signaling than T cells expressing solely MALT1B. Collectively, 
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hnRNP U controls TCR-mediated MALT1A induction, which modulates MALT1 scaffolding 
function to shape the outcome of T cell activation.  
4.1 TCR ligation induces alternative MALT1 splicing 
It is estimated that more than 90 % of mammalian multi-exon genes are alternatively spliced, 
with a bias towards genes that are expressed in the immune system, particularly in T cells 
(Lynch, 2004; Pan et al., 2008; Wang et al., 2008). High-throughput analyses revealed that 
many immunologically relevant kinases, phosphatases, cell surface receptors, signaling 
adapters and transcription factors undergo alternative splicing in response to T cell activation 
(Ip et al., 2007; Martinez et al., 2012). The present study demonstrates that the intracellular 
signaling mediator MALT1 is alternatively spliced upon TCR stimulation of murine CD4+  
T cells. MALT1A induction was also observed in human CD4+ T cells isolated from 
peripheral blood, but to a lesser extent than in the murine system. The differences in 
MALT1A/MALT1B isoform levels in humans and mice might be due to the fact that the cells 
were isolated from different compartments (peripheral blood versus spleen and lymph nodes), 
where they fulfill distinct effector functions. The less efficient MALT1A upregulation in 
human T cells can explain why alternative exon7 usage of MALT1 was never reported in 
global high-throughput analyses. Those screening approaches mainly analyzed alternative 
splicing changes in primary human CD4+ T cells or Jurkat T cells, but not in murine CD4+  
T cells (Ip et al., 2007; Martinez et al., 2012). Thereby, the stimulation-induced change in 
exon7 inclusion might not have reached the minimal detection threshold to be identified as a 
reliable alternative splicing event. It is also likely that the 33 bp long exon7 is too short to be 
detected in such global analyses using exon arrays. However, it was clearly demonstrated that 
MALT1A is significantly induced in both murine and human CD4+ T cells providing one of 
the first examples that a central regulator of TCR signaling is regulated by alternative 
splicing.   
In the study, TCR/CD28 co-stimulation, or even TCR ligation alone, promoted MALT1A 
expression. Induction of MALT1A was driven by both anti-CD3/CD28 antibodies as well as 
OVA-peptides, but was more profound in antibody-stimulated cells, which might represent 
the stronger TCR stimulus. It can be assumed that MALT1A induction correlates with the 
strength of TCR stimulation, but further experiments using differing amounts of stimulatory 
antibodies or OVA-peptides need to be performed to reinforce this notion. Nevertheless, it 
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can be concluded that TCR-driven signaling pathways are required to activate alternative 
MALT1 splicing. Several immunologically relevant proteins like the co-stimulatory receptor 
CTLA-4 (cytotoxic T lymphocyte antigen-4) or the intracellular signaling mediator FYN have 
been reported to undergo alternative splicing in response to TCR stimulation, but the 
underlying signaling pathways mediating exon inclusion or skipping are unknown 
(Magistrelli et al., 1999; Rothrock et al., 2003). A more recent study demonstrates that exon2 
of the JNK kinase MKK7 is excluded upon T cell stimulation and that the JNK signaling 
pathway itself accounts for alternative MKK7 splicing (Martinez et al., 2015). In addition, the 
Ras-MAPK pathway has been implicated in TCR-induced alternative splicing events, being 
involved in the regulation of the transmembrane phosphatase CD45, whose extracellular 
domain contains three variable exons that are skipped upon TCR ligation (Heyd and Lynch, 
2010; Lynch and Weiss, 2000). The reported findings reveal, that not one major but rather 
several signaling mediators such as protein kinases are capable of triggering alternative 
splicing events. Since those factors often modulate the functions of regulatory splicing 
factors, it seems likely that TCR-induced signaling pathways alter hnRNP U activity in order 
to promote exon7 inclusion (see section 4.6). The signaling pathways that drive alternative 
MALT1 splicing could not be elucidated in the present study, but will be addressed in future 
experiments by selective inhibition of central signaling mediators.  
Activation of alternative splicing by external stimuli mostly generates isoforms with different 
biological functions (Kornblihtt et al., 2013). T cell activation promotes numerous exon 
inclusion as well as exon exclusion events, which induce the expression of isoforms with 
elevated or reduced functionality (Martinez and Lynch, 2013). Alternative splicing of 
MALT1 is one example of how alternative splicing enriches the function of the newly 
generated isoform. The shorter isoform MALT1B represents the hypoactive isoform inducing 
moderate signaling, while the hyperactive splice variant MALT1A boosts NF-κB and JNK 
activation. Although TCR ligation promoted MALT1A induction, the shorter, hypoactive 
variant MALT1B still remained the more abundant isoform suggesting that not the absolute 
protein amounts but rather the relative MALT1A vs MALT1B expression levels determine 
downstream effects. Elevated MALT1A levels were also observed in activated T cell subsets 
underscoring the relevance of an enhanced MALTA/MALT1B ratio for T cell activation. 
In addition to MALT1, also other members of the NF-κB signaling pathway are alternatively 
spliced (Leeman and Gilmore, 2008). For example, stimulation of distinct cell types induces 
the expression of alternative splice variants of IRAK1 (interleukin 1 receptor associated 
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kinase 1), MyD88 (myloid differentiation factor 88) and TRAF3, which exert different effects 
on NF-κB signaling than the originally expressed isoforms (Birzele et al., 2011; Janssens et 
al., 2002; Michel et al., 2014; Rao et al., 2005). Whereas the signal-induced isoforms of 
IRAK1 and MyD88 are less potent to promote NF-κB activation, alternative TRAF3 splicing 
augments the NF-κB response. Thus, activation-induced alternative splicing can both enhance 
and reduce cellular responses and the sum of all alternative splicing events decides to which 
degree a cell is activated.  
By generating proteins with different functions, alternative splicing plays an important role in 
various cellular processes, such as cell growth, differentiation, and death (Chen and Manley, 
2009). For example, relative expression of the isoforms Bcl-xS/Bcl-xL or Caspase-9a/b 
determines whether a cell undergoes apoptosis (Rohrbach et al., 2005; Seol and Billiar, 1999; 
Srinivasula et al., 1999). Moreover, alterations in the Caspase-9a/9b ratio modulate the 
tumorigenic capacity of non-small cell lung cancer (NSCLC) cells (Goehe et al., 2010). With 
respect to T cells, some alternative splicing events have been described to regulate T cell 
responses (Martinez and Lynch, 2013). For example, one study suggests that changes in the 
ratio of the Wnt-signaling associated transcription factors LEF1 (lymphoid enhancer binding 
factor 1) and TCF7 (transcription factor 7) might control T cell quiescence upon activation of 
naive CD8+ T cells, but the underlying mechanisms are not understood (Willinger et al., 
2006). Changes in the ratio of the protein tyrosine kinase isoforms FynT and FynB have been 
also assumed to modulate T cell functions, since FynT upregulation promotes a more efficient 
IL-2 production (Davidson et al., 1992; Rothrock et al., 2003). The present study 
demonstrates that changes in the MALT1 isoform expression ratio impact on T cell activation 
and different ratios might lead to distinct T cell activation stages (see section 4.5). Single cell 
analyses will be required to determine precisely which MALT1 isoform expression ratio may 
account for inducing robust T cell responses. 
4.2 hnRNP U negatively regulates exon7 inclusion 
To elucidate the functional impact of alternative MALT1 splicing for T cell functions, it is 
critical to understand the underlying splicing mechanism. Trans-acting factors are key players 
in regulating alternative splicing as they enhance or suppress alternative exon usage 
(Kornblihtt et al., 2013). By searching for putative candidates controlling exon7 inclusion in 
the MALT1 mRNA, hnRNP U was identified as the most potent negative regulator of 
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alternative MALT1 splicing in two independent screening approaches in Jurkat T cells. 
hnRNP U is the most abundant and ubiquitously expressed hnRNP protein and has been 
implicated in a variety of cellular processes including mRNA stabilization (Kamma et al., 
1995; Kiledjian and Dreyfuss, 1992; Yugami et al., 2007). More recent studies have revealed 
that hnRNP U is an important regulator of alternative splicing (Huelga et al., 2012; Vu et al., 
2013; Xiao et al., 2012). Since there was no evidence that hnRNP U affects MALT1A or 
MALT1B mRNA stability, it is most likely that hnRNP U controls MALT1 isoform 
expression by counteracting exon7 inclusion. hnRNP U-mediated exon7 repression is in line 
with the general belief that hnRNP proteins act as splicing inhibitors (Busch and Hertel, 
2012). However, within the last ten years this classical paradigm has been revised, as there are 
many examples of hnRNP proteins enhancing exon inclusion (Martinez et al., 2012). 
According to hnRNP U-regulated splicing processes, one study observed that hnRNP U 
promotes exon inclusion and exclusion to a similar extent, while a second study reported a 
preferred tendency towards exon inclusion (~70 % of alternative splicing events) (Huelga et 
al., 2012; Xiao et al., 2012). Nevertheless, hnRNP U clearly suppressed MALT1 exon7 
splicing, which was further confirmed in an independent minigene approach. Consequently, it 
is not predictable whether a splicing regulator promotes exon inclusion or exclusion, because 
it depends on the cellular context.  
hnRNP proteins can mediate splicing repression by binding to either exonic or intronic 
silencer elements (Kornblihtt et al., 2013). Indeed, the present study provides evidence that 
hnRNP U associates with the MALT1 pre-mRNA and binding was strongly enriched in 
proximity to exon7 indicating the presence of silencer regions within or adjacent to exon7. 
Since binding studies were performed without crosslinking, it remains possible that hnRNP U 
does not directly target the MALT1 pre-mRNA. hnRNP proteins act in large homopolymer 
complexes and it is conceivable that other complex components bridge the association 
between hnRNP U and its target site (Fredericks et al., 2015). Therefore, more direct binding 
studies such as crosslinking in combination with hnRNP U-immunoprecipitation will be 
performed to confirm a direct linkage between hnRNP U and MALT1 pre-mRNA. 
Nevertheless, two 100 bp sequences located upstream and downstream of exon7 have been 
identified as putative binding regions. Of note, it is still possible that hnRNP U regulates 
alternative MALT1 splicing by binding to more distantly located intronic or exonic sequences 
within the MALT1 pre-mRNA. To address this question, one would need to investigate the 
total MALT1 pre-mRNA for putative hnRNP U binding sequences in a more global approach 
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using crosslinking and immunoprecipitation (CLIP). However, the interaction experiments 
performed in this study indicate that hnRNP U mainly associates with exon7 adjacent 
sequences. It has been described that hnRNP U preferentially binds to GU-rich sequences 
(Huelga et al., 2012; Kiledjian and Dreyfuss, 1992). The exon7 surrounding sequences were 
analyzed for putative silencer elements, but no striking GU-rich sequence stretches cropped 
up (data not shown). hnRNP U binding motifs are not well conserved, making it difficult to 
identify hnRNP U-responsive silencer elements. Structural studies elucidating hnRNP U 
binding preferences and mutational analyses of the localized 100 bp sequences could give a 
first hint how hnRNP U promotes exon7 skipping. Notably, hnRNP U does not solely regulate 
alternative splicing by sequence-specific pre-mRNA binding, but also by modulating the core 
splicing machinery (Xiao et al., 2012). In the latter case, hnRNP U shapes U2 snRNP 
maturation and thereby induces a multitude of splicing events suggesting that hnRNP U acts 
as a more global splicing regulator. One cannot rule out that hnRNP U contributes to exon7 
skipping via interfering with the general splicing process and future studies need to unravel 
the exact mechanism how hnRNP U affects general splicing components. However, the 
preliminary identification of two putative hnRNP U binding sites upstream and downstream 
of exon7 suggests a “looping-out” model (Figure 4.2): hnRNP U molecules bind to two exon7 
flanking silencer regions. Via protein-protein interaction, hnRNP U proteins loop out the 
intervening exon7 and thereby prevent splice site recognition by the spliceosome. 
Subsequently, exon7 is excluded resulting in the direct fusion of exon6 to exon8. Such a 
mechanism has already been proposed for hnRNP A1, which controls alternative splicing of 
its own hnRNP A1 pre-mRNA by binding to sequences flanking alternative exon7B 
(Hutchison et al., 2002; Nasim et al., 2002). Although this model is rather theoretical, it 
provides a suitable explanation for the presence of the two exon7 flanking sequence motifs 
within the MALT1 pre-mRNA. 
In the screening approaches, several other splicing factors besides hnRNP U were identified 
that promote either exon7 inclusion (e.g. RBMS1, hnRNP L, SRSF3) or skipping (e.g. hnRNP 
A1, SRRM1, RBM12B). Together with the minigene approach, which revealed the presence 
of additional cis-acting RNA elements, it seems most likely that alternative MALT1 splicing 
is regulated by a multitude of positive and negative regulatory trans-acting factors and cis-
acting sequences rather than by hnRNP U alone. This is in line with the finding that hnRNP U 
can cooperate with other splicing regulators having similar or opposing effects on the 
alternative splicing event (Huelga et al., 2012). In addition, TCR stimulation of primary  
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T cells led to an upregulation of both positive and negative regulatory splicing factors, which 
further suggests that a complex network of splicing factors competes for MALT1 pre-mRNA 
binding and thereby determines the degree of exon inclusion or exclusion (see Figure 4.3 in 
section 4.6). To unravel the underlying splicing mechanism, the individual contribution of 
each splicing factor needs to be addressed in future experiments e.g. by utilizing the generated 
minigene system. 
 
Figure 4.2: Looping out model for hnRNP U-mediated exon7 skipping. HnRNP U binds to ISSs (intronic 
splicing silencers; depicted in green) in the MALT1 pre-mRNA. hnRNP U proteins interact via protein-protein 
interactions and “loop out” the intervening exon7. 5’ and 3’ splice sites of exon7 are not recognized by the 
spliceosome (not shown) leading to exon7 exclusion.  
4.3 Exon7 inclusion augments MALT1 scaffolding function 
The recruitment of TRAF6 to MALT1 has been reported to be required for the activation of 
the IKK/NF-κB pathway (Oeckinghaus et al., 2007). Three TRAF6 binding sites have been 
mapped to MALT1, but so far only the very C-terminal TRAF6 binding motifs have been 
shown to contribute to TRAF6 recruitment and downstream signaling in T cells (Noels et al., 
2007; Sun et al., 2004). The study provides evidence that T6BM1 encoded by exon7 recruits 
TRAF6 and contributes to NF-κB activation and JNK signaling. The amount of recruited 
TRAF6 proteins was strongly enriched upon exon7 inclusion indicating the presence of an 
additional TRAF6 docking site. No complete structure of the MALT1 N-terminus is available, 
but one can assume that the critical glutamate (E) of T6BM1 is easily accessible. In contrast 
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to T6BM2 and T6BM3, the T6BM1 sequence A-V-E-C-T-E does not completely match the 
predicted consensus TRAF6 binding sequence P-X-E-X-X-Ar/Ac (Ar is an aromatic and Ac 
an acidic residue) (Ye et al., 2002). Therefore, it seems possible that T6BM1 is not a fully 
functional TRAF6 binding site. However, T6BM1 significantly recruits TRAF6 in our 
experiments. Noels et al. suggested that exon7 encodes two partial, overlapping TRAF6 
binding sites, which contribute to NF-κB activation in reporter assays (Noels et al., 2007), but 
our mutational analysis revealed that exon7 contains one critical glutamate and thus one 
TRAF6 binding motif. Moreover, the T6BM1 sequence also shows some similarities to the 
TRAF2 consensus binding motif P/S/T/A-X-Q/E-E suggesting that TRAF2 might also bind to 
T6BM1 (Ye et al., 2002). More structural information and binding studies are required to 
elucidate the binding properties of T6BM1. 
What is the contribution of T6BM1 in conjunction with the other TRAF6 binding sites to 
downstream signaling? Mutational analyses in Jurkat T cells revealed that the exon7-encoded 
T6BM1 and the very C-terminal T6BM3 in MALT1A are relevant for signaling, whereas 
MALT1B only requires T6BM3. In MALT1A, one of the two T6BMs seems to be sufficient 
to induce full NF-κB and JNK signaling in Jurkat T cells. In contrast, the individual TRAF6 
binding motifs act more cooperatively in primary CD4+ T cells to mediate a full signaling 
response (Griesbach, 2012). One can speculate that modulation of T cell signaling strength 
seems to be more relevant in primary T cells than in transformed T cell lines, presumably to 
amplify weak TCR stimuli. Moreover, while T6BM1 and T6BM3 are functional, T6BM2 
located within the Ig3 domain is dispensable for the activation of downstream signaling in 
Jurkat T cells. A previous study has reported that both T6BM2 and T6BM3 are relevant for 
signaling, but the authors only analyzed the combined mutation T6BM2/T6BM3 (Sun et al., 
2004). It has been shown that the Ig3 domain plays a crucial role for MALT1 paracaspase 
activity, although the exact mechanism of MALT1 activation is still unknown (Wiesmann et 
al., 2012; Yu et al., 2011). In its inactive state the Ig3 domain adopts an auto-inhibitory 
conformation by folding back to the caspase-like domain, preventing MALT1 activation. 
Within this closed conformation the T6BM2 is most likely unable to recruit TRAF6, 
presumably because structural rearrangements within the Ig3 domain are required to make 
T6BM2 accessible for TRAF6 binding (Wiesmann et al., 2012). However, no TRAF6 binding 
to the T6BM2 within MALT1A or MALT1B has been detected. As CBM complex formation 
is not affected in cells expressing the TRAF6 binding mutants, one can exclude severe 
structural alterations by mutating the critical TRAF6 binding sites within MALT1. Thus, 
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T6BM2 seems to be a non-functional TRAF6 binding site and might be dispensable for 
MALT1 scaffolding function. Due to its position within the Ig3 domain, one could speculate 
if T6BM2 instead contributes to MALT1 paracaspase activity. It has been reported that 
activation of MALT1 requires monoubiquitination of K644 in the C-terminal Ig3 domain of 
MALT1A (Pelzer et al., 2013). Initial experiments from our group demonstrated that this 
process does not depend on TRAF6 (data not shown) revealing that TRAF6 binding might not 
be relevant for MALT1 activation. Thus, T6BM2 might fulfill other functions than recruiting 
TRAF6, but future structural studies are required to understand how T6BM2 might be 
involved in MALT1 activation. 
TRAF6 is a RING-type E3 ligase that conjugates K63-linked ubiquitin chains in conjunction 
with the dimeric E2 enzyme Ubc13-Uev1A (Deng et al., 2000). Upon TCR ligation, TRAF6 
is recruited to MALT1 leading to TRAF6 oligomerization and activation of its ligase activity 
(Sun et al., 2004). In turn, TRAF6 polyubiquitinates MALT1 creating a docking site for the 
recruitment of NEMO, which is in turn also ubiquitinated by TRAF6 (Oeckinghaus et al., 
2007). In the present study, overall MALT1 ubiquitin levels and MALT1-mediated NEMO 
recruitment were slightly reduced in MALT1B compared to MALT1A expressing cells, 
suggesting that exon7 inclusion enhances TRAF6-mediated MALT1 ubiquitination and 
concomitant IKK complex binding. So far, it has only been reported that multiple lysine 
residues in the C-terminus of MALT1B are ubiquitinated by TRAF6 (Oeckinghaus et al., 
2007), but it is also conceivable that TRAF6 conjugates additional ubiquitin chains to lysine 
residues within or adjacent to exon7 and thereby augments overall MALT1 ubiquitination. 
The effects on MALT1 ubiquitination were more severe upon deletion of exon7 in MALT1B 
than point mutation of T6BM1 in MALT1A, suggesting that the function of exon7 is not 
solely limited to TRAF6 recruitment. It might recruit additional E3 ligases or effector 
molecules, which modulate MALT1 signaling functions (see below). In addition to NEMO, 
MALT1 ubiquitin chains also mediate the recruitment of the TAB2/3/TAK1 complex, which 
promotes IKKβ phosphorylation (Oeckinghaus et al., 2007; Sun et al., 2004). It was not 
clarified whether exon7 inclusion augments TAK1 recruitment or IKKβ phosphorylation, but 
the fact that MALT1A ubiquitination was enhanced supports this assumption. TAK1 also 
serves as an upstream kinase of JNK, which stimulates the MAP2K MKK7 to promote JNK2 
activation (Blonska et al., 2007). Mutations of the critical TRAF6 binding sites within 
MALT1 clearly abolished JNK signaling, which is in line with the observations from Malt1 
knockout mice that fail to activate JNK (Ruland et al., 2003). One can assume that T6BM1 
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augments MALT1 ubiquitination and thereby TAK1 recruitment, which in turn facilitates 
more robust activation of MKK7 and IKKβ. Additional pulldown studies and IKKβ kinase 
assays are required to unravel whether MALT1A enhances downstream signaling by 
augmenting activation of the TAK1/IKKβ axis. 
The relevance of K63-linked ubiquitin chains is underscored by the finding that T cell-
specific deletion of the E2 conjugating enzyme Ubc13 impairs NF-κB activation (Yamamoto 
et al., 2006). However, the relevance of TRAF6 for TCR-induced NF-κB and JNK signaling 
remains questionable, since T cells from mice lacking TRAF6 expression show no 
abnormalities in the activation of NF-κB and JNK upon TCR ligation (King et al., 2006). 
Nevertheless, this study reveals that the TRAF6 binding motifs within MALT1 are definitely 
required for downstream signaling. Together with the observation that single mutation of 
T6BM1 was less severe than exon7 deletion, one can assume that other E3 ligases might 
compensate for the loss of TRAF6. It has been reported that TRAF6 and TRAF2 have 
redundant functions, as knockdown of both proteins led to a stronger reduction of IKK 
activation than knockdown of one E3 ligase (Sun et al., 2004). However, no experimental 
evidence has been provided so far that TRAF2 associates with MALT1 or promotes MALT1 
ubiquitination. Furthermore, the E3 ligase MIB2 (mindbomb E3 ubiquitin protein ligase 2) 
has been shown to facilitate NEMO ubiquitination in in vitro assays, but the relevance for 
CBM complex-mediated signaling remains unknown (Stempin et al., 2011). A more recent 
study demonstrates that the ligases cIAP1/2 support IKK activation in an oncologic scenario 
of BCR-driven lymphoma as they conjugate K63-linked ubiquitin chains to BCL10 (Yang et 
al., 2016). Whether cIAP1/2 also bind to MALT1 and mediate MALT1 ubiquitination in  
T cells has not been elucidated. Clearly future studies need to determine, which E3 ligases 
associate with MALT1 and might have redundant functions with TRAF6 to mediate MALT1 
ubiquitination and subsequent IKK activation. 
4.4 Alternative MALT1 splicing is dispensable for MALT1 protease activity 
Besides its scaffolding function MALT1 is also a paracaspase, which is activated upon TCR 
stimulation and modulates T cell responses (Coornaert et al., 2008; Rebeaud et al., 2008). The 
enzymatic activity of MALT1 is not directly involved in IKK-mediated NF-κB signaling, but 
in modulating T cell responses by cleaving substrates, which are relevant for signaling and 
post-transcriptional gene regulation (Bornancin et al., 2015; Gewies et al., 2014; Jaworski et 
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al., 2014). Inclusion of exon7 did not alter MALT1 paracaspase activity, revealing that exon7 
primarily affects MALT1 scaffolding function. The production of IL-2 critically depends on 
MALT1 scaffolding function and is partially driven by MALT1 protease activity (Bornancin 
et al., 2015; Duwel et al., 2009; Jaworski et al., 2014; Oeckinghaus et al., 2007; Yu et al., 
2015). Enhanced IL-2 levels were observed upon TCR-induced MALT1A upregulation in 
CD4+ T cells, which correlated with an enhanced ability to activate downstream signaling. 
Since there is comparable MALT1 protease activity between MALT1A and MALT1B, the 
more robust IL-2 production in cells with enhanced MALT1A levels is due to an increase in 
MALT1 scaffolding function. 
MALT1 protease is essential for T cell fate decision, which was observed in Malt1-/- and 
MALT1 paracaspase mutant (Malt1PM) mice (Bornancin et al., 2015; Brustle et al., 2012; 
Gewies et al., 2014; Jaworski et al., 2014; Yu et al., 2015). Specifically, CD4+ T cells from 
both Malt1-/- and Malt1PM mice were unable to differentiate into TH17 cells, which are known 
to drive pro-inflammatory responses by producing a various amount of pro-inflammatory 
cytokines (Bornancin et al., 2015; Brustle et al., 2012). This is in line with the results from the 
in vitro differentiation experiments, in which CD4+ T cells reconstituted with a catalytically 
inactive mutant MALT1A C464A fail to differentiate into TH17 cells. Moreover, we also 
observed a decreased commitment towards the TH1 cell lineage upon reconstitution with 
MALT1A C464A, whereas TH1 cell differentiation of Malt1-/- and Malt1PM mice was only 
mildly affected (Bornancin et al., 2015; Brustle et al., 2012). Although the results might be 
due to the limiting differentiation and stimulation conditions, one can conclude that MALT1 
protease also affects differentiation into TH1 cells under weak stimulation conditions. In 
contrast, CD4+ T cells reconstituted with either MALT1A or MALT1B fully differentiated 
into TH17 and TH1 cells and there was no difference between MALT1A and MALT1B 
expressing cells. The slightly enhanced commitment of MALT1B compared to MALT1A 
cells might be due to different reconstitution efficiencies in the single experiments. Thus,  
T cell fate decisions do not depend on MALT1 scaffolding activity, but are largely controlled 
by MALT1 paracaspase activity. Thereby, MALT1 contributes to the generation of TH17 
effector cells by removing the post-transcriptional regulators Regnase-1 and Roquin, which 
dampen the upregulation of TH17 differentiation inducing factors like IκBNS and IκBζ 
(Jeltsch et al., 2014; Uehata et al., 2013). Regarding other T cell subsets, the experimental 
setup was not optimal to monitor effects of MALT1A and MALT1B on TH2 and Treg 
differentiation. Due to the fact that the generation of Treg cells also relies on MALT1 
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paracaspase function, it can be assumed that MALT1 isoforms would not differ in their 
potency to drive Treg differentiation (Bornancin et al., 2015; Gewies et al., 2014; Jaworski et 
al., 2014; Yu et al., 2015). However, it needs to be mentioned, that we only analyzed the 
differentiation potential of T cells expressing MALT1A or MALT1B only, but not different 
MALT1 isoform ratios. Variations in the relative MALT1 isoform expression might modulate 
the degree of T cell activation and thus may favor distinct cell fate decisions (see section 4.5). 
Single cell analyses will be a useful next step in elucidating whether relative MALT1 isoform 
expression modulates T cell differentiation. 
MALT1 paracaspase activity has been connected to JNK signaling by cleaving the 
deubiquitinase CYLD (Staal et al., 2011). CYLD removes K63-linked ubiquitin chains from 
signaling mediators such as NEMO and TAK1 and thus serves as a negative regulator of NF-
κB and JNK signaling (Sun, 2010). Upon T cell activation, MALT1-mediated CYLD 
cleavage inactivates CYLD and thereby supports JNK signaling and c-Jun activation (Staal et 
al., 2011). The additional TRAF6 binding motif in MALT1A contributes to JNK activation 
and enhanced JNK phosphorylation was also observed upon MALT1A induction in primary  
T cells. However, MALT1 activity and CYLD cleavage were not affected by preventing 
MALT1A induction arguing against a role of MALT1 protease in JNK activation. This is in 
line with results from Malt1PM mice that exhibit normal JNK signaling (Bornancin et al., 
2015; Gewies et al., 2014; Jaworski et al., 2014), revealing that the activation of JNK relies 
on MALT1 scaffolding function, but not on its protease activity.  
4.5 The MALT1 isoform ratio is critical for T cell activation 
Although no differences in T cell differentiation have been observed, alternative MALT1 
splicing clearly affected the degree of T cell activation. Elevated MALT1A levels in primary 
CD4+ T cells support the upregulation of T cell activation markers as well as IL-2 production, 
whereas cells with reduced MALT1A levels show moderate T cell activation. This is in line 
with the effects on downstream signaling, in which MALT1A upregulation promoted stronger 
NF-κB and JNK signaling. IL-2 is an important T cell growth factor, and IL-2-mediated T cell 
proliferation is induced by its binding to its heterotrimeric cell surface receptor (Malek, 
2008). It was also observed that expression of the IL-2 receptor subunit CD25 is strikingly 
enhanced upon MALT1A induction revealing that alternative MALT1 splicing boosts the  
IL-2-mediated feedback loop and concomitant T cell proliferation. These results are similar to 
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the observations from MALT1A and MALT1B reconstituted primary CD4+ T cells, in which 
MALT1A more potently induced IL-2 production in FACS analyses (Griesbach, 2012). As 
JNK signaling is dispensable for IL-2 production and concomitant T cell activation, elevated 
CD25 and IL-2 expression might predominantly rely on NF-κB activation (Dong et al., 2000). 
Transcription of Il2 is also driven by other transcription factors like AP-1 and NFAT (Malek, 
2008), but whether AP-1 and NFAT activation are influenced upon MALT1A induction could 
not be elucidated during this study. In addition to IL-2, elevated CD69 levels were observed 
upon MALT1A induction compared to MALT1B expressing cells, but the effects were less 
pronounced than for CD25 and IL-2. This can be explained by the fact that a high percentage 
of CD69 molecules is pre-stored in intracellular vesicles and therefore rapidly upregulated 
upon TCR stimulation (Risso et al., 1991). Thus, the data indicate that MALT1B seems to 
limit T cell signaling strength and concomitant activation, while MALT1A upregulation 
induces stronger T cell signaling to trigger a more robust T cell response.  
The relative expression of MALT1A versus MALT1B determines T cell signaling strength 
and the degree of T cell activation and can vary from cell to cell. It seems reasonable that 
different T cell activation stages might trigger distinct cell fate decisions in individual cells, as 
a number of reports provide evidence that not only the cytokine milieu but also the quality 
and the quantity of TCR signaling determine the ability to differentiate into distinct T cell 
subsets (Tubo et al., 2013; van Panhuys et al., 2014). One study suggests that an intermediate 
antigen dose promotes TH1 cell differentiation, whereas a strong TCR stimulation favors the 
generation of germinal center TFH cells (Baumjohann et al., 2013; Tubo et al., 2013). It was 
also reported that TH17 cell differentiation is favored by low-strength T cell stimulation 
(Purvis et al., 2010). In the present study, it was clearly demonstrated that MALT1A 
induction strengthens TCR signaling to NF-κB and JNK, promoting robust T cell activation, 
and that MALT1A levels are sustainably enhanced in activated TFH cell subsets in vivo. 
Furthermore, TH1 and TH17 cell differentiation were slightly enhanced in MALT1B 
expressing cells, which only induce moderate T cell signaling. In the context of the literature, 
the findings suggest a model in which low MALT1A/MALT1B ratios support TH1 and TH17 
cell differentiation, whereas elevated MALT1A levels favor TFH cell differentiation 
(Baumjohann et al., 2013; Purvis et al., 2010; Tubo et al., 2013). However, the molecular 
mechanisms translating distinct T cell signaling intensities into individual responses remain 
elusive and there are also contradictory reports proposing other antigen dosages for TH1, TH17 
or TFH cell differentiation. Certainly, modulation of T cell fate decisions by TCR signaling 
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strength cannot be considered independently, as different cytokine milieus can guide diverse 
outcomes. Therefore, TCR signaling can synergize or antagonize cytokine-driven effects 
(Huang and August, 2015). For example, the responsiveness to IL-2 signaling largely depends 
on TCR-signaling strength and this dose-dependent control is critical for iTreg differentiation 
(Chen et al., 2003; Davidson et al., 2007; Huang and August, 2015; van Panhuys, 2016). 
Strong TCR signaling together with elevated IL-2 and CD25 levels upon MALT1A induction 
might influence the generation of iTreg cells, but further differentiation studies especially on 
the single cell level are required to fully understand how MALT1 isoform expression 
influences T cell fate decisions. Nevertheless, one can speculate that the ratio of MALT1A 
versus MALT1B might constitute an early bifurcation point to translate TCR signaling 
strength into different T cell activation stages, which differentiate into diverse effector subsets 
with distinct functions.   
TCR-induced MALT1A induction clearly boosted activation of the NF-κB and JNK signaling 
pathways, which both have been reported to influence T cell fate decisions. Activated T cell 
subsets express high levels of MALT1A, with the strongest upregulation being observed in 
TFH cells. It is conceivable that elevated MALT1A levels support TFH cell differentiation by 
inducing a strong NF-κB response, which is in line with the findings that NF-κB1-deficient 
OT-II mice were less prone to differentiate into TFH cells (Serre et al., 2011). Thus, elevated 
NF-κB signaling upon MALT1A induction might be one critical mechanism for driving TFH 
cell differentiation. Moreover, NF-κB1 is a major driver of GATA3 expression, which 
supports TH2 cell differentiation (Das et al., 2001) and some components of the TCR-induced 
NF-κB signaling pathway have already been associated with the generation of TH2 cells. 
Ablation of PKCθ or the CBM component CARMA1 in mice inhibited TH2 cell 
differentiation (Marsland et al., 2004; Medoff et al., 2006). Although no evidence was 
provided for a role of MALT1A or B in the generation of TH2 cells, one can speculate 
whether enhanced NF-κB signaling by elevated MALT1 isoform expression boosts TH2 cell 
differentiation. Additionally, JNK signaling is involved in T cell fate decisions as MKK7-
mediated JNK2 activation favors TH1 cell differentiation (Dong et al., 2000), but the impact 
on the generation of other T cell effector subsets is largely unknown. Surprisingly, MALT1A 
expressing cells were less prone to undergo TH1 cell differentiation compared to MALT1B 
cells. Again, only the effects of either MALT1A or B, but not of different MALT1 isoform 
ratios were analyzed. Therefore, one cannot rule out that different activation levels of NF-κB 
and JNK by different MALT1 isoform ratios might favor distinct cell fate decisions. 
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4.6 TCR-mediated control of alternative MALT1 splicing  
Alternative splicing of MALT1 is tightly regulated by hnRNP U in conjunction with other 
splicing regulatory proteins, which may synergize or antagonize each other, and the balance 
of splice factor activities determines the extent of exon7 inclusion in the mature MALT1 
mRNA. T cell stimulation leads to increased exon7 inclusion and thus MALT1A induction in 
primary CD4+ T cells, suggesting that TCR-induced signaling pathways modulate alternative 
MALT1 splicing mainly by altering the activity of splicing regulatory proteins. How signaling 
pathways shape splice factor activity is a largely unexplored field, but results from recent 
studies and our own experiments might give a first hint of the mechanism of TCR-induced 
MALT1 splicing. 
Transcripts are usually associated with numerous trans-acting factors and subtle changes in 
splicing factor expression can alter the ratio of isoform expression. TCR stimulation 
influences the expression levels of splicing regulatory proteins, which might also be relevant 
for alternative MALT1 splicing (Heyd and Lynch, 2011). Indeed, TCR ligation modulated 
hnRNP U expression levels. Surprisingly, hnRNP U was upregulated upon stimulation, which 
is in conflict with the observation that MALT1A expression was simultaneously enhanced. 
However, at the same time putative positive regulatory splice factors, such as hnRNP R, 
SRSF3 and SRSF7, are induced upon TCR ligation, suggesting that alternative MALT1 
splicing depends on the expression of multiple positive and negative splicing regulators. It is 
conceivable that increased expression of positive-regulatory splicing factors trumps the 
negative-regulatory impact of hnRNP U and thus promotes enhanced exon7 inclusion. One 
example for an alternative splicing event that is regulated by splicing factor expression levels 
is alternative splicing of the phosphatase CD45, which relies on the induction of hnRNP LL 
(Oberdoerffer et al., 2008; Topp et al., 2008; Wu et al., 2008). Upon T cell activation,  
hnRNP LL is upregulated and is more efficient at promoting exon repression than the basal 
splicing factor hnRNP L (Topp et al., 2008), but the underlying mechanism how hnRNP LL 
induction drives a more robust exon skipping than hnRNP L alone is still unclear. It has been 
suggested that both hnRNP L and hnRNP LL act independently and bind to CD45 pre-mRNA 
simultaneously. Considering the increased expression of splicing regulatory proteins 
modulating alternative MALT1 splicing, one can assume that multiple splicing regulatory 
factors bind to distinct regions within the MALT1 pre-mRNA, and that an elevated expression 
ratio of positive versus negative regulatory factors favors splice site selection and thus exon7 
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inclusion. However, it is also conceivable that splicing factors compete for MALT1 pre-
mRNA binding, in which highly expressed positive regulatory splicing factors replace 
negative regulatory proteins such as hnRNP U. Determining which model accounts for 
alternative MALT1 splicing requires the identification of responsible cis-regulatory elements 
and their trans-acting factors. Of note, the upregulation of relevant splicing candidates was 
observed on the mRNA level, but also needs to be investigated at the level of protein 
expression. 
TCR-induced signaling pathways might not only alter splicing factor expression levels, but 
also their activity. Thereby, post-translational modifications especially phosphorylation events 
play a relevant role (Naro and Sette, 2013). Numerous signaling pathways have been 
implicated in several splicing processes modulating SR and hnRNP protein activity. For 
example, phosphorylation of the splicing factor Sam68 (Src-associated in mitosis 68 kDa) by 
ERK enhances Sam68-mediated variant exon5 inclusion into the CD44 mRNA (Matter et al., 
2002). Moreover, the AKT/PI3K pathway has been shown to phosphorylate hnRNP L and 
thereby modulate hnRNP U-regulated alternative Caspase-9a/b splicing (see below) (Vu et 
al., 2013). Initial inhibitor experiments in murine CD4+ T cells also suggest a link between 
TCR-induced AKT signaling and alternative MALT1 splicing (data not shown), but 
stimulation conditions and inhibitor concentrations need to be optimized to draw a clear 
conclusion. Regarding hnRNP U, it has been reported that hnRNP U is phosphorylated in vivo 
(Kiledjian and Dreyfuss, 1992) and a more recent study demonstrated that polo-like kinase 1 
(PLK1) phosphorylates hnRNP U on Ser59 (Douglas et al., 2015). Whether TCR-induced 
AKT signaling might induce phosphorylation of hnRNP U or other splicing factors involved 
in alternative MALT1 splicing, needs to be further investigated. Of note, multiple other 
signaling pathways can be involved and might cooperate to determine the degree of exon7 
inclusion. 
It has been reported that signaling pathways can modulate the interaction of regulatory splice 
factors to their target pre-mRNAs (Heyd and Lynch, 2011; Shin and Manley, 2004; Stamm, 
2008). One well-understood example of signaling-induced changes in splice factor binding 
properties is PTB-associated splicing factor (PSF)-mediated regulation of alternative CD45 
splicing (Heyd and Lynch, 2010). TCR ligation weakens the association of PSF and thyroid-
hormone receptor-associated protein 150 (TRAP150), enabling PSF binding to CD45 pre-
mRNA mediating exon exclusion. hnRNP U preferentially binds to exon7 adjacent sequences 
in unstimulated Jurkat T cells. In initial RIP studies, we observed a reduced association of 
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hnRNP U with the MALT1 pre-mRNA upon anti-CD3/CD28 stimulation in Jurkat T cells 
(data not shown), which indicates a stimulation-induced release of hnRNP U from its target 
site. Thereby, signaling pathways might alter hnRNP U binding affinities, as it has been 
shown for alternative caspase-9a/b splicing (Vu et al., 2013). In this study, hnRNP U 
positively regulates exon3 inclusion by binding to an RNA cis-regulatory element in the 
caspase-9 pre-mRNA, leading to an enhanced ratio of the longer splice variant caspase-9a 
versus the shorter isoform caspase-9b. AKT signaling limits exon3 inclusion, as it 
phosphorylates the repressor protein hnRNP L, which results in enhanced binding of hnRNP 
L to the same RNA sequence element. Whether hnRNP L also counteracts the association of 
hnRNP U with MALT1 pre-mRNA, needs to be addressed in further binding studies. The 
finding that several positive regulators, including hnRNP L, were identified in the two 
screening approaches indicates that hnRNP U could be replaced by multiple factors. How 
TCR-induced signaling might weaken hnRNP U binding to MALT1 pre-mRNA is highly 
speculative. It is conceivable that TCR-induced signals induce structural alterations in  
hnRNP U and thereby affect the RNA-binding motif and its interaction to other protein 
regulators. Such structural changes have been reported for a number of SR proteins including 
SRSF1 (Ser/Arg-rich splicing factor 1) (Cho et al., 2011), but are largely unexplored for 
hnRNP proteins. Thus, structural studies will be important in order to understand hnRNP U 
binding properties. 
Signaling pathways also impact on the subcellular localization of regulatory splicing factors. 
hnRNP proteins are concentrated in the nucleus, but can shuttle between the nucleus and the 
cytosol to facilitate mRNA export (Pinol-Roma, 1997). Therefore it is not surprising that 
signaling pathways might induce changes in the relative localization of splicing regulatory 
factors (Lynch, 2007). One well-documented example is hnRNP A1, which is phosphorylated 
and concomitantly degraded in the cytosol in response to osmotic shock preventing its 
association with nuclear transport factors and thus its nuclear accumulation (Guil et al., 2006; 
van der Houven van Oordt et al., 2000). Initially, it was reported that hnRNP U does not 
shuttle between nucleus and cytosol, and is restricted to the nucleus (Pinol-Roma and 
Dreyfuss, 1992). This observation has been revised, however, by a more recent study 
demonstrating that TLR signaling stimulates nuclear to cytoplasmic translocation of hnRNP 
U in macrophages (Zhao et al., 2012). Whether this event depends on hnRNP U 
phosphorylation is unclear. It is likely that TCR-induced signaling alters the nuclear-
cytoplasmic distribution of hnRNP U, which favors binding of positive-regulatory factors to 
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MALT1 pre-mRNA. Therefore, hnRNP U expression levels need to be examined in nuclear 
and cytosolic lysates in the course of stimulation.  
The results of this study demonstrate that hnRNP U controls TCR-mediated exon7 inclusion, 
but additionally indicate that alternative MALT1 splicing is regulated by a more complex 
network of splicing regulators. One can speculate the following model (Figure 4.3).  
 
Figure 4.3: Model for the regulation of exon7 inclusion by multiple splicing factors. In resting T cells, the 
splicing silencer hnRNP U bind to ISSs (intronic splicing silencers; depicted in green) and positive regulatory 
hnRNP and SR proteins associate with enhancer elements such as ISEs (intronic splicing enhancers; depicted in 
yellow) within the MALT1 pre-mRNA. hnRNP U is the dominant splicing regulator, which prevents exon7 
splice site recognition by the spliceosome (depicted in grey) and thereby mediates exon7 exclusion. Upon T cell 
activation, both positive regulatory splicing factors and hnRNP U are induced leading to enhanced binding of 
positive splicing regulators, which exceed hnRNP U-mediated exon7 repression. In addition, hnRNP U might be 
released from the MALT1 pre-mRNA due to a decreased affinity to its target sequences and might be exported 
into the cytosol. As a result, exon7 is included in the mature MALT1 mRNA.   
In resting T cells, MALT1 pre-mRNA is bound by both hnRNP U and other positive-
regulatory splicing factors. hnRNP U is the dominant splicing regulator promoting enhanced 
exon7 repression. Upon TCR ligation, signaling pathways are activated and increase overall 
splicing factor expression. Enhanced expression of positive regulatory splicing factors 
exceeds hnRNP U-mediated exon7 repression, leading to an enhanced degree of exon7 
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inclusion. Signaling pathways might also weaken hnRNP U-MALT1 pre-mRNA binding or 
increase the association of positive regulatory factors with MALT1 pre-mRNA. Moreover, the 
nuclear concentration of hnRNP U might be decreased due to enhanced nuclear export upon 
TCR ligation. It can be assumed that TCR-induced signaling regulates the functions of 
splicing factors implicated in alternative MALT1 splicing not by one simple mechanism, but 
rather by multiple steps that are required to fine tune T cell responses.  
4.7 Conclusion and perspectives 
Understanding the regulation of T cell responses by alternative splicing is a field of intensive 
research, however, the underlying mechanisms and the functional impact of those events are 
largely unexplored. In the present study, it was revealed that robust T cell signaling and 
activation requires alternative splicing of MALT1, which is controlled by a complex network 
of splicing factors including the negative regulator hnRNP U. It was observed that not the 
absolute amount, but rather the relative MALT1A versus MALT1B expression level seems to 
determine the degree of downstream T cell signaling and activation. Thus far, the impact of 
alternative MALT1 splicing has been investigated in cellular pools, but cell populations can 
be highly heterogeneous, meaning that MALT1 isoform levels can vary from cell to cell. 
Therefore, it will be a useful next step to analyze MALT1A and MALT1B expression on the 
single cell level by qPCR to determine whether different ratios promote distinct T cell 
activation stages. In this respect, it will be important to examine MALT1 isoform expression 
levels in activated T cell subsets and to dissect the role of different isoform ratios for T cell 
fate decisions. 
Inclusion of exon7 in MALT1A encodes for an additional TRAF6 binding site and this was 
shown to enhance MALT1 scaffolding function, but not MALT1 paracaspase activity. To 
date, no structure of the complete MALT1 protein has been solved. Furthermore, although 
structures of individual MALT1 domains have been published, the structure of the entire N-
terminus has not been reported. Crystallization of the N-terminus including exon7 will be 
necessary to understand the contribution of exon7 to MALT1A scaffolding function. 
MALT1A was more potent to promote JNK and NF-κB signaling than MALT1B. It remains 
to be addressed whether this increase in JNK and NF-κB activation relies on enhanced IKK 
activation and TAK1 binding. Therefore, additional pulldown experiments monitoring TAK1 
recruitment, as well as IKKβ kinase assays are required to elucidate the stronger ability of 
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MALT1A to stimulate downstream signaling. Moreover, mass spectrometry approaches using 
cells expressing MALT1A, MALT1B, and MALT1A/B TRAF6 binding mutants could reveal 
differences in the recruitment of downstream signaling mediators and help to identify 
unknown binding partners. It would be of particular interest to determine whether other E3 
ligases than TRAF6 are recruited to MALT1 and mediate MALT1 ubiquitination.  
Alternative MALT1 splicing critically depends on the splicing regulator hnRNP U. The 
putative binding sequences were narrowed to two 100 nt sequences in proximity to exon7 
using a minigene approach in Jurkat T cells. hnRNP U binding can be studied using X-link IP, 
which directly crosslinks hnRNP U to radiolabeled RNA fragments and thus enables the 
visualization of hnRNP U/RNA complexes. Reducing those RNA fragments up to 20 nt in 
combination with distinct point mutations could be a useful strategy to pinpoint both  
hnRNP U binding motifs. Characterized sequences could be further studied using our 
established minigene system. Since multiple other splicing factors like hnRNP D, hnRNP L, 
hnRNP R or SRSF3 modulate alternative MALT1 splicing, it will be necessary to dissect the 
individual contribution of splicing regulators for exon7 inclusion. Therefore, combined 
knockdown of hnRNP U and other putative factors using the minigene system would reveal 
whether they act synergistically, antagonistically or completely independently. Moreover, 
determining which signaling pathways affect alternative MALT1 splicing will uncover more 
details about the mechanisms regulating this process. Analyzing MALT1 isoform expression 
and splicing factor activity following pharmacologic inhibition of critical signaling mediators 
such as AKT, JNK and GSK3 in primary CD4+ T cells would help to elucidate the connection 
between TCR-induced signaling pathways and alternative exon7 inclusion. In this respect, it 
would be relevant to address whether TCR ligation alters the phosphorylation status, binding 
affinities, and subcellular localization of critical splicing factors. 
The present study has demonstrated that alternative MALT1 splicing has a critical role in 
regulating T cell functions in ex vivo experiments. However, MALT1 is also involved in the 
activation of other immune cells like B cells, mast cells and macrophages (Jaworski and 
Thome, 2015). Generating transgenic mouse lines expressing either MALT1A (Malt1A/A) or 
MALT1B (Malt1B/B) would be a suitable strategy to expand upon this ex vivo model and to 
elucidate the physiological relevance of alternative MALT1 splicing not only for T cell 
responses, but also other immune cell types. Thereby, the CRISPR/Cas9 technique can be 
used to generate isoform selective mouse strains. Given the results of MALT1A and 
MALT1B on T cell activation, one can expect that mice, which exclusively express the 
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hyperactive variant MALT1A, will display a more activated phenotype. It is also conceivable 
that MALT1A expressing mice will develop signs of autoimmune diseases and inflammation. 
In order to obtain a global view of the extent of the effects of alternative MALT1 splicing, it 
will be interesting to characterize the overall immune system of MALT1 isoform-specific 
mice and to monitor the activation of signaling pathways in lymphocytes and other immune 
cells. Moreover, MALT1 isoform selective mice might reveal whether alternative MALT1 
splicing is involved in the development of immunological disorders, information that could 
provide promising new therapeutic avenues. Addionally, elevated MALT1A levels were not 
only observed upon T cell activation, but also in several B cell lymphoma cell lines (data not 
shown). Future studies could extent from this finding to determine the role of alternative 
MALT1 splicing in the development and maintenance of lymphomas. 
In summary, this study has uncovered a novel mechanism by which T cell function is 
controlled: alternative splicing of the paracaspase MALT1. The thesis contributes to a better 
understanding of the functions of a central player in lymphocyte activation and represents an 
important starting point for future studies addressing the impact of alternative MALT1 
splicing on the overall immune system and for the development of diseases.  
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5 Materials 
5.1 Instruments and equipment 
Agarose gel chambers NeoLab, Heidelberg 
Autoradiography MP films GE Healthcare, Freiburg 
Bacterial culture flasks BD, Heidelberg 
Cell-counting chamber Neubauer NeoLab, Heidelberg 
Cell culture flasks BD, Heidelberg 
Cell culture plates BD, Heidelberg; Nunc, Rochester, USA 
Cell strainer (100 µM) NeoLab, Heidelberg 
Centrifuges: 
Centrifuge Avanti J-26 XP Beckmann Coulter, Krefeld 
Cell culture centrifuge, 5804 Eppendorf, Hamburg 
Cooling cell culture centrifuge, 5810R Eppendorf, Hamburg 
Cooling table centrifuge, 5417R Eppendorf, Hamburg 
Table centrifuge, 5471C Eppendorf, Hamburg 
Chemiluminescence ECL films GE Healthcare, Freiburg 
CO2 incubators Binder, Tuttlingen 
Cryo tubes Greiner Bio-One, Frickenhausen 
Developer Optimax  Protec, Dorfwiesen 
DNA/RNA UV Cleaner Box Biosan, Riga, Latvia 
Electroporation cuvettes, Gene Pulser Bio-Rad, München 
Electroporator, Gene Pulser Xcell System Bio-Rad, München 
EMSA gel chamber, X952.1 Roth, Karlsruhe 
Film Cassettes Roth, Karlsruhe 
Flow Cytometers: 
Attune Acoustic Focusing Cytometer Life Technologies, Carlsbad, USA 
LSR II BD, Heidelberg 
Freezers Liebherr, Ochsenhausen 
Geldocumentation System Intas, Göttingen 
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Gel dryer 583 Bio-Rad, München 
Heatblock Techne, Staffordshire, UK 
Incubators Sartorius, Göttingen; Heraeus, Hanau 
Incubator Shaker I26 New Brunswick Scientific, Hamburg 
Irradiation chamber HWM-D 2000 137Cs Wälischmiller Engineering, Markdorf 
LightCycler480 Roche, Mannheim 
LightCycler plates 96 well 4titude, Berlin 
MACS columns Miltenyi Biotec, Bergisch Gladbach 
MACS rack Miltenyi Biotec, Bergisch Gladbach 
Magnetic rack Qiagen, Hilden 
Magnetic stirrer IKA Labortechnik, Staufen 
Microscopes Leica, Wetzlar 
Microtiter plate (U- or V-shape), 96-well Greiner Bio-One, Frickenhausen 
Microwave SHARP, Hamburg 
Nanodrop 2000 Thermo Fisher Scientific, Waltham, USA 
Petri dishes Greiner Bio-One, Frickenhausen 
pH-Meter Sartorius, Göttingen 
Photometer Eppendorf, Hamburg 
Photometer µQuant Bio-Tek, Bad Friedrichshall 
Pipettes Eppendorf, Hamburg 
Plastic cuvettes Brand, Wertheim 
Plastic filter tips TipOne (RNase free) StarLab, Hamburg  
Plastic pipettes Greiner Bio-One, Frickenhausen  
Plastic tips Eppendorf, Hamburg 
Power supplies Consort, Turnhout, Belgium 
Precision scales Kern, Balingen 
PVDF membrane Merck Millipore, Darmstadt 
Rotator NeoLab, Heidelberg 
SDS-PAGE chamber Roth, Karlsruhe 
Semi-dry blotter PHASE, Lübeck; Peqlab, Erlangen 
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Sorter: 
FACS Aria Cell Sorter BD, Heidelberg 
FACS Star plus BD, Heidelberg 
Streptavidin-coated plates  Thermo Fisher Scientific, Waltham, USA 
Thermocycler Eppendorf, Hamburg 
Thermomix comfort Eppendorf, Hamburg 
Tissue Culture Hoods Safeflow 1.2 Nunc, Wiesbaden 
Tubes Eppendorf, Hamburg 
Typhoon Scanner GE Healthcare, Freiburg 
ViCell-XR cell viability analyzer Beckman Coulter, Krefeld 
Vortexer Scientific Industries, Bohemia, USA 
Whatman paper Roth, Karlsruhe 
Water Bath Thermo HAAKE, Karlsruhe 
5.2 Chemicals 
5.2.1 General chemicals 
Adenosine triphosphate (ATP) Sigma-Aldrich, Taufkirchen 
Acrylamide/Bisacrylamide Roth, Karlsruhe 
Agar Roth, Karlsruhe 
Agarose Biozym, Hessisch Oldendorf 
Ammonium persulfate (APS) Bio-Rad, München 
Ampicillin  Roth, Karlsruhe 
Atufect transfection reagent Silence Therapeutics, Berlin 
Autoradiography developing solution Sigma-Aldrich, Taufkirchen 
Autoradiography fixing solution Sigma-Aldrich, Taufkirchen 
Boric acid Roth, Karlsruhe 
Bovine serum albumin (BSA) GE Healthcare, Freiburg 
Brefeldin-A Sigma-Aldrich, Taufkirchen 
Calcium chloride Roth, Karlsruhe 
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Disodium hydrogen phosphate Roth, Freiburg 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Taufkirchen 
DNA 1kb plus ladder Invitrogen, Carlsbad, USA 
dNTP-Mix Thermo Fisher Scientific, Waltham, USA 
Dithiothreitol (DTT) Sigma-Aldrich, Taufkirchen 
Ethylenediaminetetraacetic acid (EDTA) Roth, Freiburg 
Ethyleneglycol-bis(2-aminoethylether)-                                                                      
N,N,N′,N′-tetraacetic acid (EGTA) Sigma-Aldrich, Taufkirchen 
Ethanol (p. a.) Merck, Darmstadt 
Ethidiumbromide Roth, Freiburg 
Ethidium monoazide bromide Sigma-Aldrich, Taufkirchen 
Ficoll 400 Roth, Freiburg 
Glycerol Roth, Freiburg 
Glycine Roth, Freiburg 
Heparine Sigma-Aldrich, Taufkirchen 
HEPES Roth, Freiburg 
Isopropyl alcohol (p.a.) Merck, Darmstadt 
LB Roth, Freiburg 
Lumi-Glo ECL reagent NEB, Frankfurt 
Lymphoprep Stemcell Technologies, Köln 
Magnesium chloride Roth, Freiburg 
Methanol (p.a.) Merck, Darmstadt 
Nonidet P40 substitude (NP-40) Sigma-Aldrich, Taufkirchen 
PageRuler Prestained Protein Ladder Thermo Fisher Scientific, Waltham, USA 
Paraformaldehyde (PFA) Sigma-Aldrich, Taufkirchen 
Phenol:chloroform:isoamylalcohol (125:24:1) Thermo Fisher Scientific, Waltham, USA 
Polybrene Sigma-Aldrich, Taufkirchen 
Poly dI-dC Roche, Mannheim 
Potassium chloride Roth, Freiburg 
Potassium hydrogen phosphate Roth, Freiburg 
Protease inhibitor mix (Roche complete) Roche, Mannheim 
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Protein-G-Sepharose Invitrogen, Carlsbad, USA  
Protein loading buffer (Rotiload) Roth, Freiburg 
Saccharose Roth, Freiburg 
Saponine Roth, Freiburg 
Sodium acetate Roth, Freiburg 
Sodium azide Roth, Freiburg 
Sodium chloride Roth, Freiburg 
Sodium dodecyl sulfate (SDS) Roth, Freiburg 
Sodium fluoride Sigma-Aldrich, Taufkirchen 
Sodium vanadate Roth, Freiburg 
Strep-Tactin Sepharose  IBA, Göttingen 
Sulfate latex beads Life Technologies, Carlsbad, USA 
Sulfuric acid Merck, Darmstadt 
Tetramethylethylenediamine (TEMED) Roth, Freiburg 
Tris(hydroxymethyl)-aminomethan (Tris) Roth, Freiburg 
TritonX-100 Roth, Freiburg 
Trypan blue Invitrogen, Carlsbad, USA 
Tween 20 Roth, Freiburg 
X-tremeGENE HP Transfection Reagent Roche, Mannheim 
32P-α-dATP Perkin Elmer, Wiesbaden 
β-Glycerophosphate Sigma-Aldrich, Taufkirchen 
β-Mercaptoethanol Roth, Freiburg 
5.2.2 Cell culture 
DMEM, Gibco Life Technologies, Carlsbad, USA 
Fetal calf serum (FCS) Life Technologies, Carlsbad, USA 
L-glutamine Life Technologies, Carlsbad, USA 
IMDM Life Technologies, Carlsbad, USA 
Non-essential amino acids (NEAA) Life Technologies, Carlsbad, USA 
Optimem Life Technologies, Carlsbad, USA 
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Penicillin/streptomycin (P/S) Life Technologies, Carlsbad, USA 
RPMI 1640 Life Technologies, Carlsbad, USA 
RPMI 1640 (advanced) Life Technologies, Carlsbad, USA 
Sodium pyruvate Life Technologies, Carlsbad, USA  
Trypsin/EDTA Life Technologies, Carlsbad, USA 
β-Mercaptoethanol Life Technologies, Carlsbad, USA 
5.2.3 Stimulants, inhibitors and cytokines 
Actinomycin D Sigma-Aldrich, Taufkirchen 
Ionomycin Calbiochem, Schwalbach 
Murine IL-12 BD, Heidelberg 
Murine IL-6 R&D Systems, Minneapolis, USA 
Murine TGFβ R&D Systems, Minneapolis, USA 
Ovalbumin peptide                                                                                                               
(OVA, chicken, aa 323-339) Biotrend, Köln 
Phorbol 12-myristate 13-acetate (PMA) Merck Millipore, Darmstadt  
5.3 Enzymes and Kits 
CD4+ T cell Isolation Kit (mouse) Miltenyi Biotec, Bergisch Gladbach 
CD4+ T cell Isolation Kit (human) Miltenyi Biotec, Bergisch Gladbach 
DreamTaq DNA polymerase Thermo Scientific, Waltham, USA 
Dynabeads human T-Activator CD3/CD28 Life Technologies, Carlsbad, USA 
Gel Extraction Kit Qiagen, Hilden 
Herculase II DNA Polymerase Agilent Technologies, Waldbronn 
Indol-1  Life Technologies, Carlsbad, USA 
Magna RIPTM Kit Merck Millipore, Darmstadt 
KAPA SYBR FAST qPCR Mastermix Peqlab, Erlangen 
Klenow Polymerase NEB, Frankfurt 
LightCycler 480 SYBR Green I Mastermix Roche, Mannheim 
Naive CD4+ T cell Isolation Kit, mouse Miltenyi Biotec, Bergisch Gladbach 
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QIAshredder Qiagen, Hilden 
QIAQuick Nucleotide Removal Kit Qiagen, Hilden 
PCR Purification Kit Qiagen, Hilden 
Plasmid Maxi Kit Qiagen, Hilden 
Plasmid Mini Kit Qiagen, Hilden 
Proteinase K NEB, Frankfurt 
Rapid DNA ligation Kit Roche, Mannheim 
Restriction enzymes NEB, Frankfurt 
Restriction buffers NEB, Frankfurt 
RNaseH Life Technologies, Darmstadt 
RNeasy RNA isolation Kit Qiagen, Hilden 
RQ1 RNase-Free DNase Promega, Mannheim 
Superscript First Strand Synthesis Kit Invitrogen, Carlsbad, USA 
SuperScript II Reverse Transcriptase Invitrogen, Carlsbad, USA 
T4 DNA ligase NEB, Frankfurt 
3,3′,5,5′-Tetramethylbenzidine (TMB) eBioscience, Frankfurt am Main 
Verso cDNA Synthesis Kit Thermo Fisher Scientific, Waltham, USA  
5.4 Mice strains 
BALB/c Charles River 
C57BL/6 Charles River or Jackson Laboratory 
Malt1-/- and wt  from J. Ruland and A. Gewies (Klinikum 
rechts der Isar, Technische Universität 
München) 
R26/CAG-CARΔ1stop-flCd4-Cre a truncated, signaling-deficient version of the 
human CAR receptor is expressed in CD4+ T 
cells making them susceptible for adenoviral 
transduction (Heger et al., 2015); obtained 
from M. Schmidt-Supprian (Klinikum rechts 
der Isar, Technische Universität München) 
Malt1-/-R26/CAG-CARΔ1stop-flCd4-Cre from J. Ruland and A. Gewies (Klinikum 
rechts der Isar, Technische Universität 
München) 
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OT-II (C57BL/6Tg(TcraTcrb)425Cbn/Crl)  express α- and β-chain TCR that pairs with the 
CD4 co-receptor and is specific for chicken 
ovalbumin (OVA, 323-339); obtained from 
Charles River 
5.5 Eukaryotic cell lines  
A549  human lung adenocarcinoma epithelial cell line 
HEK293A human embryonic kidney cell line; contains stably integrated copy 
of the E1 gene that is required to generate recombinant adenovirus 
HEK293T human embryonic kidney cell line; transformed with SV40 large  
T antigen 
Jurkat T cells human T cell line; derived from acute T cell leukemia 
MALT1-/- Jurkat T cells human T cell line; exon2 was deleted by CRISPR/Cas9 (generated 
by T. Gehring, AG Krappmann) 
MEF mouse embryonic fibroblasts 
5.6 Bacteria 
TOP10  Escherichia coli, F-mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 
ΔlacX74 nupG recA1 araD139 Δ(ara-leu)7697 galE15 galK16 
rpsL(StrR) endA1λ- 
5.7 Vectors and oligonucleotides 
5.7.1 Vectors 
General vectors Information 
pcAT7-CDMS2 Minigene vector with constitutive exon3 and 
exon7 of the CD45 gene (Motta-Mena et al., 
2010). Obtained from Prof. Dr. Florian Heyd. 
pHAGE-PGK-L1-hΔCD2-T2A Lentiviral vector. Obtained from Dr. Marc 
Schmidt-Supprian. 
pHAGE-PGK-L1-hΔCD2-T2A-Flag-Strep-
Strep (pHAGE-StrepTagII; mock) 
Flag-Strep-Strep-Tag was cloned into pHAGE-
PGK-L1-hΔCD2-T2A by SalI/SalI 
Table 1: List of general vectors. 
5 Materials 
93 
 
Additional vectors Information 
pHAGE-MALT1A-Strep MALT1 cDNA was transferred into pHAGE-
StrepTagII (NotI/SalI).  
pHAGE-MALT1A T6BM1 EA-Strep Point mutation (E316A) was introduced by 
PCR-based mutagenesis. MALT1 cDNA was 
transferred into pHAGE-StrepTagII (NotI/SalI). 
pHAGE-MALT1A T6BM3 EA-Strep Point mutation (E806A) was introduced by 
PCR-based mutagenesis. MALT1 cDNA was 
transferred into pHAGE-StrepTagII (NotI/SalI). 
pHAGE-MALT1A T6BM1/3 EA-Strep Point mutations (E316A/E806A) were 
introduced by PCR-based mutagenesis. MALT1 
cDNA was transferred into pHAGE-StrepTagII 
(NotI/SalI). 
pHAGE-MALT1B-Strep MALT1 cDNA was transferred into pHAGE-
StrepTagII (NotI/SalI). 
pHAGE-MALT1B T6BM2 EA-Strep Point mutation (E642A) was introduced by 
PCR-based mutagenesis. MALT1 cDNA was 
transferred into pHAGE-StrepTagII (NotI/SalI). 
pHAGE-MALT1B T6BM3 EA-Strep Point mutation (E795A) was introduced by 
PCR-based mutagenesis. MALT1 cDNA was 
transferred into pHAGE-StrepTagII (NotI/SalI). 
pHAGE-MALT1B T6BM2/3 EA-Strep Point mutations (E642A/E795A) were 
introduced by PCR-based mutagenesis. MALT1 
cDNA was transferred into pHAGE-StrepTagII 
(NotI/SalI). 
Minigene pcAT7 M1 Genomic MALT1 region (intron6 56 bp-exon7-
intron7 51 bp) was amplified by PCR from 
human genomic clone pBACe3.6 (Source 
BioScience) and cloned into pcAT7-CDMS2 
(BglII/BglII). 
Minigene pcAT7 M2 Genomic MALT1 region (intron6 100 bp-exon7-
intron7 94 bp) was amplified by PCR from 
human genomic clone pBACe3.6 (Source 
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BioScience) and cloned into pcAT7-CDMS2 
(BglII/BglII). 
Minigene pcAT7 M3 Genomic MALT1 region (intron6 56 bp-exon7-
intron7 197 bp) was amplified by PCR from 
human genomic clone pBACe3.6 (Source 
BioScience) and cloned into pcAT7-CDMS2 
(BglII/BglII). 
Minigene pcAT7 M4 Genomic MALT1 region (intron6 200 bp-exon7-
intron7 51 bp) was amplified by PCR from 
human genomic clone pBACe3.6 (Source 
BioScience) and cloned into pcAT7-CDMS2 
(BglII/BglII). 
Minigene pcAT7 M5 Genomic MALT1 region (intron6 200 bp-exon7-
intron7 197 bp) was amplified by PCR from 
human genomic clone pBACe3.6 (Source 
BioScience) and cloned into pcAT7-CDMS2 
(BglII/BglII). 
Minigene pcAT7 M6 Genomic MALT1 region (intron6 506 bp-exon7-
intron7 539 bp) was amplified by PCR from 
human genomic clone pBACe3.6 (Source 
BioScience) and cloned into pcAT7-CDMS2 
(BglII/BglII). 
pMD2.G Lentiviral envelope plasmid (Addgene ID 12259)
psPAX2 Lentiviral packaging plasmid (Addgene ID 12260)
Table 2: List of additional vectors.  
5.7.2 shRNAs 
Primary adenoviruses containing shRNAs against hnRNP U were obtained from Sirion 
Biotech, München. 
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shRNA Sequence 5‘-3‘ 
sh-hnRNP U #1 CCATAACTGTGCAGTTGAATT 
sh-hnRNP U #2 GGCTGGTCACTAACCACAAGT 
Table 3: Sequences of shRNAs for adenoviral knockdown of hnRNP U. 
5.7.3 siRNAs and morpholino 
siRNA libraries:  
siGENOME smart pool siRNA library (radioactive PCR) Dharmacon, Lafayette, USA 
ON-TARGETplus smart pool siRNA library (qPCR) Dharmacon, Lafayette, USA 
Smart pool siRNAs: 
si-control (ON-TARGETplus Non-Targeting Pool) Dharmacon, Lafayette, USA 
si-hnRNP U (ON-TARGETplus smart pool siRNA,  
human hnRNP U) Dharmacon, Lafayette, USA 
individual siRNAs:  Eurogentec, Seraing, Belgium 
siRNA Sequence 5‘-3‘ 
si-control  si-GFP 
si-hnRNP U #1 ACAGAAAGGCGGAGAUAAAUU 
si-hnRNP U #2 GAAGAAAGAUUGUGAAGUUUU 
si-hnRNP U #3 GAUGAAGACUAUAAGCAAAUU 
Table 4: Sequences of individual siRNAs. 
Morpholino (MO) sequences: GeneTools, Philomath 
Morpholino Sequence 5‘-3‘ 
AMO  GAACCAAAGGATTGCACTACCTTCA 
cMO CCTCTTACCTCAGTTACAATTTATA 
Table 5: Sequences of morpholinos. 
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5.7.4 EMSA oligonucleotides 
Target Sequence 5‘-3‘ 
NF-κB (H2K) fw GATCCAGGGCTGGGGATTCCCCATCTCCACAGG
NF-κB (H2K) rev GATCCCTGTGGAGATGGGGAATCCCCAGCCCTG
OCT1 fw  GATCTGTCGAATGCAAATCACTAGAA 
OCT1 rev GATCTTCTAGTGATTTGCATTCGACA 
Table 6: EMSA oligonucleotide sequences. 
5.7.5 Primer for qPCR and semi-qPCR 
Target (mouse) Sequence 5‘-3‘ 
Malt1 ex6 fw ACCGAGACAGTCAAGATAGC 
Malt1 ex9/10 rev GACTTTGTCCTTTGCCAAAGG 
Malt1 ex5 fw  AAGTCCTATGCCTCACTACCAGTG 
Malt1 ex7/8 rev GTTTAATTCATCTTCAGTGCACTCC 
Malt1 ex6/8 rev GATGCCCCAAATTGTTTAATTCATCTATG 
Hmbs fw GCGCTAACTGGTCTGTAGGG 
Hmbs rev TGAGGGAAAGGCAGATATGGAGG 
Il2 fw GAGTGCCAATTCGATGATGAG 
Il2 rev AGGGCTTGTTGAGATGATGC 
hnRNP U fw ATCTCGAGAGACCGTCTGAG 
hnRNP U rev CTTCACCAAGCAACATTCCAC 
hnRNP D fw TGCAACTTATCCCCAACAGG 
hnRNP D rev TCCATTCAGGAACTTGATAGAAAA 
hnRNP H2 fw CATACCTGAAGTGGATTTTCTGTC 
hnRNP H2 rev CTGACCTTCACCACGAACC 
hnRNP K fw TCTGAAGATCGGATCATTACCA 
hnRNP K rev TCTTGCATTAGAATCCTTCAACAT 
hnRNP L fw TGACTGAGGAGAACTTCTTTGAGA 
hnRNP L rev CTCTTCGAGTCCCACTCCAG 
hnRNP LL fw AGACATGATGGCTATGGATCGC 
hnRNP LL rev CACTAACCATTACAACGGAGCCA 
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hnRNP R fw TCTGGAAGAGTTCAGTAAAGTCACA 
hnRNP R rev GTGCTGCTGACTTGTGATCC 
Srsf3 fw TCGTCGTCCTCGAGATGATT 
Srsf3 rev CCTATCTCTAGAAAGTGACCTGCTC 
Srsf9 fw CGAGATCGAGCTCAAGAACC 
Srsf9 rev GTAACCGTTTCTTCCATAGATCG 
Table 7: Murine primer sequences. 
Target (human) Sequence 5‘-3‘ 
MALT1 ex6 fw (radioactive PCR) TAATGATCGAGACAGTCAAGATAGC 
MALT1 ex9/10 rev (radioactive PCR) AACCTTGTCCTTCGCCAAAG 
MALT1A fw GAAGGTAGAAATCATCATAGGAAG 
MALT1A rev GCTTTGAGCTTGGGGTGCTCC 
MALT1B fw  AAGCCCTATTCCTCACTACCAGTGG 
MALT1B rev GGATGACCAAGATTATTTAATTCATCTATG
RP2 fw GCACCACGTCCAATGACAT 
RP2 rev GTGCGGCTGCTTCCATAA 
PPIB fw CCAGGGGAGATGGCACA 
PPIB rev CTTCCGCACCACCTCCA 
GAPDH fw ACCACAGTCCATGCCATCAC 
GAPDH rev TCCACCACCCTGTTGCTGTA 
18S rRNA fw GCTTAATTTGACTCAACACGGGA 
18S rRNA rev AGCTATCAATCTGTCAATCCTGTC 
hnRNP U fw CGGTCCTCAAAATGAAAGGA 
hnRNP U rev CTATGGCCACCACCTCTGTT 
MALT1 in1-ex2 fw TGGAAGAAAGCTGTTGACTTGA 
MALT1 in1-ex2 rev TCCTTCAGGCTCCAGTACCTT 
MALT1 in5-ex6 fw TGTTATGTTTTGGAGCGTATTTTT 
MALT1 in5-ex6 rev CAAATCCACATAAGGCACCTA 
MALT1 ex6-in6 fw GACAGTCAAGATAGCAAGAAG 
MALT1 ex6-in6 rev CTTTGCTTAATTAAACGTTGCAG 
MALT1 in6/ex7-in7 fw TTTTCTGAAACAAGGAAGAACAGA 
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MALT1 in6/ex7-in7 rev GTAGGCTAAAAGCACTCCAC 
MALT1 in7 fw AGAACCTAACTGTATTGCAAATGTATG 
MALT1 in7 rev CTTCAGTATTAGGCTCAACTCATT 
MALT1 in7/ex8-in8 fw ACACTATAACATGATTCACTGGC 
MALT1 in7/ex8-in8 rev TGTATTACTCACCAGGATGACC 
MALT1 in8 fw AAAGAAGAATGTTGTATAGGGAAAGC 
MALT1 in8 rev TGTCCACTACTGTCGGGAGAT 
MALT1 ex9-in9 fw AGCCTTTGGGTGAGTAGAAC 
MALT1 ex9-in9 rev AGCCTCCTCTTCTAAACCTTC 
CD45 fw (minigene) GGGAGCTTGGTACCACGCGTCGACC 
CD45 rev (minigene) CAGCGCTTCCAGAAGGGCTCAGAGTGG 
Table 8: Human primer sequences. 
5.8 Antibodies 
5.8.1 Antibodies for cell purification, stimulation and differentiation 
anti-CD28 (37.51) BD, Heidelberg 
anti-CD28 (37N) produced by V. Heissmeyer and E. Kremmer 
anti-CD3 (145-2C11) BD, Heidelberg 
anti-CD3 (145-2C11) produced by V. Heissmeyer and E. Kremmer 
anti-IFNγ (Xmg1.2) produced by V. Heissmeyer and E. Kremmer 
anti-IL-12 (C17.8) produced by V. Heissmeyer and E. Kremmer 
anti-IL-2 (JES6-5H4) Miltenyi Biotec, Bergisch Gladbach 
anti-IL-4 (11B11) produced by V. Heissmeyer and E. Kremmer 
anti-TCRβ-Biotin eBioscience, Frankfurt am Main 
rabbit anti-syrian hamster IgG JacksonImmunoResearch, Newmarket, UK 
5.8.2 FACS antibodies 
anti-CD2-APC (RPA-2.10) eBioscience, Frankfurt am Main 
anti-CD25-PE (PC61.5) eBioscience, Frankfurt am Main 
anti-CD4-PE-Cy7 (GK1.5) eBioscience, Frankfurt am Main 
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anti-CD4-PerCP (RM4-5) eBioscience, Frankfurt am Main 
anti-CD44-AlexaFluor 405 (IM7) Caltag, Buckingham, UK 
anti-CD45.2-APC-Cy7 (30-F11) eBioscience, Frankfurt am Main 
anti-CD62L-AlexaFluor 647 (MEL-14) BioLegend, San Diego, USA 
anti-CD69-APC (H1.2F3) eBioscience, Frankfurt am Main 
anti-CXCR5 (RF8B2, unconjugated) BD, Heidelberg 
anti-IFNγ-APC (XMG1.2) eBioscience, Frankfurt am Main 
anti-IL-2-APC (JES6-5H4) eBioscience, Frankfurt am Main 
anti-IL-2-FITC (JES6-5H4) eBioscience, Frankfurt am Main 
anti-IL-17A-PE (eBio17B7) eBioscience, Frankfurt am Main 
anti-PD-1-FITC (J43) eBioscience, Frankfurt am Main 
biotinylated goat anti-rat IgG Abcam, Cambridge, UK 
Streptavidin-PE  BD, Heidelberg 
5.8.3 Primary antibodies for Western Blot 
anti-β-ACTIN (I-19) Santa Cruz, Heidelberg 
anti-BCL10 (EP606Y) Abcam, Cambridge, UK 
anti-CARMA1 (1D12) NEB, Frankfurt am Main 
anti-CYLD (E10) Santa Cruz, Heidelberg 
anti-ERK (442704) Merck Millipore, Darmstadt  
anti-hnRNP U (3G6) Abcam, Cambridge, UK 
anti-IκBα (L35A5) NEB, Frankfurt am Main 
anti-JNK1/2 (9252) NEB, Frankfurt am Main 
anti-MALT1 (mouse, 2494) NEB, Frankfurt am Main 
anti-MALT1 (human, B12) Santa Cruz, Heidelberg 
anti-MALT1 (mouse, H300) Santa Cruz, Heidelberg 
anti-MALT1A (GRTDEAVEC) produced by E. Kremmer 
anti-NEMO (Clone 54, WB) BD, Heidelberg 
anti-NEMO (FL-419, IP) Santa Cruz, Heidelberg 
anti-phospho-ERK (9101) NEB, Frankfurt am Main 
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anti-phospho-IκBα (9246) NEB, Frankfurt am Main 
anti-phospho-JNK (9255) NEB, Frankfurt am Main 
anti-phospho-p38 (9211) NEB, Frankfurt am Main 
anti-p38 (C-20) Santa Cruz, Heidelberg 
anti-TRAF6 (EP591Y) Abcam, Cambridge, UK  
5.8.4 Secondary antibodies for Western Blot 
HRP-conjugated anti-rabbit JacksonImmunoResearch, Newmarket, UK 
HRP-conjugated anti-mouse JacksonImmunoResearch, Newmarket, UK 
HRP-conjugated anti-goat JacksonImmunoResearch, Newmarket, UK 
5.8.5 RNA-binding protein immunoprecipitation (RIP) antibodies 
anti-hnRNP U (CS207320) Merck Millipore, Darmstadt 
normal mouse IgG (CS200621) Merck Millipore, Darmstadt 
5.9 Buffers and solutions 
Agar plates: LB (20 g/l), Agar (15 g/l) 
Annealing buffer: Tris-HCl pH 8.0 (50 mM), NaCl (70 mM) 
B1 buffer: PBS (1x), BSA (0.1 % (w/v)), EDTA (2 mM) 
Blocking buffer: BSA in PBS-T (3 % (w/v)) 
Blotting buffer:  Tris pH 8.3 (48 mM), Glycine (39 mM), Methanol (20 % (v/v)), 
SDS (0.03 % (w/v)) 
CB buffer: PBS (1x), BSA (0.5 % (w/v)), EDTA (2 mM) 
Co-IP buffer:  HEPES pH 7.5 (25 mM), NaCl (150 mM), Glycerol (1 mM), 
NP-40 (0.2 % (v/v)), DTT (1 mM), NaF (10 mM), β-
Glycerophosphate (8 mM), NaVanadate (300 μM), Protease 
inhibitor mix 
DNA loading buffer: Glycerol (30 %), Orange G (0.35 %) 
FACS buffer: PBS (1x), FCS (2 % (w/v)), NaN3 (0.01 % (v/v)) 
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IC buffer: PBS (1x), Saponine (0.5 % (w/v)), NaN3 (0.01 % (v/v)) 
High-salt buffer:   HEPES pH 7.9 (20 mM), NaCl (350 mM), Glycerol (20 % 
(v/v)), MgCl2 (1 mM), EDTA (0.5 mM), EGTA (0.1 mM), NP-
40 (1 %), DTT (1 mM), NaF (10 mM), β-Glycerophosphate (8 
mM), NaVanadate (300 μM), Protease inhibitor mix 
LB medium: LB (20 g/l) 
PBS (1x):  NaCl (137 mM), Na2HPO4 (10 mM), KCl (2.7 mM), KH2PO4 
 (1.7 mM) 
PBS-T (WB): PBS, Tween-20 (0.1 % (v/v)) 
PBS-T (ELASA): PBS, Tween-20 (0.05 % (v/v)) 
Poly dI-dC: Poly dI-dC (2 mg/ml), Tris pH 8.0 (10 mM), NaCl (100 mM) 
Polyacrylamide gel, native: TBE buffer (1x), Acrylamide/Bisacrylamide (5 %), APS (0.75    
% (v/v)), TEMED (0.075 % (v/v)) 
Proteinase K buffer (RIP): RIP wash buffer (1x, Merck Millipore), SDS (1 % (v/v)), 
Proteinase K (12 % (v/v)) 
RIP lysis buffer:   RIP lysis stock (1x, Merck Millipore), Protease inhibitor 
cocktail (0.5 % (v/v)), RNase inhibitor (0.25 % (v/v)) 
RIP IP buffer: RIP wash buffer (1x, Merck Millipore), EDTA (2 mM), RNase 
inhibitor (0.55 % (v/v)) 
SDS electrophoresis                                  
buffer (1x):   Tris pH 8.8 (25 mM), Glycine (192 mM), SDS (0.1 % (w/v)) 
Separation gel:  Tris/HCl pH=8.8 (375 mM), Acrylamide/Bisacrylamide (7.5-11 
%), SDS (0.1 %), APS (0.075 %), TEMED (0.05 %) 
Shift buffer (2x): HEPES pH 7.9 (20 mM), KCl (120 mM), Ficoll (4 % (w/v)) 
Stacking gel:  Tris/HCl pH 6.8 (125 mM), Acrylamide/Bisacrylamide (5 %), 
SDS (0.1 %), APS (0.1 %), TEMED (0.1 %)                
Stripping buffer: Glycine (0.2 M), SDS (0.1 %), Tween-20 (1 % (v/v)), pH 2.2 
TAC (Tris ammonium                           
chloride) lysis buffer: Tris pH 7.2 (20 mM), NH4Cl (0.83 % (w/v)) 
TBE buffer: Tris (50 mM), Boric acid (50 mM), EDTA (1 mM), pH 8.3 
TE (Tris EDTA) buffer: Tris/HCl pH 8.0 (10 mM), EDTA (1 mM)  
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6 Methods 
6.1 Cell culture 
6.1.1 Storage of cell lines 
For the storage of suspension or adherent cells, 1x 107 cells were pelleted and resuspended in 
1 ml freezing medium (DMEM/RPMI, 20 % FCS, 15 % DMSO). After transfer into cryo 
tubes, samples were put into an isopropanol-containing freezing chamber over night at -80 °C. 
For long-term storage, cells were stored in liquid nitrogen. 
6.1.2 Cultivation of adherent cells 
A549, HEK293T, HEK293A and MEF cells were cultured in DMEM medium supplemented 
with 10 % FCS and 100 U/ml P/S. Cells were splitted after they reached 80 % confluency. To 
detach cells from dishes, cells were washed with PBS and treated with 0.5–1.5 ml 0.05 % 
trypsin/EDTA solution for approximately 5 min. The reaction was stopped by adding fresh 
DMEM medium. Finally, cells were diluted in flasks or seeded in appropriate dishes for 
further experiments. 
6.1.3 Cultivation of suspension cells 
For cultivation of Jurkat T cells, RPMI medium supplemented with 10 % FCS and 100 U/ml 
P/S was used. Jurkat T cells were kept at a densitiy between 0.5x and 1.5x 106 cells/ml. 
Primary murine CD4+ T cells were cultured in RPMI medium supplemented with 10 % heat-
inactivated FCS, 1 % P/S, 1 % NEAA, 1 % HEPES, 1 % L-glutamine, 1 % sodium pyruvate 
and 0.1 % β-mercaptoethanol. For primary human CD4+ T cells, advanced RPMI medium 
supplemented with 10 % heat-inactivated FCS and 2 mM L-glutamine was used. 
6.1.4 Isolation and cultivation of primary murine CD4+ T cells 
For stimulation and knockdown experiments, primary murine CD4+ T cells were isolated 
from spleen and lymph nodes (axial, inguinal and cervical) from BALB/c, OT-II or 
R26/CAG-CARΔ1stop-flCd4-Cre mice by negative magnetic-activated cell sorting (MACS) 
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selection using the murine CD4+ T cell isolation kit (Miltenyi Biotec). First, spleen and lymph 
nodes were put into primary T cell medium (RPMI medium + 10 % heat-inactivated FCS,  
1 % P/S, 1 % NEAA, 1 % HEPES, 1 % L-glutamine, 1 % sodium pyruvate and 0.1 % β-
mercaptoethanol) and grinded through a cell strainer (100 µM). To separate the cells from 
residual tissue particles, the homogenate was pelleted by centrifugation (1300 rpm, 8 min). 
Afterwards, the pellet was resuspended in TAC lysis buffer for 5 min on ice to destroy 
erythrocytes. Samples were washed, centrifuged and refiltered through a cell strainer to 
further eliminate residual tissue particles. The remaining cells were resuspended in ice-cold 
CB buffer (500 µl/mouse) before adding a cocktail of biotin-conjugated antibodies  
(100 µl/mouse, Miltenyi Biotec) to deplete non-CD4+ T cells. After incubation for 5 min at  
4 °C, samples were filled up with 300 µl of ice-cold CB buffer and incubated with 
magnetically labeled anti-biotin microbeads (200 µl/mouse, Miltenyi Biotec) for 10 min at  
4 °C. Finally, the cell suspension was applied to LS columns (Miltenyi Biotec) in a MACS 
separator, whereby the magnetically labeled cells were retained in the columns and the 
unlabeled CD4+ T cells were enriched in the flow-through. The separated CD4+ T cells were 
pelleted and resuspended in an appropriate volume of primary T cell medium. For 
differentiation experiments, naive CD4+ T cells from wt, Malt1-/- or Malt1-/-R26/CAG-
CARΔ1stop-flCd4-Cre mice were isolated using the naive, murine CD4+ T cell isolation kit 
(Miltenyi Biotec), which additionally contains anti-CD62L antibodies in the biotin-conjugated 
antibody cocktail.  
6.1.5 Isolation and cultivation of primary human CD4+ T cells 
For isolation of human CD4+ T cells, blood was taken from healthy donors and treated with 
heparine (1000 U/50 ml blood). Blood was centrifuged (300 x g, 10 min, RT, no break) to 
separate plasma (upper layer), buffy coat (intermediate layer) and erythrocytes (lowest layer). 
After removal of the plasma fraction, the intermediate buffy coat layer containing leukocytes 
and platelets was collected (approx. 10-18 ml/50 ml blood) and diluted with PBS up to a 
volume of 35 ml. To isolate mononuclear cells (MNCs), diluted buffy coat was carefully 
layered onto 15 ml Lymphoprep density gradient medium (Stemcell Technologies) and 
centrifuged (160 x g, 20 min, RT, no break). About 20 ml supernatant were removed without 
touching the next layer and the sample was again centrifuged (350 x g, 20 min, RT, no break). 
Finally, the intermediate layer containing the MNCs was collected and washed three times 
with PBMC buffer B1 (300 x g, 8 min, 4 °C). CD4+ T cells were isolated by negative MACS 
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selection using the human CD4+ T cell isolation kit (Miltenyi Biotec) according to the 
manufacturer’s instructions (see 6.1.4). Purified cells were resuspended in human, primary  
T cell medium (Advanced RPMI 1640 + 10 % heat-inactivated FCS, 1 % P/S, 2 mM L-
glutamine) at a density of 2x 106 cells/ml. Written consent and approval by the ethics board of 
the Medical Faculty at the Technical University Munich was obtained for the use of 
peripheral blood from healthy donors. 
6.1.6 Immunization and isolation of different murine T cell subsets 
To obtain CD4+CD62L+CD44- naive T cells, CD4+CD62L-CD44+ effector T cells and 
CD4+CXCR5+PD-1+ TFH cells, BALB/c mice were immunized i.v. with approx. 2x 108 sheep 
erythrocytes (Acila AG). After one week, spleens were collected, homogenized and single cell 
suspensions were prepared. To enrich for T cells, B cells were depleted by using anti-CD19 
microbeads (Miltenyi, 10 µl per 107 cells) according to the manufacturer’s instructions. 
Samples are loaded onto MACS columns and CD19+ cells are retained within the columns. 
Purified cells were stained with the following antibodies and reagents for 20 min at 4 °C: anti-
CXCR5, biotinylated goat anti-rat IgG, Streptavidin-PE, anti-CD4-PerCP, anti-PD-1-FITC, 
anti-CD62L-AlexaFluor 647 and anti-CD44-AlexaFluor 405. After washing, different T cell 
subsets (CD4+CD62L+CD44- naive T cells, CD4+CD62L-CD44+ effector T cells and 
CD4+CXCR5+PD-1+ TFH cells) were sorted on a FACS Aria cell sorter (BD) and subsequently 
lysed in Trizol for RNA extraction. Immunization, purification and sorting were performed by 
J. Kranich, Institute for Immunology, LMU München.  
6.2 Cell transfection and transduction 
6.2.1 Transfection of Jurkat T cells by electroporation 
Transfection of Jurkat T cells with minigene constructs (M1–M6) was performed by 
electroporation. Thereby electric pulses are used to induce pores in the cell membrane, which 
enable the uptake of foreign DNA. 2.5x 106 Jurkat T cells in 200 µl Jurkat T cell medium 
were mixed with 1 µg plasmid DNA and transferred into an electroporation cuvette (0.4 cm). 
Cells were electroporated at 180 V and 1000 µF using a Gene Pulser (Bio-Rad) and 
transferred into pre-warmed RPMI medium. Cells were analyzed after 24 h of incubation. 
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6.2.2 Transfection of Jurkat T cells with siRNA and morpholino 
Transfection of cells with siRNAs enables silencing of specific genes by promoting mRNA 
degradation, a process that is known as RNA interference (RNAi). A siRNA represents a 
short RNA stretch of about 21–23 nt and interacts with the RNA-induced silencing complex 
(RISC). The guide strand of the siRNA guides the RISC complex to complementary target 
mRNAs promoting mRNA destruction. For siRNA transfection, 0.5 µl siRNA (100 µM stock) 
was diluted in 100 µl Optimem medium and mixed with 100 µl of a mixture containing 1 µl  
Atufect (1 µg/ml) and 99 µl Optimem. Atufect contains cationic lipids, which bind siRNAs 
and form liposomes that are taken up by the cell via fusion with the cell membrane. After  
30 min incubation at 37 °C, the siRNA mixture was added dropwise to 0.5x 106/800 µl Jurkat 
T cells. Cells were feeded with 1 ml medium 6 h post transfection and further cultivated until 
48 h post transfection.  
Morpholinos (MO) are nonionic DNA analogs that bind to specific target sites in the RNA to 
prevent splice site selection. To efficiently enter the cells, vivo MOs were used which contain 
an additional delivery moiety. For knockdown of MALT1A, a vivo MO targeting the exon7-
intron7 boundary of the Malt1 pre-mRNA (AMO) was designed and a control vivo MO 
(cMO) was used for comparison. Murine CD4+ T cells (3x 106 cells/ml) or MEFs  
(0.5x 106 cells) were transfected with 5 nmol of AMO or cMO and cultured for 3 h (for RNA 
analyses) or 18 h (for protein analyses).  
6.2.3 Lentiviral transduction of Jurkat T cells 
To generate stable MALT1 expressing cell lines, we lentivirally transduced MALT1-deficient 
Jurkat T cells with different pHAGE-hΔCD2-T2A-MALT1 constructs. The T2A sequence 
allows translation of both truncated human surface marker CD2 (hΔCD2) and MALT1 from 
the same mRNA by a mechanism called ribosomal skipping. Thereby the formation of the 
glycyl-prolyl peptide bond at the 2A C-terminus is inhibited resulting in a translational stop 
and the release of the nascent polypeptide from the ribosome (Szymczak et al., 2004). 
Subsequently, translation of downstream sequences is resumed by the ribosome, which leads 
to the generation of two distinct proteins (Szymczak et al., 2004). 
First, lentiviruses were produced by transfecting HEK293T cells with MALT1 expression 
plasmids and lentiviral packaging vectors. In more detail, 1x 106 HEK293T cells were seeded 
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in a 10 cm2 dish in 8 ml DMEM medium one day before transfection. The next day, 
HEK293T cells (~ 20 % confluency) were transfected with 1 µg of the lentiviral envelope 
plasmid pMD2.G, 1.5 µg of the packaging vector psPAX2 and 2 µg MALT1 transfer plasmid 
(pHAGE-hΔCD2-T2A-MALT1-SrepTagII) using X-tremeGENE HP DNA Transfection 
Reagent (Roche Diagnostics) according to the manufacturer’s instructions. After 3 days, the 
supernatant containing the virus particles was removed and sterile filtered (0.45 µM). 500 µl 
virus together with 8 µg/ml polybrene was added to 2x 105 MALT1-deficient Jurkat T cells 
(500 µl virus). 24 h later, cells were washed with PBS and resuspended in 1 ml fresh RPMI 
medium. After one week in culture, infection efficiency was determined by analyzing hΔCD2 
expression using flow cytometry or by checking MALT1 expression levels via Western Blot.  
6.2.4 Adenoviral transduction of primary, murine CD4+ T cells 
For adenoviral transduction of murine CD4+ T cells with MALT1, full-length MALT1A, 
MALT1B or MALT1A C464A mutant were cloned in the pCAGAdDu-IRES-eGFP vector. 
1x 105 HEK293A cells were seeded in 6 well plates and transfected with 3 µg linearized 
plasmids using jetPEI reagent. When all cells show cytopathic effects (CPE), supernatant and 
cells were harvested and primary virus was collected by three freeze-thaw cycles (Warth and 
Heissmeyer, 2013). Cloning of adenoviral plasmids and primary virus production was 
performed by S. Warth, Research Unit Molecular Immune Regulation, Helmholtz Zentrum 
München.  
The primary virus lysate was amplified in HEK293A cells. Thereby, 5x 106 HEK293A cells 
were seeded in a 20 cm tissue culture dish one day before infection. At about 90 % 
confluency, cells were infected with primary virus lysate and incubated until cells show CPE, 
but before detachment. Cells and supernatant were harvested and disrupted by three freeze-
thaw-cycles. After centrifugation (800 x g, 15 min, 4 °C), concentrated virus was aliquoted 
and stored at -80 °C. Adenovirus titer was determined by infecting A549 cells with several 
virus concentrations. In more detail, 1x 105 A549 cells were seeded in a 12-well plate in 1 ml 
DMEM medium. Concentrated virus was diluted in medium (1:10, 1:100, 1:500, 1:1000, 
1:2000) and 10 µl dilution was added to one well. After 36 h, cells were detached, washed 
with PBS and GFP expression was analyzed by flow cytometry (Attune). Virus titer was 
calculated the following: Titer (TU/ml) = (1x 105 A549 cells x (% GFP cells/100))/ml. 
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Primary adenoviruses encoding control or sh-hnRNP U #1 and #2 were purchased from Sirion 
Biotec and amplified and titrated as indicated above. 
Concentrated virus was used for the infection of primary, murine CD4+ T cells. For 
differentiation experiments, naive CD4+ T cells from Malt1-/-R26/CAG-CARΔ1stop-flCd4-Cre 
mice were isolated and transduced with GFP control, MALT1A, MALT1B or MALT1A 
C464A virus using an MOI (multiplicity of infection) of 50 in an infection volume of 165 µl 
per 106 cells in a 15 ml tube. For knockdown experiments, CD4+ T cells from R26/CAG-
CARΔ1stop-flCd4-Cre mice were infected with control or sh-hnRNP U virus (MOI of 50). 
After 5 h incubation at 37 °C, cells were washed twice with PBS, resuspended in primary  
T cell medium and rested for 40 h before analysis. GFP+ cells of CD4+ T cells (infected with 
control or sh-hnRNP U adenoviruses) were sorted if RNA and intracellular IL-2 levels were 
analyzed. 
6.3 Cell stimulation and differentiation  
6.3.1 Stimulation of Jurkat T cells and primary human CD4+ T cells 
Jurkat T cells were stimulated with P/I (Phorbol 12-myristate 13-acetate (PMA)/Ionomycin) 
using a concentration of 200 ng/ml PMA and 300 ng/ml Ionomycin. P/I stimulation acts 
downstream of TCR/CD28 as PMA directly stimulates PKCθ and Ionomycin triggers Ca2+ 
release from the endoplasmatic reticulum into the cytosol. Stimulation was performed in tubes 
at 37 °C. 
Primary human CD4+ T cells were stimulated with human T-Activator CD3/CD28 Dynabeads 
(Life Technologies). Thereby, 2x 106 cells (in 1 ml) were incubated with 50 µl pre-washed 
Dynabeads at 37 °C for 3h. 
6.3.2 Stimulation of primary murine CD4+ T cells 
Primary murine CD4+ T cells were stimulated with P/I, anti-CD3 and/or anti-CD28 antibodies 
or OVA-loaded APCs in primary T cell medium. For P/I stimulation, 30 ng/ml PMA and  
300 ng/ml Ionomycin were used. Anti-CD3, anti-CD28 or anti-CD3/CD28 stimulation was 
performed either on pre-coated plates or with pre-coated sulfate latex beads (Life 
Technologies). For plate-bound stimulation, plates were coated with rabbit anti-hamster IgG 
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(20 µl in 1 ml PBS per 6-well) over night at 4 °C. Afterwards, plates were washed two times 
with PBS before cells were stimulated with anti-CD3 (0.5 µg/ml) or anti-CD28 (1 µg/ml) or 
both antibodies and added to the pre-coated wells. Cells were stimulated at a density between 
1x 106 and 5x 106 cells per ml. For lower cell numbers, stimulation conditions were adjusted. 
For the analysis of cell surface marker expression of control or sh-hnRNP U infected cells, 
0.1-0.5x 106 T cells were stimulated by using 96-well plates pre-coated with anti-CD3 (0.5 
µg/ml in PBS over night at 4 °C) and soluble anti-CD28 (1 µg/ml). 
If cells were stimulated with sulfate latex beads, anti-CD3 (13.3 µg/ml) and/or anti-CD28 
(26.6 µg/ml) antibodies were added to a mixture of 250 µl beads and 750 µl sterile phosphate 
buffer (5 mM) and incubated over night at RT by rotation. Beads were washed three times 
with phosphate buffer (200 x g, 2 min, RT) and finally resuspended in phosphate buffer 
containing 2 mM BSA. Beads were counted and incubated with primary, murine CD4+ T cells 
in a cell to bead ratio of 3:1.  
Stimulation of CD4+ T cells from OT-II mice was performed by using APCs loaded with 
OVA peptide (Figure 6.1).  
 
Figure 6.1: Schematic of stimulation of OT-II CD4+ T cells with T cell-depleted, OVA-loaded APCs. 
To obtain APCs, spleen and lymph nodes from C57BL/6 wt mice were homogenized, lysed in 
TAC lysis buffer and resuspended in CB buffer as indicated above (see 6.1.4). The cell 
suspension was depleted for T cells by adding 30 µl anti-TCRβ (H57-597, eBioscience) and 
samples were incubated for 5 min at 4 °C. Afterwards, the suspension was treated with 
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magnetically labeled anti-biotin microbeads (200 µl/mouse, Miltenyi Biotec) for 10 min at  
4 °C before it was applied to LS columns (Miltenyi Biotec) in a MACS separator. The 
purified cells represent the APCs, which were subsequently irradiated (2000 rad), washed 
with CB buffer and pulsed with 1 µg/ml OVA peptide (aa 323-339, Biotrend) for 1 h at 37 °C. 
2x 106 APCs were incubated with 2x 106 OT-II CD4+ T cells (ratio 1:1) at 37°C before FACS 
analysis or RNA lysis. 
6.3.3 In vitro differentiation of murine CD4+ T cells 
Polarization into TH1 and TH17 cells was performed using naive CD4+ T cells from wt or 
Malt1-/- mice or naive CD4+ T cells from Malt1-/-R26/CAG-CARΔ1stop-flCd4-Cre mice 
transduced with GFP control, MALT1A, MALT1B or MALT1 C464A viruses (see section 
6.2.4). For TH1 conditions, medium was supplemented with IL-12 (10 ng/ml) and anti-IL-4 
(10 μg/ml); for TH17 conditions, TGFβ (10 μg/ml), IL-6 (60 ng/ml), anti-IL-12 (10 μg/ml), 
anti-IL-4 (10 μg/ml), anti-IFNγ (5 μg/ml) and anti-IL-2 (2.5 μg/ml) were added to the primary 
medium. Naive CD4+ T cells (0.2x 106) were resuspended in differentiation medium (100 µl) 
and transferred into a 96-well plate. T cells were stimulated with anti-CD3 (145-2C11, 
produced by V. Heissmeyer and E. Kremmer) and irradiated APCs (2x 106) in a ratio 1:10 and 
were cultured at 37 °C. APCs were isolated from CD45.1 mice (see section 6.3.1) and 
irradiated with 2000 rad. After 72 h incubation time, T cells were re-stimulated with PMA  
(20 nM) and Ionomycin (1 µM) for 4 h before they were analyzed for intracellular IFNγ and 
IL-17A expression using flow cytometry (see section 6.4.2). Experiments were performed in 
cooperation with D. Hu, Research Unit Molecular Immune Regulation, Helmholtz Zentrum 
München/Institute for Immunology, Biomedical Center, LMU München. 
6.4 Flow cytometry and cell sorting 
Cell populations were analyzed regarding their surface protein expression and intracellular 
cytokine levels either on an Attune Acoustic Focusing Cytometer (Life Technologies) or on a 
LSR II (BD) or on a LSR Fortessa (BD). For sorting, FACS Star plus (BD) or FACS Aria cell 
sorter (BD) were used. 
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6.4.1 Staining of surface molecules 
To check hΔCD2 surface expression of infected MALT1-deficient Jurkat T cells, ca. 0.2x 106 
cells were collected and resuspended in 500 µl FACS buffer. Cells were stained with anti-
CD2-APC antibody (human, dilution 1:500) for 10 min at RT. Afterwards samples were 
washed with FACS buffer, taken up in ca. 200 µl FACS buffer and acquired on Attune 
Acoustic Focusing Cytometer. 
For staining of CD69 and CD25 in primary murine CD4+ T cells, cells (0.2-1x 106) were 
collected after stimulation and were resuspended in FACS buffer. To prevent unspecific 
antibody binding to Fc receptors, samples were treated with anti-CD16/32 (mouse, dilution 
1:50) for 10 min at 4 °C. Afterwards, staining with anti-CD69-APC (mouse, 1:100) and anti-
CD25-PE (mouse, 1:100) was performed for 10-15 min at 4 °C in the dark. Samples were 
washed, resuspended in FACS buffer and acquired on Attune Cytometer or LSR II.  
6.4.2 Intracellular cytokine staining 
For intracellular IL-2 staining, primary murine CD4+ T cells (0.5-1x 106) were stimulated for 
6 h with anti-CD3/CD28. 3 h before staining, cells were treated with Brefeldin-A (10 ng/ml, 
Sigma) to prevent exocytosis of signaling molecules. After stimulation, cells were collected, 
centrifuged (300 x g, 5 min, 4 °C), resuspended in FACS buffer and incubated with ethidium 
monoazide bromide (dilution 1:100) to distinguish between live and dead cells. Thereby, 
samples were incubated in the dark for 15 min at RT before they were exposed to light  
(10 min, 4 °C). Afterwards, samples were washed and fixed in 2 % PFA for 15 min at RT. 
Then, cells were washed and permeabilized in IC buffer (10 min, RT). Unspecific antibody 
binding was blocked with anti-CD16/32 (mouse, dilution 1:50 in Saponine buffer, 15 min,  
4 °C) before samples were incubated with anti-IL-2-FITC or anti-IL-2-APC (both mouse, 
dilution 1:100 in IC buffer) for 30 min on ice. Afterwards, cells were washed (300 x g, 5 min, 
4 °C) and filled up with FACS buffer to wash out unbound antibodies (> 15 min, RT). 
Samples were again washed (300 x g, 5 min, 4 °C), resuspended in FACS buffer and acquired 
on Attune Cytometer. 
In differentiation experiments, cells were re-stimulated with PMA (20 nM) and Ionomycin  
(1 µM) in the presence of Brefeldin-A for 2 h before staining. After cells were resuspended in 
FACS buffer, live-dead cell staining was conducted by treating the samples with a fixable 
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dead cell staining solution (indol-1, Life Technologies) for 30 min at 4 °C. Samples were 
washed and surface proteins CD45.2 and CD4 were stained by adding anti-CD45.2-APC-Cy7 
and anti-CD4-PE-Cy7 (both mouse, dilution 1:200) for 15 min at 4 °C. Cells were fixed with 
4 % PFA for 10 min at 20 °C and permeabilized for 20 min at 4 °C using PBS/0.5 % 
Saponine/1 % BSA. For intracellular staining of IL-17A and IFNγ, samples were treated with 
anti-IL-17A-PE and anti-IFNγ-APC (both mouse, dilution 1:200) for 50 min at 4°C. Samples 
were washed and acquired on LSR Fortessa. Staining was performed in cooperation with  
D. Hu, Research Unit Molecular Immune Regulation, Helmholtz Zentrum München/Institute 
for Immunology, Biomedical Center, LMU München. 
6.4.3 Sorting of primary murine CD4+ T cells 
Different T cell subsets (CD4+CD62L+CD44- naive T cells, CD4+CD62L-CD44+ effector T 
cells and CD4+CXCR5+PD-1+ TFH cells) were sorted on a FACS Aria cell sorter (BD) after 
samples have been stained with the respective antibodies. Sorting was performed by  
J. Kranich, Institute for Immunology, LMU München. CD4+ T cells, which were infected 
with control or sh-hnRNP U adenoviruses, were resuspended in FACS buffer, filtered and 
subsequently sorted for GFP+ cells using FACS Star plus. 
6.5 Molecular biology methods 
6.5.1 Polymerase chain reaction (PCR) 
Amplification of DNA was performed using polymerase chain reaction (PCR).  
Thereby, the following standard protocol was used: 
Component Amount 
Template DNA 30 ng 
5’ primer (10 µM) 1.25 µl 
3’ primer (10 µM) 1.25 µl 
dNTP (10 mM) 1,25 µl 
Herculase buffer (10x) 10 µl 
DNA polymerase (Herculase) 1 µl 
 Ad 50 µl H2O 
Table 9: PCR standard protocol. 
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PCR program: 
 
 
 
PCR products were checked for correct amplification on an agarose gel. Purification of PCR 
products was performed using PCR Purification Kit (Qiagen). For the generation of MALT1 
TRAF6 binding mutants, megaprimer PCR was used to introduce glutamate (E) to alanine (A) 
point mutations. First, two primers were designed to generate the megaprimer: one primer 
bears the desired mutation, whereas the other primer flanks the coding sequence. After 
purification, the generated PCR product was used in a second PCR round. Thereby, the 
megaprimer was combined with a third primer to amplify the whole gene sequence. Finally, 
the PCR product can be cloned into the target vector. 
6.5.2 DNA restriction digestion, agarose gel electrophoresis and DNA extraction 
PCR products or plasmid DNA were digested using endonucleases from NEB and the 
appropriate buffers. After restriction digest, DNA was mixed with 6x DNA loading buffer and 
separated on an agarose gel. For gel preparation, agarose was dissolved in TBE buffer and 
supplemented with ethidium bromide. Agarose gels were run in TBE buffer at 8 V/cm. To 
determine DNA fragment size, 3 µl 1 kb plus DNA ladder was loaded. DNA bands were 
visualized with UV light and were cut out for extraction using the Gel Extraction Kit (Qiagen) 
according to the manufacturer’s instruction. 
6.5.3 DNA ligation and transformation of Escherichia coli 
For ligation of digested plasmids and PCR products, Rapid DNA ligation Kit (Roche) 
containing the T4 DNA ligase was used according to the manufacturer’s protocol. Depending 
on the size ratio between vector and PCR fragment, ligation was performed using a molar 
ratio of 1:3 to 1:5 vector to insert. The complete ligation mixture was added to competent 
Escherichia coli (E. coli) TOP10 cells and was incubated for 30 min on ice. After a heat-
Step Temperature Time 
Melting 94 °C 10 min 
Melting 94 °C 1 min 
Annealing Tm primer -5 °C 1 min 
Extension 72 °C 30 sec/1 kb 
Extension 72 °C 10 min 
Table 10: PCR standard program. 
30 cycles 
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shock at 42 °C for 45 sec, competent cells were cooled down on ice for 5 min and 
subsequently supplemented with 400 µl LB medium. Cells were raised in a shaker at 37 °C 
for 60 min and afterwards plated on LB agar plates containing the appropriate antibiotic. 
Plates were incubated over night at 37 °C. 
6.5.4 Cultivation of E. coli and plasmid preparation 
To isolate the generated plasmid DNA, LB medium was prepared and supplemented with the 
appropriate antibiotic (e.g. ampicillin 100 µg/ml). 3 ml of LB medium were inoculated with 
one colony from LB agar plates and cultivated in a shaker (180 rpm) over night at 37 °C. 
Plasmid DNA was isolated using the Plasmid Mini Kit (Qiagen) according to the 
manufacturer’s protocol. To generate larger DNA amounts, 100-500 ng of the purified 
plasmid were re-transformed into competent E. coli cells (see 6.1.4). Afterwards, the cells 
were directly transferred into 150-200 ml LB medium and grown over night at 37 °C. For 
plasmid isolation, the Plasmid Maxi Kit (Qiagen) was used. 
6.5.5 DNA sequencing 
Purified DNA and the appropriate sequencing primers were send to Eurofins MWG Operon 
(Ebersberg) for sequencing. 
6.5.6 RNA isolation 
For extraction of RNA, 0.5-2x 106 cells were lysed in 350 µl RLT lysis buffer (Qiagen). 
Afterwards, lysates were transferred onto shredder columns for homogenization (Qiagen). 
RNA was isolated according to the protocol of the Qiagen RNeasy RNA isolation Kit. In a 
next step, RNA concentration was measured using Nanodrop and RNA levels were adjusted 
up to 1 µg. Genomic DNA was removed by adding 1 µl DNase I (1 U) (Promega) and the 
corresponding buffers for 30 min at 37 °C. Afterwards, the samples were treated with 1 µl 
stop solution at 65 °C for 10 min to inactivate the DNase I reaction before they were stored at 
-80 °C.  
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6.5.7 Reverse transcription into cDNA 
Digested RNA samples were reverse transcribed into cDNA using Superscript First Strand 
Synthesis Kit (Invitrogen) or Verso cDNA Synthesis Kit (Thermo Fisher Scientific) according 
to the manufacturer’s instructions. Thereby, random hexamers were used as primers for the 
Reverse Transcriptase. If reverse transcription was performed with Superscript First Strand 
Kit, samples were treated with RNaseH (1.5 U) (Life Technologies) at 37 °C for 20 min to 
degrade the RNA template. Generated cDNA was stored at -80 °C. 
6.5.8 Quantitative real-time PCR (qPCR) and semi-quantitative PCR (semi-qPCR) 
Quantitative real-time PCR (qPCR) is a useful method to quantify RNA amounts, in which 
DNA amplification can be detected by using a fluorescent dye LightCycler 480 SYBR Green 
I Mastermix (Roche) or KAPA SYBR FAST qPCR Mastermix (Peqlab) that binds double 
stranded DNA. The fluorescence increases with each cycle of amplification and can be 
detected with a LightCycler 480 (LC-480, Roche). The following standard protocol was used: 
Component Amount 
Template cDNA 2 µl 
5’ primer (20 µM) 1 µl 
3’ primer (20 µM) 1 µl 
SYBR Green I Mastermix (2x) 10 µl 
 Ad 20 µl H2O 
Table 11: qPCR standard protocol. 
Step Temperature Time 
Melting 95 °C 10 min 
Melting 95 °C 10 sec 
Annealing 60 °C 10 sec 
Extension 72 °C 10 sec 
Melting curve 65 °C – 95 °C  
Table 12: qPCR standard program. 
To quantify target gene expression, murine hydroxymethylbilane synthase (Hmbs), human 
peptidylprolyl isomerase B (PPIB), human 18S ribosomal RNA (18S rRNA), human RNA 
polymerase II (RP2) or human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were 
used as internal controls. Relative expression levels were calculated using the ΔΔCp method 
(Pfaffl, 2001). 
40–45 cycles 
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For semi-qPCR, DreamTaq DNA polymerase and 10x DreamTaq green buffer (both Thermo 
Scientific) were used according to the following protocol: 
Component Amount 
Template cDNA 2 µl 
5’ primer (10 µM) 1.25 µl 
3’ primer (10 µM) 1.25 µl 
dNTP (10 mM) 1 µl 
DreamTaq green buffer (10x) 10 µl 
DNA polymerase (DreamTaq) 0.3 µl 
 Ad 50 µl H2O 
Table 13: Semi-qPCR standard protocol. 
 
 
 
PCR samples were loaded on a 2-3 % agarose gel together with 3 µl 1 kb plus DNA ladder. 
DNA bands were visualized with UV light using a Geldocumentation system (Intas). In 
minigene experiments, alternatively spliced products were quantified by densitometry using 
Adobe Photoshop. Percentage of exon7 inclusion was calculated relative to total PCR 
product. 
6.6 Biochemical and immunological methods 
6.6.1 Preparation of whole cell lysates 
For analysis of protein expression levels and activation of downstream signaling pathways 
including NF-κB DNA binding (see section 6.6.7), 1x 106–5x 106 cells were harvested  
(1800 rpm, 5 min, 4 °C), washed with PBS and subsequently lysed in 80–120 µl high-salt 
buffer. Lysates were incubated on a shaker for 10–20 min at 4 °C before insoluble cellular 
debris were removed by centrifugation (14 000 rpm, 15 min, 4 °C). For Western Blot 
analysis, samples were mixed with 4x SDS loading buffer (Rotiload, Roth) and boiled for  
Step Temperature Time 
Melting 94 °C 10 min 
Melting 94 °C 10 sec 
Annealing Tm primer -5 °C 10 sec 
Extension 72 °C 10 sec 
Extension 72 °C 10 min 
Table 14: Semi-qPCR standard program. 
25–30 cycles 
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5–10 min at 95 °C. Signaling potential of MALT1 TRAF6 binding mutants was analyzed in 
cooperation with T. Seeholzer, AG Krappmann. 
6.6.2 Co-immunoprecipitation and Strep-Tactin pulldown 
For protein interaction studies, 1x 107–3x 106 cells were lysed in 900 µl Co-IP buffer 
supplemented with protease inhibitors. Lysates were incubated for 20 min at 4 °C in an 
overhead rotator before samples were cleared by centrifugation (14 000 rpm, 15 min, 4 °C). 
30 µl supernatant were collected as lysate controls and were mixed with 4x SDS loading 
buffer (Rotiload, Roth) and boiled for 5 min at 95 °C. The residual supernatant (ca. 830 µl) 
was used for binding studies. Immunoprecipitations (IPs) were carried out by using antibodies 
against NEMO (9 µl) or MALT1A (15 µl) and samples were incubated in an overhead rotator 
overnight at 4 °C. After antibody incubation, 20 µl Protein G Sepharose (1:1 suspension) was 
added and lysates were rotated for additional 1–2 h at 4 °C. For Strep-Tactin pulldowns 
(StrepT-PDs), Strep-tagged MALT1 proteins were precipitated by using 30 µl Strep-Tactin 
Sepharose (1:1 suspension, IBA) at 4 °C overnight. After incubation with Protein  
G Sepharose or StrepTactin Sepharose, beads were washed four times with 500 µl ice-cold 
Co-IP buffer without protease inhibitors (200 x g, 5 min, 4 °C). Supernatant was completely 
removed by aspiration and ca. 20 µl 2x SDS loading buffer (Rotiload) was added to the beads. 
Samples were boiled at 95 °C for 8 min before they were separated by SDS-PAGE. 
6.6.3 RNA-binding protein immunoprecipitation 
RNA-binding protein immunoprecipitation (RIP) is a useful method to analyze whether 
specific nuclear or cytosolic proteins associate with specific RNA molecules. Analysis of 
hnRNP U binding to MALT1 pre-mRNA in Jurkat T cells was performed using Magna RIPTM 
Kit (Merck Millipore). First, 2x 107 Jurkat T cells were harvested, washed with PBS  
(1500 rpm, 5 min, 4 °C) and lysed in 100 µl RIP lysis buffer (complete) for 5 min at 4 °C. 
Lysates were stored at -80 °C for 24 h. For immunoprecipitation, 100 µl pre-washed protein 
A/G magnetic beads (in RIP wash buffer) were labeled with 5 µg anti-hnRNP U or 5 µg 
normal mouse IgG antibody (both Merck Millipore) for 30 min at RT in a rotator. Beads-
antibody complexes were washed with RIP wash buffer and placed in a magnetic separator 
(Qiagen) to remove the supernatant. In the meantime, cell lysates were thawed and 
centrifuged (14 000 rpm, 10 min, 4 °C) to pellet insoluble cellular debris. Afterwards, 10 µl of 
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the lysate supernatant were removed and stored at -80 °C as input fraction, while 100 µl of the 
lysate supernatant together with 900 µl RIP immunoprecipitation (RIP IP) buffer were added 
to the antibody-beads complexes and incubated overnight at 4 °C. Afterwards the supernatant 
was removed by magnetic separation and beads were washed six times with RIP wash buffer. 
The immunoprecipitates were incubated with 150 µl Proteinase K buffer for 30 min at 55 °C 
to digest RNA-bound proteins. After transferring the tubes into the magnetic rack, supernatant 
was collected and mixed with 250 µl RIP wash buffer. In the meantime, input samples were 
treated with 140 µl Proteinase K buffer for 30 min at 55 °C before adding 250 µl RIP wash 
buffer. To purify RNA, IP and input samples were mixed with 400 µl 
phenol:chloroform:isoamylalcohol (125:24:1, Thermo Fisher Scientific). After centrifugation 
(14 000 rpm, 10 min, RT), the aqueous phase was removed and treated with 400 µl 
chloroform. The mixture was again centrifuged (14 000 rpm, 10 min, RT) and 300 µl aqueous 
phase were transferred into a new reaction tube. For precipitation of RNA, 50 µl salt solution 
I, 15 µl salt solution II, 5 µl precipitation enhancer and 850 µl ethanol were added to each 
sample before storage at -80 °C overnight. After thawing and centrifugation (14 000 rpm,  
30 min, 4 °C), the supernatant was removed, pellets were washed with 1 ml 80 % ethanol  
(14 000 rpm, 30 min, 4 °C), dried at RT and resupsended in 20 µl RNase free water. Finally, 
RNA was reverse transcribed into cDNA and MALT1 pre-mRNA enrichment was analyzed by 
qPCR (see sections 6.5.7 and 6.5.8) normalizing IP samples relative to input fractions.  
6.6.4 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins of cellular lysates were separated by SDS-PAGE, which was performed under 
reducing conditions. Different concentrations of acrylamide (7–15 %) were used for the 
generation of separation gels with different pore sizes. APS (ammonium persulfate) and 
TEMED were added to the mixture to enable polymerization. After full polymerization of the 
separation gel, a 5 % polyacrylamide stacking gel containing pockets for the lysate samples 
was layered on top of the separation gel. When gels were fully polymerized, protein lysates 
were loaded. A prestained protein ladder (Thermo Fisher Scientific) was also loaded to 
estimate the molecular weight of the separated proteins. Electrophoresis was performed in 
SDS electrophoresis buffer at 90 V for 30 min before voltage was increased to 110 V for  
60 min. 
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6.6.5 Western Blot (WB) 
To enable detection of proteins separated by SDS-PAGE, proteins were transferred onto 
PVDF membranes using a semi-dry transfer system. Thereby, PVDF membranes were 
activated in methanol and Whatman filter papers were soaked in 1x blotting buffer. The SDS 
gel and the membrane were placed between soaked Whatman filter papers in the blotting 
apparatus. Proteins are transferred to the PVDF membrane by using an electric field (70 mA 
per gel for 110 min).  
After blotting, membranes were blocked with 3 % BSA/PBS-T for 60 min to avoid unspecific 
antibody binding. Blocked membranes were incubated with primary antibody (dilution 1:1000 
in 1.5 % BSA/PBS-T) overnight at 4 °C. Membranes were washed at least three times with 
PBS-T for 5 min at RT to remove unspecifically bound antibodies. Afterwards, HRP-coupled 
secondary antibody (dilution 1:10 000 in 1.5 % BSA/PBS-T) was added for 1 h at RT. 
Membranes were again washed with PBS-T to remove unbound antibodies. HRP activity was 
detected by using enhanced chemiluminescence (ECL) substrate (Cell Signaling) in a 1:20 
dilution in water. HRP catalyzes oxidation of the substrate and is accompanied by the 
emission of light, which was detected by ECL films exposed to the membrane. For detection 
of further proteins on the same membrane, membranes were washed with PBS-T and treated 
with stripping buffer for 30 min at RT to remove all bound primary and secondary antibodies. 
Membranes were washed at least three times with PBS-T for 5 min, blocked with 3 % BSA 
solution and incubated with a specific primary and secondary antibody as described before. 
6.6.6 MALT1 activity detection using MALT1 activity based probes 
MALT1 activity based probes (ABPs) can be used to monitor cellular MALT1 activity 
(Eitelhuber et al., 2011). The MALT1 ABPs consist of a specific recognition element LRSR, 
an electrophile (AOMK) that forms a covalent bond with the active cysteine and a certain 
detection marker. An ABP coupled to the fluorophore BODIPY (boron-dipyrromethene) was 
used for measuring MALT1 activity of different MALT1-Strep constructs. In this assay, 
Jurkat T cells (2-5x 107) were lysed in 900 µl Co-IP buffer, centrifuged (14 000 rpm, 10 min, 
4 °C) and overexpressed MALT1-Strep constructs were precipitated using Strep-Tactin 
Sepharose (see section 6.6.2). After three washing steps with Co-IP buffer, bead-bound 
MALT1-Strep was incubated with 3 µM fluorescent MALT1-ABP (BODIPY) for 1 h at  
30 °C, mixed with 4x SDS loading buffer (Rotiload, Roth) and boiled. Proteins were 
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separated by SDS-PAGE and fluorescence was detected by a Typhoon Scanner (FITC laser 
488nm/filter 526 SP).  
A biotin-coupled MALT1-ABP was used to detect active MALT1 in primary CD4+ T cells in 
a plate-bound assay called ELASA (enzyme-linked activity sorbent assay). Cells (1 x 107) 
were lysed in 200 µl Co-IP buffer, centrifuged (14 000 rpm, 10 min, 4 °C) and extract was 
incubated with 0.1 µM biotinylated MALT1 ABP (Biotin K). Extract was transferred to 
streptavidin-coated plates (Thermo Scientific) and incubated overnight at 4 °C. After washing 
in PBS-T (0.05 % Tween-20) and blocking with 2 % BSA/PBS-T, detection was performed 
by incubation with MALT1 primary antibody (2494; 1:800 in 1 % BSA/ PBS-T; 1 h, RT) and 
HRP-coupled secondary antibody (1:1500 in 1 % BSA/PBS-T; 1 h, RT). 3-5 washing steps 
with PBS-T were used after antibody incubation. Luminescence was determined after TMB 
substrate (eBioscience) incubation for 10-20 min and subsequent stop reaction with  
1 M H2SO4 in a photometer (Bio-Tek) at 450 nm and 570 nm. 
6.6.7 Electrophoretic mobility shift assay (EMSA) 
Electrophoretic mobility shift assays (EMSAs) enable the visualization of transcription factor 
binding to DNA. Thereby, radioactive labeled oligonucleotides containing specific DNA 
response elements are incubated with protein lysates, and the mixture is separated on a native 
polyacrylamide gel, in which protein-DNA complexes migrate more slowly than free 
unbound DNA. Due to the radioactive labeling, DNA-transcription factor complexes can be 
detected with X-Ray films. 
To produce radioactive labeled DNA probes, single oligonucleotides were annealed resulting 
in the formation of 5’ overhanging dsDNA-oligonucleotides. Overhangs were filled in with 
radioactive nucleotides by Klenow polymerase according to the following protocol: 
Component Amount 
DNA oligonucleotide 400 ng 
Klenow buffer (10x) 2.5 µl 
dNTP-A (10 µM) 1.8 µl 
[32]P-α-dATP 30 µCi 
Klenow Fragment 1 U 
 ad 25 µl H2O 
Table 15: Labling of DNA probes. 
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The reaction was incubated for 30 min at 37 °C. Afterwards, samples were purified using 
QIAQuick Nucleotide Removal Kit (Qiagen).  
To determine DNA binding activity of NF-κB and OCT1, EMSAs were performed using cells 
which were lysed in high-salt lysis buffer (see section 6.6.1) and 32P-α-dATP-labeled NF-κB 
(H2K) or OCT1 DNA binding site probes. Assays were conducted according to the following 
protocol: 
Component Amount 
Protein extract ~ 5 µg 
2x Shift buffer 10 µl 
BSA 10 µg 
DTT (100 mM) 1 µl 
Poly dI-dC (2 μg/μl) 1 µl 
[32]P-α-dATP-labeled probe 1 µl (10 000–20 000 cpm) 
 ad 20 µl H2O 
Table 16: EMSA standard protocol. 
Reaction mixture was incubated for 30 min at RT and separated on a native polyacrylamide 
gel (5 %) in 1x TBE buffer at 26 mA/gel. Gels were dried on a Whatman filter paper at 80 °C 
for 1 h and exposed to autoradiography films. To determine NF-κB fold induction, intensities 
of NF-κB bands were quantified relative to OCT1 signal using ImageJ software. 
6.7 Statistical analysis 
All experiments were performed at least three times unless otherwise indicated. Values 
represent the mean ± standard deviation (SD). Experiments were analyzed by using unpaired 
Student’s t-test. Statistical significance values are *p < 0.05; **p < 0.01; ***p < 0.001. 
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7 Abbreviations 
° C   ° Celsius 
18S rRNA 18S ribosomal RNA 
A/Ala  alanine 
aa  amino acid 
ABP  activity based probe 
Ac  acidic amino acid 
API2  cellular inhibitor of apoptosis 2 
AMO  MALT1A morpholino 
AOMK acyloxymethyl ketone 
AP-1   activator protein-1 
APC  antigen presenting cell 
APC  allophycocyanin 
APS   ammonium persulfate 
Ar  aromatic amino acid 
ARS  activation responsive motif 
ATF2  activating transcription factor 2 
ATP   adenosine triphosphate 
BCL-6  B cell chronic lymphocytic leukemia/lymphoma 6 
BCL10  B cell chronic lymphocytic leukemia/lymphoma 10 
BCR   B cell receptor 
BODIPY boron-dipyrromethene 
BPS  branch point sequences 
BSA   bovine serum albumin 
C/Cys  cysteine 
Ca2+  calcium 
CAG  chicken actin promoter and cytomegalovirus enhancer 
CaMKII  calmodulin-dependent protein kinase II 
CAR  coxsackievirus and adenovirus receptor 
CARD  caspase-recruitment domain 
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CARMA1  CARD-containing MAGUK 1 
Cas9  CRISPR-associated protein-9 
CBM  CARMA1-BCL10-MALT1 
CC   coiled-coil 
CCR  CC chemokine receptor 
CD  cluster of differentiation 
CD62L CD62 ligand 
cDNA   complementary DNA 
Ci   Curie 
cIAP   cellular inhibitor of apoptosis 
CLIP  crosslinking and immunoprecipitation 
cMO  control morpholino 
Co-IP   Co-immunoprecipitation 
CPE  cytopathic effects 
cpm   counts per minute 
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats 
C-terminus  Carboxyl-terminus 
CTLA-4  cytotoxic T lymphocyte antigen-4 
CXCR  CXC chemokine receptor 
CYLD  cylindromatosis 
D/Asp  aspartate 
DAG   diacylglycerol 
dATP   desoxyadenosine triphosphate 
DD   death domain 
DMEM  Dulbecco’s Modified Eagle Medium 
DMSO dimethyl sulfoxide 
DNA   deoxyribonucleic acid 
dNTP   deoxyribonucleotide triphosphate 
ds  double-stranded 
DTT   dithiothreitol 
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E/Glu  glutamate 
EAE  experimentally induced autoimmune encephalomyelitis 
ECL  enhanced chemiluminescence 
EDTA  ethylenediaminetetraacetic acid 
eGFP  enhanced green fluorescent protein 
EGTA  Ethyleneglycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid 
ELASA  enzyme-linked activity sorbent assay 
EMSA  electrophoretic mobility shift assay 
ERK   extracellular signal-regulated kinase 
ESE  exonic splicing enhancers  
ESS  exonic splicing silencers 
FACS  fluorescence-activated cell sorting 
FCS   fetal calf serum 
FITC  fluorescein isothiocyanate 
FOXP3 forkhead box p3 
G/Gly  glycine 
g  gravity 
GADS  GRB2-related adapter downstream of Shc 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GATA3 GATA binding protgrbein 3 
GDP  guanosine diphosphate 
GEF   guanine nucleotide exchange factor 
GFP   green fluorescent protein 
GRB2   growth factor receptor-bound protein 2 
GSK3  glycogen synthase kinase 
GTP  guanosine triphosphate 
GUK   guanylate kinase 
H/His  histidine 
h   human 
h  hour 
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H2SO4  sulfuric acid 
HEK   human embryonic kidney 
HEPES  2-[4-(2-Hydroxyethyl)-1-piperazino]-ethansulfonic acid 
HEV  high-endothelial venules 
HMBS  hydroxymethylbilane synthase 
hnRNP heterogeneous nuclear ribonucleoproteins 
HOIL1 heme-oxidized IRP2 ubiquitin ligase 1 
HOIP  HOIL1-interacting protein 
HPK1  hematopoietic progenitor kinase 1 
HRP   horseradish peroxidase 
I  Ionomycin 
IC  intracellular 
ICOS  inducible T cell co-stimulator 
IFNγ   interferon gamma 
Ig   immunoglobulin 
IKK   IκB kinase 
IL   interleukin 
IMDM  Iscove's Modified Dulbecco's Medium 
IP   immunoprecipitation 
IP3  inositol 1,4,5-trisphosphate 
IRAK  interleukin 1 receptor associated kinase 1 
IRP2  iron regulatory protein 2 
IS  immunological synapse 
ISE  intronic splicing enhancers  
ISS  intronic splicing silencers 
ITAM   immunoreceptor tyrosine-based activation motif 
iTreg  inducible Treg 
IκB   inhibitor of NF-κB 
JAK  janus kinase 
JNK   c-Jun N-terminal kinase 
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K/Lys   lysine 
kb   kilo base 
KCL  potassium chloride 
kDa   kilo Dalton 
KH2PO4 potassium hydrogen phosphate 
LAT   linker for activation of T cells 
LB   Luria-Bertani (medium) 
LCK  lymphocyte-specific protein tyrosine kinase 
LEF  lymphoid enhancer binding factor 1 
LUBAC linear ubiquitin chain assembly complex 
MACS  magnetic-activated cell sorting 
MAGUK  membrane associated guanylate kinase 
MALT1  mucosa associated lymphoid tissue lymphoma translocation protein 1 
MAPK  mitogen activated protein kinase 
MAP3K MAPK kinase kinase 
MAP2K MAPK kinase 
MEF  mouse embryonic fibroblast 
MFI  mean fluorescence intensity  
mg   milligram 
MgCl2  magnesium chloride 
MHC   major histocompatibility complex 
MIB2   mindbomb E3 ubiquitin protein ligase 2 
min   minute 
MKK  MAPK kinase 
ml   milliliter 
MNC  mononuclear cells 
MO  morpholino 
MOI  multiplicity of infection 
mRNA  messenger RNA 
MyD88 myloid differentiation factor 88 
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Na2HPO4 disodium hydrogen phosphate 
NaCl  sodium chloride 
NaF  sodium fluoride 
NaN3  sodium azide 
NEAA  non-essential amino acids 
NEMO NF-κB essential modulator 
NES  nuclear export sequence 
NFAT   nuclear factor of activated T cells 
NF-κB  nuclear factor kappa B 
ng   nanogram 
NH4Cl  ammonium chloride 
NLS   nuclear localization sequence 
nm   nanometer 
NP-40  nonidet P40 substitude 
NSCLC non-small cell lung cancer 
nt   nucleotide 
N-terminus  amino-terminus 
nTreg  natural Tregs 
OD   optical density 
OVA  ovalbumin 
P  proline 
P/S  penicillin/streptomycin 
PBMC  peripheral blood mononuclear cells 
PBS   phosphate buffered saline 
PBS-T  PBS-Tween 20 
PCR   polymerase chain reaction 
PD-1  programmed cell death protein-1 
PDK1   phosphoinositide-dependent kinase 1   
PDZ   PSD-95/DLG/ZO1 homology 
PE  phycoerythrin 
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PFA  paraformaldehyde 
PH  pleckstrin homology 
PI3K   phosphoinositide 3 kinase 
PIP2   phosphatidyl inositol 4,5-bisphosphate 
PIP3  phosphatidyl inositol 3,4,5-trisphosphate 
PKB  protein kinase B 
PKC   protein kinase C 
PLCγ1  phospholipase C gamma 1 
PLK1  polo-like kinase 1 
PM  paracaspase mutant 
PMA   phorbol 12-myristate 13-acetate 
PP2A  protein phosphatase 2A 
PPIB  peptidylprolyl isomerase B 
PPT  polypyrimidine tract 
pre-mRNA precursor messenger RNA 
PSF  PTB-associated splicing factor 
PTB  polypyrimidine tract binding protein 
Q/Gln  glutamine 
qPCR  quantitative polymerase chain reaction 
R  arginine 
Ras   rat sarcoma 
RasGRP Ras guanyl nucleotide-releasing protein 
RBM12B RNA-binding motif protein 12B 
RBMS1 RNA-binding motif single-stranded-interacting protein 1 
RHD   Rel homology domain 
RING  really interesting new gene 
RISC  RNA-induced silencing complex 
RNA   ribonucleic acid 
RNAi  RNA interference 
RNase  ribonuclease 
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RORγt  RAR-related orphan receptor gamma t 
RP2  RNA polymerase II 
rpm   rounds per minute 
RRM  RNA recognition motif 
RT   room temperature 
RT-PCR real-time PCR 
S  serine 
SAF-A scaffold attachment factor A 
Sam68  Src-associated in mitosis 68 kDa 
SCF   Skp1-Cullin-Roc1/Rbx/Hrt1-F-box 
SD  standard deviation 
SDS   Sodium dodecyl sulfate 
SDS-PAGE  SDS polyacrylamide gel electrophoresis 
semi-qPCR semi-quantitative PCR 
SH2   Src homology 2 
SH3  Src homology 3 
SHARPIN SHANK-associated RH domain interacting protein 
shRNA small hairpin RNA 
siRNA  small interfering RNA 
SLP76  SH2-domain containing leukocyte protein of 76 kDa 
SMAC  supramolecular activation cluster 
snRNP  small nuclear ribonucleoprotein particles  
SOS  son of sevenless 
SPRM1 sperm-associated POU domain protein 1 
SR  serine/arginine-rich 
Src   sarcoma 
SRSF  serine/arginine-rich splicing factor 
SS  splice site 
StrepT-PD Strep-Tactin pulldown 
SV40  simian virus 40 
7 Abbreviations 
129 
 
T/Thr  threonine 
T6BM  TRAF6 binding motif 
TAB   TAK1 binding protein 
TAC   tris ammonium cloride 
TAD   transactivation domain 
TAK   transforming growth factor beta activated kinase 
TBE  Tris borate EDTA 
TCF7  transcription factor 7 
TCR   T cell receptor 
TE   Tris EDTA 
TEMED  Tetramethylethylenediamine 
TFH  follicular T helper 
TGFβ   transforming growth factor beta  
TH  T helper 
TLR   toll like receptor 
Tm  melting temperature 
TMB  3,3′,5,5′-Tetramethylbenzidine 
TNF   tumour necrosis factor 
TNFAIP3  tumour necrosis factor alpha induced protein 3 
TRAF   tumor-necrosis factor associated receptor-associated factor 
TRAP150 thyroid-hormone receptor-associated protein 150 
Treg  regulatory T cell 
Tris   Tris(hydroxymethyl)-aminomethan 
U   Unit 
U2AF  U2 auxiliary factor 
Ubc13  E2 ubiquitin-conjugating enzyme 13 
Uev1A ubiquitin E2 variant 1AA 
USA   United States of America 
UTR  untranslated region 
UV   ultraviolet radiation 
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V  valine 
V   volt 
WT  wildtype 
ZAP70  zeta-chain-associated protein 70 kDa 
β-TrCP  beta-transducin repeat containing protein 
γc  common gamma chain 
μg   microgram 
μl   microliter  
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